<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication Issue 6, 2011" DOI="10.1002/14651858.CD004974.pub2" GROUP_ID="ARI" ID="009204010620292301" MERGED_FROM="" MODIFIED="2011-04-21 04:39:54 +0200" MODIFIED_BY="Liz Dooley" REVIEW_NO="A043" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2011-04-21 04:28:34 +0200" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2010-04-02 12:24:54 +1000" MODIFIED_BY="[Empty name]">Immunostimulants for preventing respiratory tract infection in children</TITLE>
<CONTACT MODIFIED="2011-04-21 04:28:34 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="B45E825182E26AA200022324E2FFDF53" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Blanca Estela</FIRST_NAME><LAST_NAME>Del-Rio-Navarro</LAST_NAME><POSITION>Chief</POSITION><EMAIL_1>blancadelrionavarro@gmail.com</EMAIL_1><EMAIL_2>blancadelrionavarro@yahoo.com.mx</EMAIL_2><ADDRESS><DEPARTMENT>Department of Allergy and Immunology</DEPARTMENT><ORGANISATION>Hospital Infantil de México "Federico Gómez"</ORGANISATION><ADDRESS_1>Dr. Marquez 162</ADDRESS_1><ADDRESS_2>Colonia de los Doctores</ADDRESS_2><CITY>Mexico City</CITY><ZIP>CP 06720</ZIP><REGION>DF</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+55 5527 8177</PHONE_1><FAX_1>+55 5399 5429</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-04-21 04:28:34 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="B45E825182E26AA200022324E2FFDF53" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Blanca Estela</FIRST_NAME><LAST_NAME>Del-Rio-Navarro</LAST_NAME><POSITION>Chief</POSITION><EMAIL_1>blancadelrionavarro@gmail.com</EMAIL_1><EMAIL_2>blancadelrionavarro@yahoo.com.mx</EMAIL_2><ADDRESS><DEPARTMENT>Department of Allergy and Immunology</DEPARTMENT><ORGANISATION>Hospital Infantil de México "Federico Gómez"</ORGANISATION><ADDRESS_1>Dr. Marquez 162</ADDRESS_1><ADDRESS_2>Colonia de los Doctores</ADDRESS_2><CITY>Mexico City</CITY><ZIP>CP 06720</ZIP><REGION>DF</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+55 5527 8177</PHONE_1><FAX_1>+55 5399 5429</FAX_1></ADDRESS></PERSON><PERSON ID="577F569182E26AA201F801F7BDBF670C" ROLE="AUTHOR"><FIRST_NAME>Francisco</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Espinosa-Rosales</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Chief of Immunology Department</POSITION><EMAIL_1>espinosa_francisco@yahoo.com.mx</EMAIL_1><ADDRESS><DEPARTMENT>Department of Immunology</DEPARTMENT><ORGANISATION>Instituto Nacional de Pediatría (National Institute of Pediatrics)</ORGANISATION><ADDRESS_1>Insurgentes Sur # 3700-C colonia Insurgentes Cuicuilco</ADDRESS_1><ADDRESS_2>Coyoacán</ADDRESS_2><CITY>México D.F.</CITY><ZIP>CP 04530</ZIP><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 55 1084 0900 ext. 1485</PHONE_1><FAX_1>+52 55 1084 0900 ext. 1485</FAX_1></ADDRESS></PERSON><PERSON ID="4620" ROLE="AUTHOR"><FIRST_NAME>Vicki</FIRST_NAME><LAST_NAME>Flenady</LAST_NAME><EMAIL_1>Vicki.Flenady@mater.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Translating Research Into Practice (TRIP) Centre - Mater Medical Research Institute</DEPARTMENT><ORGANISATION>Mater Health Services</ORGANISATION><ADDRESS_1>Level 2 Quarters Building</ADDRESS_1><ADDRESS_2>Annerley Road</ADDRESS_2><CITY>Woolloongabba</CITY><ZIP>4102</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 38401591</PHONE_1><FAX_1>+61 7 38401588</FAX_1></ADDRESS></PERSON><PERSON ID="19383" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Juan</FIRST_NAME><MIDDLE_INITIALS>JL</MIDDLE_INITIALS><LAST_NAME>Sienra-Monge</LAST_NAME><POSITION>Investigator</POSITION><EMAIL_1>jjsienra@hotmail.com</EMAIL_1><MOBILE_PHONE>+55 55408 7442</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Allergy and Immunology</DEPARTMENT><ORGANISATION>Hospital Infantil de México "Federico Gómez"</ORGANISATION><ADDRESS_1>Dr. Marquez 162</ADDRESS_1><ADDRESS_2>Colonia de los Doctores</ADDRESS_2><CITY>Mexico City</CITY><ZIP>CP 06720</ZIP><REGION>DF</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+55 55761 0947</PHONE_1><PHONE_2>+55 55228 9917 ext 1120,1121,1251</PHONE_2><FAX_1>+55 55761 0947</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-05 10:56:36 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="3" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="3" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-14 07:27:17 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-14 07:27:17 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Searches conducted. We included three new trials (<LINK REF="STD-Mora-2007" TYPE="STUDY">Mora 2007</LINK>; <LINK REF="STD-Mora-2010a" TYPE="STUDY">Mora 2010a</LINK>; <LINK REF="STD-Wahl-2008" TYPE="STUDY">Wahl 2008</LINK>) and the mean and standard deviation on the number of acute respiratory tract infections in <LINK REF="STD-Schaad-2002" TYPE="STUDY">Schaad 2002</LINK>. We excluded six new trials (<LINK REF="STD-Grimfeld-2004" TYPE="STUDY">Grimfeld 2004</LINK>; <LINK REF="STD-Heinz-2010" TYPE="STUDY">Heinz 2010</LINK>; <LINK REF="STD-Mora-2010b" TYPE="STUDY">Mora 2010b</LINK>; <LINK REF="STD-Razi-2010" TYPE="STUDY">Razi 2010</LINK>; <LINK REF="STD-Riedl_x002d_Seifert-1993" TYPE="STUDY">Riedl-Seifert 1993</LINK>; <LINK REF="STD-Steinsbekk-2005" TYPE="STUDY">Steinsbekk 2005</LINK>). We included sub-analyses on the efficacy of D53 and OM-85. The conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-08-05 10:38:47 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-05 10:38:47 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-21 13:13:25 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-04-02 11:57:21 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-04-02 11:57:21 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-04-02 11:57:21 +1000" MODIFIED_BY="[Empty name]">
<NAME>Allergy and Clinical Immunolgy Service, Children Hospital of Mexico Federico Gomez</NAME>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<DESCRIPTION>
<P>The review was supported by the local institution</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-04-21 12:18:00 +1000" MODIFIED_BY="Liz Dooley">
<SUMMARY MODIFIED="2011-04-21 12:17:40 +1000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2010-07-19 08:15:30 +1000" MODIFIED_BY="[Empty name]">Immunostimulants to prevent acute respiratory tract infections in children</TITLE>
<SUMMARY_BODY MODIFIED="2011-04-21 12:17:40 +1000" MODIFIED_BY="Liz Dooley">
<P>Acute respiratory tract infections (ARTIs) are responsible for 19% of all deaths in children younger than five years of age, mainly in low-income countries in Africa, Asia and Latin America. In high-income countries ARTIs are among the most frequent illnesses, leading to 20% of medical consultations, 30% of days lost from work and 75% of antibiotic prescriptions. In the USA the total cost of non-influenza-related viral ARTIs is around $40 billion annually, while the corresponding cost for influenza is US $87.1 billion. The main signs and symptoms of ARTIs include sneezing, runny nose, sore throat, cough and malaise. Children living in rural communities, not attending daycare centres, suffer about seven ARTI episodes in the first year of life; eight ARTIs per year from the ages of one to four; six per year aged five to nine; and five per year aged 10 to 19. Children exposed to risks factors, such as attendance at daycare centres, overcrowding, contact with older siblings, smoking at home and lack of breast feeding, may suffer more ARTIs.</P>
<P>Several treatments have been used to reduce the incidence of ARTIs (vitamin A, vitamin C, zinc, antibiotics). Among them are immunostimulants (herbal extracts, bacterial extracts, synthetic compounds), which aim to increase the immune defences of the respiratory tract. We searched for clinical trials of immunostimulants to prevent ARTIs in children compared to placebo. Our review includes 35 studies with 4060 participants. However, the quality of many of the studies was poor and the results were very diverse.</P>
<P>By combining results, immunostimulants reduced 1.24 ARTIs in a six-month period, equivalent to a 39% reduction in ARTIs compared to the placebo group. Only 20 studies provided adequate data on adverse events: the most frequent were rash, nausea, vomiting, abdominal pain and diarrhea. The main limitations of this review were the poor methodological quality and diverse trial results. We conclude that ARTI-susceptible children may benefit from immunostimulants, but more high-quality studies are needed. We suggest that national health authorities conduct high-quality randomized controlled trials to assess the true effects of immunostimulant preparations.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-04-21 12:17:40 +1000" MODIFIED_BY="Liz Dooley">
<ABS_BACKGROUND>
<P>Acute respiratory tract infections (ARTIs) are a major cause of childhood morbidity and mortality. Immunostimulants (IS) may reduce the incidence of ARTIs. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy and safety of IS in preventing ARTIs in children. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-05 10:58:04 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, issue 1, which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to February week 4, 2011), EMBASE (1990 to February 2011), Google Scholar (2009 to February 2011), Scopus (2009 to February 2011), PASCAL (1990 to February 2010), SciSearch (1990 to February 2010) and IPA (1990 to February 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-04-21 12:17:40 +1000" MODIFIED_BY="Liz Dooley">
<P>We included all comparative randomized controlled trials (RCTs) which enrolled participants less than 18 years of age. The intervention was IS medication, administered by any method, compared to placebo to prevent ARTIs.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-04-21 12:17:40 +1000" MODIFIED_BY="Liz Dooley">
<P>We analyzed the outcome on ARTIs both as the mean number of ARTIs by group and as a percent change in the rate of ARTIs. We undertook meta-analyses using a random-effects model and presented results as mean differences (MD) with 95% confidence intervals (CI). Two review authors independently assessed the search results and risk of bias, and extracted data. A funnel plot suggested there may be publication bias in the identified trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-04 23:36:56 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty-five placebo-controlled trials (4060 participants) provided data in a form suitable for inclusion in the meta-analyses. When compared with placebo, the use of IS was shown to reduce ARTIs measured as the total numbers of ARTIs (MD -1.24; 95% CI -1.54 to -0.94) and the difference in ARTI rates (MD -38.84%; 95% CI -46.37% to -31.31%). Trial quality was generally poor and a high level of statistical heterogeneity was evident. The subgroup analysis of bacterial IS, D53 and OM-85 studies produced similar results, with lower heterogeneity. No difference in adverse events was evident between the placebo and IS groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-20 09:34:47 +1000" MODIFIED_BY="[Empty name]">
<P>This review shows that IS reduce the incidence of ARTIs by 40% on average in susceptible children. Studies in healthy children are not available. Although the safety profile in the studies was good, some IS may be unsafe. ARTI-susceptible children may benefit from IS treatment. Further high-quality trials are needed and we encourage national health authorities to conduct large, multicentre, double-blind, placebo-controlled RCTs on the role of IS in preventing ARTIs in children.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<BACKGROUND MODIFIED="2010-11-04 23:44:11 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-11-04 19:53:23 +1000" MODIFIED_BY="[Empty name]">
<P>In 1998 the World Health Organization (WHO) considered acute respiratory tract infections (ARTIs) to be "the forgotten pandemic" as ARTIs caused 19% of all deaths in children younger than five years and 8.2% of all disabilities and premature mortality (<LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). In 2000, 1.9 million (95% confidence interval (CI) 1.6 to 2.2 million) children died from ARTIs worldwide, with 70% of the deaths in Africa and South-East Asia (<LINK REF="REF-Williams-2002" TYPE="REFERENCE">Williams 2002</LINK>). ARTIs are the leading cause of morbidity in high-income countries (USA, Canada, Western Europe) and account for 20% of medical consultations, 30% of days lost from work and 75% of antibiotic prescriptions (<LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). ARTIs are responsible for most sick days amongst school children (<LINK REF="REF-Haskins-1986" TYPE="REFERENCE">Haskins 1986</LINK>) and parental absenteeism from work (<LINK REF="REF-Bell-1989" TYPE="REFERENCE">Bell 1989</LINK>). The cost of ARTIs in high-income countries is significant. For example, between 2000 and 2002 there were approximately 500 million non-influenza-related viral ARTI episodes in the USA per year; the total economic impact of these episodes was around $40 billion annually (direct costs of $17 billion per year and indirect costs of $22.5 billion per year) (<LINK REF="REF-Fendrick-2003" TYPE="REFERENCE">Fendrick 2003</LINK>). Based on the 2003 US population, it has been calculated that the total economic burden of annual influenza epidemics in the USA was $87.1 billion US dollars ($47.2 to $149.5) (<LINK REF="REF-Molinari-2007" TYPE="REFERENCE">Molinari 2007</LINK>). Risk factors for ARTIs in childhood include attendance at daycare centres (<LINK REF="REF-Schwartz-1994" TYPE="REFERENCE">Schwartz 1994</LINK>), overcrowding (<LINK REF="REF-Bell-1989" TYPE="REFERENCE">Bell 1989</LINK>; <LINK REF="REF-Selwyn-1990" TYPE="REFERENCE">Selwyn 1990</LINK>), contact with elder siblings (<LINK REF="REF-Selwyn-1990" TYPE="REFERENCE">Selwyn 1990</LINK>), male gender (<LINK REF="REF-Monto-2002" TYPE="REFERENCE">Monto 2002</LINK>), smoking at home (<LINK REF="REF-Jin-1993" TYPE="REFERENCE">Jin 1993</LINK>) and lack of breast feeding (<LINK REF="REF-Wright-1989" TYPE="REFERENCE">Wright 1989</LINK>).</P>
<P>Community health studies in high-income countries have provided basic information on the incidence of ARTIs in children. In the Cleveland Family Study, 100 families were visited weekly by nurses during 1948 to 1957. The annual frequency of respiratory illness was 6.72 in children less than one year old; 7.95 in children aged one to four years; 6.21 in children aged five to nine years; 5.02 in children aged 10 to 14 years; and 4.71 in 15 to 19-year olds (<LINK REF="REF-Monto-2002" TYPE="REFERENCE">Monto 2002</LINK>). In the first phase of the Tecumseh study, from 1965 to 1971, 4905 residents registered their incidence of ARTIs for the six-year period. In the first report the residents had suffered approximately 14,600 ARTIs. The annual incidence of ARTIs per person was 6.1 in children less than one year old; 5.7 in children aged one to two years; 4.7 in children aged three to four years; 3.5 in children aged five to nine years; 2.7 in children aged 10 to 14 years old; and 2.4 in 15 to 19-year olds (<LINK REF="REF-Monto-1974" TYPE="REFERENCE">Monto 1974</LINK>). In the second report of the Tecumseh study, which covered two phases comprising a total of 11 years (1965 to 1971 and 1976 to 1981), the mean annual number of ARTIs was 4.9 in the group aged from zero to four years; and 2.8 in the group aged five to 19 years (<LINK REF="REF-Monto-1993" TYPE="REFERENCE">Monto 1993</LINK>). In both phases of the study viruses were the most common agents causing ARTIs.</P>
<P>During the 1980s, the Board on Science and Technology for International Development (BOSTID) undertook a co-ordinated effort to establish the aetiology and epidemiology of ARTIs in children in high-income countries. The project was carried out in populations from 0 to 59 months of age in Africa, Asia and Latin America. The incidence rate in six community-based studies ranged from 12.7 to 16.8 ARTIs per 100 child-weeks and the incidence of lower ARTIs was from 0.2 to 0.4 per 100 child-weeks. The children studied spent from 21.7% to 40.1% of the observed weeks with ARTIs and from 1% to 14.4% of the observed weeks with lower ARTIs. Viral agents were more frequently recovered than bacterial agents; respiratory syncytial virus (RSV) was the most frequent virus (<LINK REF="REF-Selwyn-1990" TYPE="REFERENCE">Selwyn 1990</LINK>). In Mexico, a study assessing the effect of daycare centres on ARTI incidence followed 144 children (aged 43 days to 4 months at entry) at home for one year. The study found that these children had six ARTIs each year, with a median of 40 sick days in a year (<LINK REF="REF-Flores_x002d_Hernandez1999" TYPE="REFERENCE">Flores-Hernandez1999</LINK>). Viruses were the main aetiological agents for ARTIs in children at daycare centres (<LINK REF="REF-Denny-1986" TYPE="REFERENCE">Denny 1986</LINK>) and in the community (<LINK REF="REF-Monto-1993" TYPE="REFERENCE">Monto 1993</LINK>). The most common virus isolates are rhinovirus, respiratory syncytial virus, parainfluenza virus and adenovirus. Lower ARTIs are also frequently associated with viral infections, but bacterial agents may be found in 4.5% to 40% of the cases (<LINK REF="REF-Selwyn-1990" TYPE="REFERENCE">Selwyn 1990</LINK>). Up to 50% of children admitted to hospital with proven bacterial ARTIs also have evidence of concurrent or recent viral ARTIs (<LINK REF="REF-Campbell-1995" TYPE="REFERENCE">Campbell 1995</LINK>). The damage caused by viruses to epithelial cells in the airways may increase the adherence of bacteria and lead to a bacterial superinfection (<LINK REF="REF-Hament-1999" TYPE="REFERENCE">Hament 1999</LINK>).</P>
<P>History of respiratory infections in the first 12 years among children was established in a cohort of German children living in urban areas. The mean cumulative number of ARTIs in the 12 years was 21.9 (standard deviation (SD) 9.0) episodes; the mean annual number was 1st year, 3.1 (2.1) episodes; 2nd year, 3.2 (2.5); 3rd year, 2.1 (2.0); 4th year, 2.3 (2.1); 5th year, 1.8 (1.6); 7th through to the 9th year, 1.1 (1.0) episodes; 10th year through 12th year, 1.0 (0.9) episodes (<LINK REF="REF-Gr_x00fc_ber-2008" TYPE="REFERENCE">Grüber 2008</LINK>). The frequency of ARTIs in this study was about a half of the classic Monto studies (<LINK REF="REF-Monto-1974" TYPE="REFERENCE">Monto 1974</LINK>; <LINK REF="REF-Monto-1993" TYPE="REFERENCE">Monto 1993</LINK>). The authors regarded incidence above the twofold standard deviation as clinically relevant; more than seven episodes in the 1st year of life, more than eight episodes in year two, more than six episodes in year three and year four more than five episodes in year five, more than four episodes in year six, and more than three episodes from year seven onwards.</P>
<P>In a healthy population without any special risk factors or immunodeficiencies, there is a subgroup of people with a higher incidence of ARTIs. A cohort of children from Nijmegen, Netherlands was followed for 21 years to register the occurrence of ARTIs. The number of respiratory infections was assessed at the ages of two, four, eight and 21. It was considered that a person had a recurrent infection if the number of ARTIs was above 75th percentile of the distribution of respiratory infection at each assessment. Twenty-three percent of the people had recurrent respiratory infection in two or more assessments and 1% suffered from recurrent infection in the four assessments (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>).</P>
<P>Recent influenza epidemics have increased interest in effective unspecific measures to protect the global population, outside the production of appropriate vaccines which could take more than six to nine months to be ready for use. These unspecific measures include physical methods to reduce the spread of respiratory viruses such as hand washing, wearing masks, gloves and gowns (<LINK REF="REF-Jefferson-2009" TYPE="REFERENCE">Jefferson 2009</LINK>). In military populations, reported additional measures to prevent respiratory tract infections include reducing contact between units, reducing crowding, installing cloth barriers between beds, indoor air dilution and ventilation, dust suppression and air sterilisation (<LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK>). Other measures include vitamin and mineral supplementation, such as vitamin A (<LINK REF="REF-Chen-2008a" TYPE="REFERENCE">Chen 2008a</LINK>), vitamin C (<LINK REF="REF-Hemil_x00e4_-2010" TYPE="REFERENCE">Hemilä 2010</LINK>), vitamin D (<LINK REF="REF-Yamshchikov-2009" TYPE="REFERENCE">Yamshchikov 2009</LINK>) and zinc (<LINK REF="REF-Aggarwal-2007" TYPE="REFERENCE">Aggarwal 2007</LINK>). Interventions which stimulate the immune system (immunostimulants) have been proposed as effective measures to reduce ARTIs.</P>
<P>Some years ago, the idea that bacterial lysates, plant extracts or imidazole compounds, could induce unspecific immunity against viruses and distinct bacteria was not very solid. However, the recent discovery of Toll-like-receptors (TLRs) supports the possible mechanism of action of immunostimulants (<LINK REF="REF-Krieg-2003" TYPE="REFERENCE">Krieg 2003</LINK>). TLRs were discovered in the 1990s and their importance on immunity was found later, see <LINK TAG="THEORY" TYPE="SECTION">How the intervention might work</LINK> below. In fact, there is evidence that two bacterial lysates may act on TLR2 (<LINK REF="REF-Alyanakian-2006" TYPE="REFERENCE">Alyanakian 2006</LINK>; <LINK REF="REF-Nikolova-2009" TYPE="REFERENCE">Nikolova 2009</LINK>), as well as levamisole (<LINK REF="REF-Chen-2008b" TYPE="REFERENCE">Chen 2008b</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-09-28 09:46:59 +1000" MODIFIED_BY="[Empty name]">
<P>The main way to prevent ARTI complications is to prevent these infections and administer early antibiotic treatment when bacterial ARTIs are diagnosed (<LINK REF="REF-Heikkinen-1999" TYPE="REFERENCE">Heikkinen 1999</LINK>; <LINK REF="REF-Henderson-1982" TYPE="REFERENCE">Henderson 1982</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Non-specific preventative measures for ARTIs studied in clinical trials include general hygiene methods in children attending daycare centres (<LINK REF="REF-CDCIDSG-1984" TYPE="REFERENCE">CDCIDSG 1984</LINK>); the administration of nutritional supplements such as vitamin A to malnourished children (<LINK REF="REF-Barreto-1994" TYPE="REFERENCE">Barreto 1994</LINK>), vitamin C to normal and malnourished children (<LINK REF="REF-Hemila-1997" TYPE="REFERENCE">Hemila 1997</LINK>; <LINK REF="REF-Jefferson-2001" TYPE="REFERENCE">Jefferson 2001</LINK>) and trace elements to malnourished and susceptible children (<LINK REF="REF-Sazawal-1998" TYPE="REFERENCE">Sazawal 1998</LINK>); preventive antibiotics (<LINK REF="REF-Dajani-1995" TYPE="REFERENCE">Dajani 1995</LINK>); administration of gamma globulins (<LINK REF="REF-Nydahl_x002d_Persson-1995" TYPE="REFERENCE">Nydahl-Persson 1995</LINK>); nasal spray of immunoglobulins (<LINK REF="REF-Heikkinen-1998" TYPE="REFERENCE">Heikkinen 1998</LINK>); herbal extracts (<LINK REF="STD-Grimm-1999" TYPE="STUDY">Grimm 1999</LINK>); xylitol sugar syrup or chewing gum (<LINK REF="REF-Uhari-1998" TYPE="REFERENCE">Uhari 1998</LINK>); and the use of immunostimulants (IS) from different sources. The sources are synthetic (<LINK REF="STD-Passali-1994a" TYPE="STUDY">Passali 1994a</LINK>); thymic extracts or factors (<LINK REF="REF-De-Mattia-1993" TYPE="REFERENCE">De Mattia 1993</LINK>); or of biological origin such as <I>Klebsiella</I> extracts containing lipopolysaccharide (<LINK REF="REF-Dahan-1986" TYPE="REFERENCE">Dahan 1986</LINK>) and mixtures of bacterial extracts (<LINK REF="REF-Berber-1996" TYPE="REFERENCE">Berber 1996</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-04 19:54:00 +1000" MODIFIED_BY="[Empty name]">
<P>The actual mechanism of IS is not yet fully understood. Currently the mechanisms of action are known for only two synthetic IS, tucaresol and imiquimod. The mechanism of tucaresol is to form a complex on the surface of T cells (a Schiff reaction with the amines, probably on CD2). This complex provides an additional stimulant which facilitates the activation of the T cells (a co-stimulatory signal activating the MAPK ERK2 pathway) (<LINK REF="REF-Rhodes-1995" TYPE="REFERENCE">Rhodes 1995</LINK>). Imiquimod and other related molecules activate the immune cells by binding to the receptor for the bacterial products that activate the unspecific defence mechanism and promote the immune response; they bind to the Toll-like receptor 7 (TLR7) activating the MyD88-dependent signalling pathway (<LINK REF="REF-Hemmi-2002" TYPE="REFERENCE">Hemmi 2002</LINK>).</P>
<P>It may be postulated that products with IS properties activate the immune cells using the receptors that recognise common bacterial products or receptors that provide additional stimulation for activation. For instance, Toll-like receptors (TLR) recognise components common to a range of bacteria, so-called pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide, peptidoglycan, lipoteichoic acid, lipoarabinomannan, un-methylated DNA with CpG motif and bacterial lipoproteins which activate the innate immune responses. The innate immune response is responsible for the early mechanisms of defence against infection; for instance the phagocytosis and neutralisation of bacteria entering the body. The mechanisms that enhance the innate immune responses (cytokines and chemokines) also stimulate the adaptive immune response (production of specific antibodies and reproduction of specific T cells) (<LINK REF="REF-Hoffmann-1999" TYPE="REFERENCE">Hoffmann 1999</LINK>; <LINK REF="REF-Schnare-2001" TYPE="REFERENCE">Schnare 2001</LINK>; <LINK REF="REF-Takeuchi-2001" TYPE="REFERENCE">Takeuchi 2001</LINK>). In fact, there is evidence that two bacterial lysates may act on TLR2 (<LINK REF="REF-Alyanakian-2006" TYPE="REFERENCE">Alyanakian 2006</LINK>; <LINK REF="REF-Nikolova-2009" TYPE="REFERENCE">Nikolova 2009</LINK>), as well as levamisole (<LINK REF="REF-Chen-2008b" TYPE="REFERENCE">Chen 2008b</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-11-04 23:44:11 +1000" MODIFIED_BY="[Empty name]">
<P>Most ARTIs are caused by viruses, hundreds of which may cause this type of infection. It would be impractical, therefore, to have a vaccine for each possible pathogenic agent. Therefore, specific immunisation may not be the ultimate solution to prevent ARTIs. The introduction of the pneumococcal conjugate vaccine decreased carriage and invasive infections due to the vaccine serotypes, but it has been replaced by other non-vaccine serotypes that are becoming antibiotic resistance (<LINK REF="REF-Hsu-2009" TYPE="REFERENCE">Hsu 2009</LINK>; <LINK REF="REF-Huang-2009" TYPE="REFERENCE">Huang 2009</LINK>; <LINK REF="REF-Mera-2009" TYPE="REFERENCE">Mera 2009</LINK>).</P>
<P>IS could provide an alternative to vaccines for preventing ARTIs but the efficacy of these medications is controversial (<LINK REF="REF-Collet-1992" TYPE="REFERENCE">Collet 1992</LINK>; <LINK REF="REF-Valleron-1992" TYPE="REFERENCE">Valleron 1992</LINK>). Several bacterial extracts and synthetic compounds are used in Europe and the Americas to prevent ARTIs. However, the evidence of the safety and efficacy of this approach is unclear. A systematic review of immunostimulation for the prevention of ARTIs in children is required to enable a robust appraisal of the current evidence on the safety and efficacy of this approach and to provide clues for the development of new IS.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the safety and efficacy of immunostimulants (IS) administered to children to prevent ARTIs when compared with placebo, in terms of frequency of these infections and reported adverse effects. Trials comparing two IS were also included.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<SELECTION_CRITERIA MODIFIED="2010-11-04 19:55:40 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-11-04 19:55:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing IS, administered by any method, to placebo to prevent ARTIs. Trials referring to interferon inducers, vitamins and nutritional supplements were not included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-04 19:55:23 +1000" MODIFIED_BY="[Empty name]">
<P>Participants younger than 18 years of age. We did not include trials that included participants who suffered from asthma, allergy and atopy, or chronic respiratory diseases.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-04 19:55:35 +1000" MODIFIED_BY="[Empty name]">
<P>The use of an IS administered by any method to prevent ARTIs. Administration of IS could begin in the presence of active ARTI. We considered trials utilising concomitant therapies such as antipyretics or antibiotics for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-04 19:55:40 +1000" MODIFIED_BY="[Empty name]">
<P>A broad definition of ARTI was accepted and included using different specific diagnoses, such as cold, influenza, tonsillitis, pharyngitis, bronchitis and otitis media. Aetiological agents were not studied and no distinction was made between bacterial and viral ARTIs.<I>
<B> </B>
</I>Physician diagnosis of ARTI and adverse events was accepted.<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-09-28 09:51:16 +1000" MODIFIED_BY="[Empty name]">
<P>The number of ARTIs in children suffered during the study period.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-06-09 13:17:57 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>The percentage of ARTIs.</LI>
<LI>The incidence of adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-04-21 12:17:58 +1000" MODIFIED_BY="Liz Dooley">
<ELECTRONIC_SEARCHES MODIFIED="2011-04-21 12:17:43 +1000" MODIFIED_BY="Liz Dooley">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, issue 1, which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to February week 4, 2011), EMBASE (1990 to February 2011), Google Scholar (2009 to February 2011), Scopus (2009 to February 2011), PASCAL (1990 to February 2010), SciSearch (1990 to February 2010) and IPA (1990 to February 2010). Details of the previous searches are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We used the following search strategy to search MEDLINE and CENTRAL. To search MEDLINE, we combined the search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2009" TYPE="REFERENCE">Lefebvre 2009</LINK>). The search strategy was adapted for EMBASE (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). Details of the PASCAL, SciSearch, IPA and previous Embase search are in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1 exp Respiratory Tract Infections/<BR/>2 (respiratory adj5 infection*).tw.<BR/>3 1 or 2<BR/>4 exp Adjuvants, Immunologic/<BR/>5 immunostimulant*.tw,nm.<BR/>6 immunomodulat*.tw,nm.<BR/>7 immunoadjuvant*.tw,nm.<BR/>8 immunologic adjuvant*.tw,nm.<BR/>9 (immunobalt or lw50020 or luivac or paspat or munostin).tw,nm.<BR/>10 (om-85 bv or om85bv or om 85 bv).tw,nm.<BR/>11 (bronchovaxom or broncho-vaxom or broncho vaxom).tw,nm.<BR/>12 (pulmonar-om or pulmonar om).tw,nm.<BR/>13 d53.tw,nm.<BR/>14 (ribomunyl or ribovac or immucytal).tw,nm.<BR/>15 Lipopolysaccharides/<BR/>16 lipopolysaccharide*.tw,nm.<BR/>17 (ru41740 or ru-41740 or ru 41740 or biostim).tw,nm.<BR/>18 Thymus Extracts/<BR/>19 thymus extract*.tw,nm.<BR/>20 (thymic extract* or thymomodulin*).tw,nm.<BR/>21 Pelargonium/<BR/>22 (pelargonium* or umckaloabo).tw,nm.<BR/>23 (am3 or imunoferon or immunoferon or inmunoferon).tw,nm.<BR/>24 glycophosphopep*.tw,nm.<BR/>25 (pidotimod or adimod).tw,nm.<BR/>26 Levamisole/<BR/>27 levamisole.tw,nm.<BR/>28 or/4-27<BR/>29 3 and 28</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-04-21 12:17:58 +1000" MODIFIED_BY="Liz Dooley">
<P>We used identified articles as references for a Science Citation Index search. We searched bibliographies of all included trials as well as those of relevant reviews to identify additional studies. Finally, we sent a letter to all first authors, as well as pharmaceutical companies that manufacture immunostimulant drugs, requesting data and references for any relevant published and unpublished trials. There were no language or publication restrictions. We also searched for studies in the trial registration web site: <I>meta</I>Register of Controlled Trials (<A HREF="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</A>). We searched for IS trial registries in the U.S. National Institutes of Health in <A HREF="http://www.clinicaltrials.gov">http://www.ClinicalTrials.gov</A>.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<STUDY_SELECTION MODIFIED="2010-09-28 10:08:41 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (BN, JSM) independently searched for trials for inclusion and risk of bias assessment. We resolved differences by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<P>We analyzed and managed data using Review Manager (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). Two authors (BN, JSM) independently extracted data. We sought missing data from investigators of individual trials, as necessary, in order to perform analyses on an intention-to-treat (ITT) basis.</P>
<P>Dr Arturo Berber contacted trial authors to request unpublished data. Responses were received from 10 trial authors (<LINK REF="STD-Arroyave-1999" TYPE="STUDY">Arroyave 1999</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-G_x00f3_mez_x002d_Barreto-1998" TYPE="STUDY">Gómez-Barreto 1998</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>; <LINK REF="STD-Karam_x002d_Bechara-1995" TYPE="STUDY">Karam-Bechara 1995</LINK>; <LINK REF="STD-Paupe-1991" TYPE="STUDY">Paupe 1991</LINK>; <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK> (co-worker Vázquez-Ramos); <LINK REF="STD-Schaad-1986" TYPE="STUDY">Schaad 1986</LINK>; <LINK REF="STD-Schaad-2002" TYPE="STUDY">Schaad 2002</LINK>). However, no additional data were provided. A further 11 trial authors were contacted by Dr Berber without response (<LINK REF="STD-Aymard-1994" TYPE="STUDY">Aymard 1994</LINK>; <LINK REF="STD-Careddu-1994a" TYPE="STUDY">Careddu 1994a</LINK>; <LINK REF="STD-Careddu-1994b" TYPE="STUDY">Careddu 1994b</LINK>; <LINK REF="STD-Fiocchi-1986" TYPE="STUDY">Fiocchi 1986</LINK>; <LINK REF="STD-Fiocchi-1988" TYPE="STUDY">Fiocchi 1988</LINK>; <LINK REF="STD-Fiocchi-1989" TYPE="STUDY">Fiocchi 1989</LINK>; <LINK REF="STD-Fiocchi-1990" TYPE="STUDY">Fiocchi 1990</LINK>; <LINK REF="STD-Motta-1994" TYPE="STUDY">Motta 1994</LINK>; <LINK REF="STD-Paupe-1986" TYPE="STUDY">Paupe 1986</LINK>; <LINK REF="STD-Rutishauser-1998" TYPE="STUDY">Rutishauser 1998</LINK> (co-worker Grevers); <LINK REF="REF-Valleron-1992" TYPE="REFERENCE">Valleron 1992</LINK>). Dr. Arturo Berber provided the database for OM-85 trials from Mexico. In 2010, we made attempts to contact the following authors: Joseph Bellanti, Jean Bousquet, Herman A. Cohen, Craig I Coleman, Jean Paul Collet, Alessandro Fiocchi, Sergio Marcassa,<I> </I>Renzo Mora, RJ Riedl-Seifert, Urs B. Schaad, Draganka Stankulova, Claudia Steurer-Stey and James A. Taylor, and manufacturers Luipold (luivac), OM Pharma (broncho-vaxom), Pierre Fabre (ribomunyl) and Polichem (adimod). Only Sergio Marcassa,<I> </I>Renzo Mora, RJ Riedl-Seifert, Urs B. Schaad (by himself and in name of OM Pharma) replied; no information regarding new studies was obtained.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-04-21 12:16:49 +1000" MODIFIED_BY="Liz Dooley">
<P>We measured trial quality using seven domains.</P>
<OL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding (performance bias and detection bias).</LI>
<LI>Blinding of participants and personnel (performance bias).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Selective reporting (reporting bias).</LI>
</OL>
<P>We assigned a quality rating for above domains for each included trial using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) as high risk, low risk or uncertain risk . <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows the results of risk of bias assessment for the seven domains.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-04 20:00:03 +1000" MODIFIED_BY="[Empty name]">
<P>We reported the mean differences (MD) (and 95% confidence intervals (CI)) for the meta-analysis of data measured on a continuous scale. We assessed heterogeneity by visual inspection of the outcomes tables and by using two statistics of heterogeneity (H and I<SUP>2</SUP> statistic) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Due to the observed statistical heterogeneity, we used the random-effects model.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-09-16 11:17:43 +1000" MODIFIED_BY="[Empty name]">
<P>Regarding the trials with a description of randomisation and allocation, the unit of randomisation was the individual subject (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-11-04 20:00:11 +1000" MODIFIED_BY="[Empty name]">
<P>The studies only analyse the available data, ignoring the missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-10-05 09:59:48 +1000" MODIFIED_BY="[Empty name]">
<P>The way in which the outcomes were reported varied widely across the trials. We decided to use the mean number of ARTIs and its standard deviation (SD) as the outcome as it allows the use of parametric statistical methods that provide more power to the tests. We assumed that the number of ARTIs in the IS-treated group would be comparable to the number of ARTIs in the placebo group; and both of these would depend on the susceptibility of the children (determined by age, duration of trial and seasons of the year during the trial). Consequently we expected to have heterogeneity in the mean number of ARTIs. Therefore, we decided to standardise the results using the percentage of infections considering the mean number of infections in the placebo group as 100%.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-18 07:40:48 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed publication bias using a funnel plot (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). The results indicated possible publication bias. The funnel plot for the number of ARTIs was asymmetrical with a large base skewed to the left and narrower distribution at the top; the funnel plot for the percentage of ARTIs was more symmetrical but the most of the points were on the left side. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> are funnel plots showing the differences in the number of ARTIs and the percentage of ARTIs.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-11-04 20:00:35 +1000" MODIFIED_BY="[Empty name]">
<P>Due to the heterogeneity of the results we selected the random-effects model of meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-04 20:00:47 +1000" MODIFIED_BY="[Empty name]">
<P>We also conducted bivariate correlation as well as linear regression and sensitivity analyses of subgroups to investigate the sources of statistical heterogeneity (please refer to <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> section).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-11-04 20:00:59 +1000" MODIFIED_BY="[Empty name]">
<P>To determine whether conclusions were robust, we performed analyses of different set of studies as follows: any IS; bacterial IS; bacterial IS trials with the total sample size of equal to or greater than 40; bacterial IS trials with total sample size equal to or greater than 40 including only OM-85 and BV D53 and OM-85 alone and D53 alone.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<STUDY_DESCRIPTION MODIFIED="2011-04-18 07:31:29 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-11-04 20:01:12 +1000" MODIFIED_BY="[Empty name]">
<P>The electronic search produced 764 references. No other potentially eligible studies were found as a result of contact with the trial authors or searching of trial registries. Of the references obtained, we identified 93 studies as potentially eligible.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-04-18 07:31:29 +1000" MODIFIED_BY="[Empty name]">
<P>We included 61 placebo-controlled clinical trials involving 4149 participants. The studies were very heterogenous in the interventions studied, the number of ARTIs in the placebo groups and in the reporting of outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="4">Population</HEADING>
<P>The participants enrolled in the included trials were children ranging from six months to 18 years of age. The echinacea trials differed in the selection criteria of participants as they used children without a significant health problem and without a history of recurrent ARTI. The remainder of the trials included a history of recurrent ARTIs in the inclusion criteria. All the trials were conducted in the Northern (boreal) hemisphere except Fukuda's (<LINK REF="STD-Fukuda-1999" TYPE="STUDY">Fukuda 1999</LINK>). Fall and winter seasons referred to the months from September to January. The year of the trial was not specified in most of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Forty studies used bacterial products, four studies used herbal extracts (echinacea and garlic), 11 studies used synthetic compounds, five studies used thymic extracts (thymomodulin) and one study used a synthetic interferon. All trials used a placebo control. The common names of the medications are in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Twenty-two studies had a duration shorter than six months, 33 studies had a duration of six months and only six studies had a duration longer than six months. The duration of seven D53 trials was less than six months and nine D53 trials had a duration of six months. In all D53 trials the description of the methodology was not clear and different routes of administration were used (nasal spray or by mouth). Ten OM-85 BV trials lasted six months; two trials had a duration of longer than six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Only 35 of the 61 included studies reported the mean and SD of the incidence of respiratory infections or provided data to calculate these measure, allowing their inclusion in the meta-analysis (<LINK REF="STD-Ahrens-1984" TYPE="STUDY">Ahrens 1984</LINK>; <LINK REF="STD-Arroyave-1999" TYPE="STUDY">Arroyave 1999</LINK>; <LINK REF="STD-Careddu-1994a" TYPE="STUDY">Careddu 1994a</LINK>; <LINK REF="STD-Clerici-1988" TYPE="STUDY">Clerici 1988</LINK>; <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-De-Loore-1979" TYPE="STUDY">De Loore 1979</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Fiocchi-1986" TYPE="STUDY">Fiocchi 1986</LINK>; <LINK REF="STD-Garabedian-1990" TYPE="STUDY">Garabedian 1990</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="STD-G_x00f3_mez_x002d_Barreto-1998" TYPE="STUDY">Gómez-Barreto 1998</LINK>; <LINK REF="STD-Hauguenauer-1987" TYPE="STUDY">Hauguenauer 1987</LINK>; <LINK REF="STD-H_x00fc_ls-1995" TYPE="STUDY">Hüls 1995</LINK>; <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>; <LINK REF="STD-Karam_x002d_Bechara-1995" TYPE="STUDY">Karam-Bechara 1995</LINK>; <LINK REF="STD-Lacomme-1985" TYPE="STUDY">Lacomme 1985</LINK>; <LINK REF="STD-Litzman-1999" TYPE="STUDY">Litzman 1999</LINK>; <LINK REF="STD-Maestroni-1984" TYPE="STUDY">Maestroni 1984</LINK>; <LINK REF="STD-Motta-1994" TYPE="STUDY">Motta 1994</LINK>; <LINK REF="STD-Paupe-1986" TYPE="STUDY">Paupe 1986</LINK>; <LINK REF="STD-Pech-1987" TYPE="STUDY">Pech 1987</LINK>; <LINK REF="STD-Piquett-1986" TYPE="STUDY">Piquett 1986</LINK>; <LINK REF="STD-RB10-1994" TYPE="STUDY">RB10 1994</LINK>; <LINK REF="STD-RB17-1988" TYPE="STUDY">RB17 1988</LINK>; <LINK REF="STD-RB21-1988" TYPE="STUDY">RB21 1988</LINK>; <LINK REF="STD-RB22-1990" TYPE="STUDY">RB22 1990</LINK>; <LINK REF="STD-RB24-1990" TYPE="STUDY">RB24 1990</LINK>; <LINK REF="STD-RB25-1990" TYPE="STUDY">RB25 1990</LINK>; <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK>; <LINK REF="STD-Schaad-1986" TYPE="STUDY">Schaad 1986</LINK>; <LINK REF="STD-Schaad-2002" TYPE="STUDY">Schaad 2002</LINK>; <LINK REF="STD-Van-Eygen-1976" TYPE="STUDY">Van Eygen 1976</LINK>; <LINK REF="STD-Van-Eygen-1979" TYPE="STUDY">Van Eygen 1979</LINK>; <LINK REF="STD-Vautel-1993" TYPE="STUDY">Vautel 1993</LINK>; <LINK REF="STD-Zagar-1988" TYPE="STUDY">Zagar 1988</LINK>). In these studies the ARTIs were defined by the presence of respiratory signs and symptoms.</P>
<P>The remaining 24 studies reported a variety of end points: symptoms, clinical scales or presence or absence of respiratory infections. Some trials reported the frequency of ARTIs as either equal to or more than one infection (<LINK REF="STD-Burgio-1994" TYPE="STUDY">Burgio 1994</LINK>; <LINK REF="STD-Careddu-1994b" TYPE="STUDY">Careddu 1994b</LINK>; <LINK REF="STD-Fukuda-1999" TYPE="STUDY">Fukuda 1999</LINK>; <LINK REF="STD-Mora-2010a" TYPE="STUDY">Mora 2010a</LINK>; <LINK REF="STD-Paupe-1991" TYPE="STUDY">Paupe 1991</LINK>; <LINK REF="STD-Rutishauser-1998" TYPE="STUDY">Rutishauser 1998</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>; <LINK REF="STD-Wahl-2008" TYPE="STUDY">Wahl 2008</LINK>); equal to or more than two infections (<LINK REF="STD-Mora-2007" TYPE="STUDY">Mora 2007</LINK>); equal to or more than three infections (<LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>); the total number of ARTIs; mean number of ARTIs (<LINK REF="STD-Caramia-1994" TYPE="STUDY">Caramia 1994</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-Dils-1979" TYPE="STUDY">Dils 1979</LINK>; <LINK REF="STD-Fiocchi-1988" TYPE="STUDY">Fiocchi 1988</LINK>; <LINK REF="STD-Longo-1988" TYPE="STUDY">Longo 1988</LINK>; <LINK REF="REF-Passali-1994" TYPE="REFERENCE">Passali 1994</LINK>; <LINK REF="STD-Pozzi-2004" TYPE="STUDY">Pozzi 2004</LINK>; <LINK REF="STD-Riedl_x002d_Seifert-1995" TYPE="STUDY">Riedl-Seifert 1995</LINK>; <LINK REF="STD-Sramek-1986" TYPE="STUDY">Sramek 1986</LINK>); or reduction in the number of ARTIs (Andrianova 2003; <LINK REF="STD-Iuldashev-1988" TYPE="STUDY">Iuldashev 1988</LINK>). Others measured the severity of symptoms using clinical scales that were not validated (<LINK REF="STD-Fiocchi-1989" TYPE="STUDY">Fiocchi 1989</LINK>; <LINK REF="STD-Giovannini-2000" TYPE="STUDY">Giovannini 2000</LINK>; <LINK REF="STD-Mora-2002" TYPE="STUDY">Mora 2002</LINK>; <LINK REF="STD-Renzo-2004" TYPE="STUDY">Renzo 2004</LINK>) or as days suffering symptoms (<LINK REF="STD-Martin-du-Pan-1982" TYPE="STUDY">Martin du Pan 1982</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-03-07 12:51:12 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded 36 studies: 32 did not comply with the selection criteria; two compared several IS treatments without a placebo group; and two were duplicate reports of trials already included. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<P>The description of the methodology was not clear in most of the studies. Only 17.1% (6 out of 35) studies reported adequate randomisation and blinding (participants and treating physicians were blinded) (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Using the quality rating criteria (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), the quality of the rest of the trials (28 out of 34 (82.4%)) was B; randomisation and follow through of participants was unclear. See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a description of the quality of the trials.</P>
<P>Only 17.1% (6 out of 35) studies reported on the number of participants lost to follow up (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>). Of these, five studies reported losses. While losses were minimal, 0.5% to 7% in three studies, two studies reported a loss of 18% and 24%. As additional data were not obtained from the investigators on the outcomes of participants who were lost to follow up an intention-to-treat (ITT) analysis could not be undertaken. The numbers lost to follow up are explained in further detail.</P>
<P>In the <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> trial, 160 out of 215 in the IS group completed the trial (27 dropped out because the medication had an unpleasant taste, 24 due to non-compliance which was not fully explained, four dropped out due to a lack of confidence in the treatment); and 168 out of 215 of the placebo group completed the trial (22 dropped out because the placebo had an unpleasant taste, 21 due to non-compliance which was not fully explained, and one dropped out due to a lack of confidence in the treatment). A total of 24% were lost to follow up.</P>
<P>In the <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK> trial, 20 out of 25 in the IS group completed the trial. Five children were lost to follow up. Twenty out of 24 in the placebo group completed the trial. Two children were lost to follow up (the parents of one participant withdrew consent for their child to continue in the trial and one left because the trial medication caused the child to have diarrhea). A total of 18% were lost to follow up.</P>
<P>In the <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK> trial, 199 out of 210 in the IS group and 196 out of 213 placebo group completed the trial. For both groups, the 28 lost to follow up were related either to the parents moving to a different location or the mothers stopped working and no longer took their children to the daycare centres where the trials were being held. A total of 7% were lost to follow up.</P>
<P>In the <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK> trial, 242 out of 263 in the IS group completed the trial (six withdrew before the first ARTI, five changed their minds about participating, one never received the study medication, five withdrew during the first ARTI, three refused the study medication, one was concerned about the effect on their immune system, for one the protocol was too complicated, six log books were never received, four were lost to follow up); 244 out of 261 in the placebo group completed the trial (three withdrew before the first ARTI, two changed their minds about participating, one was excluded for taking another medication, one withdrew during the first ARTI, nine log books were never received and four were lost to follow up). A total of 7% were lost to follow up.</P>
<P>In the <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK> trial, 99 out of 100 in the IS group completed the trial. The case report from one child was lost. One hundred out of 100 in the placebo group completed the trial. A total of 0.5% were lost to follow up.</P>
<P>In the <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK> trial, outcomes were reported for all enrolled children. All the participants completed the trial.</P>
<P>The outcome assessor was blinded to the treatment allocation in 8.8% (three out of 34) of the studies (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>). Only 14.7% (five out of 34) of studies (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>) were considered of quality A (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The rest of the studies were of poor quality.</P>
<ALLOCATION MODIFIED="2011-04-18 07:40:48 +1000" MODIFIED_BY="[Empty name]">
<P>In the studies with a proper description of randomisation and allocation (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>), the implementation of the random sequence of the treatments was reported. In <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> active medication and the placebo were supplied directly by the manufacturer and all randomisation lots were stored in a sealed envelope at the pharmacy of the company, to be opened only in the event of an emergency. In <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK> participants were allocated to IS or placebo according to a program for remote data entry (Minitel a national telecommunication system network in France). Additionally, randomisation was also stratified by study centre and blocked for every four children. In the studies by <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK> and <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK> consecutive numbered study medication boxes, as well as a closed opaque envelope describing the treatment, were supplied directly by the manufacturer; participants received a patient number coincident with treatment number when the selection criteria were completed. In the <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK> study consecutive numbered study medication boxes, as well as a closed opaque envelope describing the treatment, were supplied directly by the manufacturer; participants received a patient number corresponding a treatment according to an alphabetical name list. In <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>, each study centre had a supply of study medication (active medication and placebo) in consecutively numbered bottles that were identical in appearance, contents of each bottle were randomly determined using a computer-generated randomisation list, and randomisation was stratified by site and in blocks of 10. Enrolled children were assigned a unique study number corresponding to the numbers on the bottles of study medication. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the review authors' judgement of the risk of bias related to allocation concealment presented as percentages across all included studies and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>shows the risk for each included study.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-06-09 13:59:16 +1000" MODIFIED_BY="Liz Dooley">
<P>Six studies (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>) claimed that IS and placebo treatment had identical appearance and that the taste of both were similar. Investigators and participants were not aware of the received treatment.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-11-04 20:10:58 +1000" MODIFIED_BY="[Empty name]">
<P>Only six studies (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>) reported the number of patients lost to follow up. All used only the available data for the analyses. No imputation for the incomplete data were intended.</P>
<P>
<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> had a total of 24% lost to follow up; the frequencies and causes of it were similar in active and placebo groups. In the <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK> trial 18% of participants were lost to follow up; more children in the active group were lost (5/25 in active group versus 2/25 in the placebo group). In the <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK> trial, 7% of participants were lost to follow up; in both groups the rates and the reasons were similar. In the <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK> trial, 7% of participants were lost to follow up; in both groups the rates and the reasons were similar. In the <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK> trial only the data of one participant on IS was lost. In the <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK> trial, all the participants completed the trial.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<P>The study protocols were not available. Sixty-one randomized, placebo-controlled clinical trials were identified. Only 35 studies reported the mean and SD of the incidence of respiratory infections or provided data to calculate these measure (<LINK REF="STD-Ahrens-1984" TYPE="STUDY">Ahrens 1984</LINK>; <LINK REF="STD-Arroyave-1999" TYPE="STUDY">Arroyave 1999</LINK>; <LINK REF="STD-Careddu-1994a" TYPE="STUDY">Careddu 1994a</LINK>; <LINK REF="STD-Clerici-1988" TYPE="STUDY">Clerici 1988</LINK>; <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-De-Loore-1979" TYPE="STUDY">De Loore 1979</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Fiocchi-1986" TYPE="STUDY">Fiocchi 1986</LINK>; <LINK REF="STD-Garabedian-1990" TYPE="STUDY">Garabedian 1990</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="STD-G_x00f3_mez_x002d_Barreto-1998" TYPE="STUDY">Gómez-Barreto 1998</LINK>; <LINK REF="STD-Hauguenauer-1987" TYPE="STUDY">Hauguenauer 1987</LINK>; <LINK REF="STD-H_x00fc_ls-1995" TYPE="STUDY">Hüls 1995</LINK>; <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>; <LINK REF="STD-Karam_x002d_Bechara-1995" TYPE="STUDY">Karam-Bechara 1995</LINK>; <LINK REF="STD-Lacomme-1985" TYPE="STUDY">Lacomme 1985</LINK>; <LINK REF="STD-Litzman-1999" TYPE="STUDY">Litzman 1999</LINK>; <LINK REF="STD-Maestroni-1984" TYPE="STUDY">Maestroni 1984</LINK>; <LINK REF="STD-Motta-1994" TYPE="STUDY">Motta 1994</LINK>; <LINK REF="STD-Paupe-1986" TYPE="STUDY">Paupe 1986</LINK>; <LINK REF="STD-Pech-1987" TYPE="STUDY">Pech 1987</LINK>; <LINK REF="STD-Piquett-1986" TYPE="STUDY">Piquett 1986</LINK>; <LINK REF="STD-RB10-1994" TYPE="STUDY">RB10 1994</LINK>; <LINK REF="STD-RB17-1988" TYPE="STUDY">RB17 1988</LINK>; <LINK REF="STD-RB21-1988" TYPE="STUDY">RB21 1988</LINK>; <LINK REF="STD-RB22-1990" TYPE="STUDY">RB22 1990</LINK>; <LINK REF="STD-RB24-1990" TYPE="STUDY">RB24 1990</LINK>; <LINK REF="STD-RB25-1990" TYPE="STUDY">RB25 1990</LINK>; <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK>; <LINK REF="STD-Schaad-1986" TYPE="STUDY">Schaad 1986</LINK>; <LINK REF="STD-Schaad-2002" TYPE="STUDY">Schaad 2002</LINK>; <LINK REF="STD-Van-Eygen-1976" TYPE="STUDY">Van Eygen 1976</LINK>; <LINK REF="STD-Van-Eygen-1979" TYPE="STUDY">Van Eygen 1979</LINK>; <LINK REF="STD-Vautel-1993" TYPE="STUDY">Vautel 1993</LINK>; <LINK REF="STD-Zagar-1988" TYPE="STUDY">Zagar 1988</LINK>). Seven trials reported the frequency of ARTIs (<LINK REF="STD-Burgio-1994" TYPE="STUDY">Burgio 1994</LINK>; <LINK REF="STD-Careddu-1994b" TYPE="STUDY">Careddu 1994b</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Fukuda-1999" TYPE="STUDY">Fukuda 1999</LINK>; <LINK REF="STD-Paupe-1991" TYPE="STUDY">Paupe 1991</LINK>; <LINK REF="STD-Rutishauser-1998" TYPE="STUDY">Rutishauser 1998</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>). The rest of the studies did not use outcome measures relevant to the prevention of respiratory infections.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-12-21 11:22:10 +1000" MODIFIED_BY="[Empty name]">
<P>In 29 out of the 35 included studies, the process of randomisation and allocation was not described. Additionally, the disposition of participants and reasons for withdrawals were not reported.</P>
<P>Funnel plots of IS effects have a considerable asymmetry, indicating possible publication bias, i.e. publishing only positive results (see <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>). Language bias is also possible (publication in languages other than English and publication in non-indexed, small, local journals).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<SUBSECTION>
<HEADING LEVEL="3">Effect of immunostimulants (IS) on acute respiratory tract infections (ARTIs)</HEADING>
<P>Of the 61 included studies only 35 provided data in a form suitable for inclusion in the meta-analysis for this outcome. All 35 trials compared IS with a placebo.</P>
<P>Twenty-four out of 35 studies showed a reduction of ARTIs, both as total numbers and as a percentage reduction of ARTIs (considering the mean number of ARTIs in the placebo group as 100%). In the meta-analysis the use of IS was shown to reduce the total number of ARTIs (mean difference (MD) -1.24 95% CI -1.54 to -0.94) as well as producing a percentage change in the rate of ARTIs (MD -38.84%; 95% CI -46.37% to -31.31%). The total number of ARTIs outcome showed high heterogeneity (I<SUP>2</SUP> statistic = 94.0%, Chi<SUP>2</SUP> test = 582.02, P &lt; 0.00001); the use of percentage change in the rate of ARTIs reduced the heterogeneity but it remained very high (I<SUP>2</SUP> statistic = 83.0%, Chi<SUP>2</SUP> test = 195.07, P &lt; 0.00001). Therefore, we decided to use the random-effects model with MD to calculate the global effect of immunostimulants (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>We investigated heterogeneity by bivariate correlation as well as by linear regression. The variables considered were total number of children in the study, duration of the trial, mean number of ARTIs in the control group versus the mean difference in number of ARTIs and mean difference in the percentage of ARTIs. The main source of heterogeneity was the mean number of ARTIs in the control group, using the mean difference in number of ARTIs (linear regression model correlation - 0.672, P &lt; 0.001). Using the mean difference in the percentage of ARTIs, the source of heterogeneity was related to the mean difference in the number of ARTIs and mean number of ARTIs in the control group (linear regression model correlation 0.834, P &lt; 0.001). The age of the participants in each trial could be another important source of variation in the number of ARTIs, as younger children would suffer more ARTIs. Yet the age in each trial was diverse, including enrolled preschool children, school-aged children and adolescents. This made the exploration of this potential source of variation problematic. In general, the net reduction in the number of ARTIs was dependent on the background rate of ARTIs.</P>
<P>Another potential source of heterogeneity was the type of IS. We decided to investigate this source of heterogeneity by performing sub-analyses as follows.</P>
<OL>
<LI>Including the bacterial IS studies data (and excluding the <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK> trial because it was the only trial with more ARTIs in the IS group than in the placebo group, probably due to a clerical mistake inverting ARTI incidences). The number of trials was 24; total number of participants was 2154, the number of IS participants was 1091 and the number of placebo participants was 1063. The reduction in the total number of ARTIs was MD -1.41 (95% CI -1.85 to -0.98); the reduction in the number of ARTIs as a percentage was MD -41.21 (95% CI -49.10 to -33.31).</LI>
<LI>Only bacterial IS studies data (excluding <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK>) with a total number of participants of at least 40. The number of trials was 19; the total number of participants was 2009, the number of IS participants was 1019 and the number of placebo participants was 990. The reduction in the total number of ARTIs was MD -1.42 (95% CI -1.92 to -0.93); and the reduction in the number of ARTIs as a percentage was MD -38.44 (95% CI -47.25 to -29.63).</LI>
<LI>Only bacterial IS studies where the total number of participants was more than 40 (including D53 and OM-85 BV). The number of trials was 16; the total number of participants was 1811, the number of IS participants was 921 and the number of placebo participants was 890. The reduction in the total number of ARTIs was MD -1.17 (95% CI -1.56 to -0.78); and the reduction in the number of ARTIs as a percentage was MD -36.16 (95% CI -44.51 to -27.80).</LI>
<LI>Only OM-85 studies. The number of trials was nine; total number of participants was 852, the number of IS participants was 437 and the number of placebo participants was 415. The reduction in the total number of ARTIs was MD -1.20 (95% CI -1.75 to -0.66) and the reduction in the number of ARTIs as a percentage was MD -35.90 (95% CI -49.46 to -22.35) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</LI>
<LI>Only D53 studies. The number of trials was 11; total number of participants was 852, the number of IS participants was 437 and the number of placebo participants was 415. The reduction in the total number of ARTIs was MD -1.32 (95% CI -1.86 to -0.79); and the reduction in the number of ARTIs as a percentage was MD -43.47 (95% CI -53.22 to -33.72) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</LI>
</OL>
<P>We did not perform the sub-analyses for good quality trials as only two out of five trials provided data as mean and SD (<LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>). The selection of bacterial IS studies reduced the heterogeneity of the percentage difference outcome from very high (I<SUP>2</SUP> statistic &gt; 75) to moderate (I<SUP>2</SUP> statistic &lt; 75) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). However, the percentage differences and 95% CI in the total number of ARTIs were similar to the overall analysis for all sub-analyses. The reduction of the I<SUP>2</SUP> statistic when only the bacterial IS were analyzed confirmed that the different kinds of IS were another major source of heterogeneity. The combined analysis of percentage difference outcome of D53 and OM-85 had an I<SUP>2</SUP> statistic of 65%; D53 alone 55%; OM-85 alone 75%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Twenty studies provided data on adverse events in a form suitable for inclusion in the meta-analysis. The most frequent events were skin and gastrointestinal effects (nausea, vomiting, abdominal pain and diarrhea). No statistically significant difference was shown in these adverse events when comparing IS with a placebo. A summary of the reported safety data for each trial is noted in the outcome section of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. In 22 studies, authors did not report the presence or absence of adverse events (<LINK REF="STD-Andrianova--2003" TYPE="STUDY">Andrianova 2003</LINK>; <LINK REF="STD-B_x00e1_novein-1992" TYPE="STUDY">Bánovein 1992</LINK>; <LINK REF="STD-Clerici-1988" TYPE="STUDY">Clerici 1988</LINK>; <LINK REF="STD-Fiocchi-1986" TYPE="STUDY">Fiocchi 1986</LINK>; <LINK REF="STD-Fiocchi-1988" TYPE="STUDY">Fiocchi 1988</LINK>; <LINK REF="STD-Garabedian-1990" TYPE="STUDY">Garabedian 1990</LINK>; <LINK REF="STD-Giovannini-2000" TYPE="STUDY">Giovannini 2000</LINK>; <LINK REF="STD-Hauguenauer-1987" TYPE="STUDY">Hauguenauer 1987</LINK>; <LINK REF="STD-Iuldashev-1988" TYPE="STUDY">Iuldashev 1988</LINK>; <LINK REF="STD-Longo-1988" TYPE="STUDY">Longo 1988</LINK>; <LINK REF="STD-Maestroni-1984" TYPE="STUDY">Maestroni 1984</LINK>; <LINK REF="STD-Martin-du-Pan-1982" TYPE="STUDY">Martin du Pan 1982</LINK>; <LINK REF="STD-Piquett-1986" TYPE="STUDY">Piquett 1986</LINK>; <LINK REF="STD-Prusek-1987" TYPE="STUDY">Prusek 1987</LINK>; <LINK REF="STD-RB10-1994" TYPE="STUDY">RB10 1994</LINK>; <LINK REF="STD-RB17-1988" TYPE="STUDY">RB17 1988</LINK>; <LINK REF="STD-RB21-1988" TYPE="STUDY">RB21 1988</LINK>; <LINK REF="STD-RB22-1990" TYPE="STUDY">RB22 1990</LINK>; <LINK REF="STD-RB24-1990" TYPE="STUDY">RB24 1990</LINK>; <LINK REF="STD-RB25-1990" TYPE="STUDY">RB25 1990</LINK>; <LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK>; <LINK REF="STD-Sramek-1986" TYPE="STUDY">Sramek 1986</LINK>). In eight studies, trial authors claimed that no adverse event were observed (<LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-De-Loore-1979" TYPE="STUDY">De Loore 1979</LINK>; <LINK REF="STD-Dils-1979" TYPE="STUDY">Dils 1979</LINK>; <LINK REF="STD-Karam_x002d_Bechara-1995" TYPE="STUDY">Karam-Bechara 1995</LINK>; <LINK REF="STD-Mora-2007" TYPE="STUDY">Mora 2007</LINK> <LINK REF="STD-Renzo-2004" TYPE="STUDY">Renzo 2004</LINK>; <LINK REF="STD-Van-Eygen-1976" TYPE="STUDY">Van Eygen 1976</LINK>; <LINK REF="STD-Zagar-1988" TYPE="STUDY">Zagar 1988</LINK>). In four studies no adverse events were observed in the immunostimulant group (<LINK REF="STD-Burgio-1994" TYPE="STUDY">Burgio 1994</LINK>; <LINK REF="STD-Fiocchi-1989" TYPE="STUDY">Fiocchi 1989</LINK>; <LINK REF="STD-Lacomme-1985" TYPE="STUDY">Lacomme 1985</LINK>; <LINK REF="STD-Schaad-1986" TYPE="STUDY">Schaad 1986</LINK>). Five studies reported a single case of adverse events in the IS group (<LINK REF="STD-Fukuda-1999" TYPE="STUDY">Fukuda 1999</LINK>; <LINK REF="STD-G_x00f3_mez_x002d_Barreto-1998" TYPE="STUDY">Gómez-Barreto 1998</LINK>; <LINK REF="STD-Paupe-1986" TYPE="STUDY">Paupe 1986</LINK>; <LINK REF="STD-Paupe-1991" TYPE="STUDY">Paupe 1991</LINK>; <LINK REF="STD-Van-Eygen-1979" TYPE="STUDY">Van Eygen 1979</LINK>). One study reported only two adverse events (<LINK REF="STD-Wahl-2008" TYPE="STUDY">Wahl 2008</LINK>). In three studies no adverse events related to administration of the trial medications were reported (<LINK REF="STD-Arroyave-1999" TYPE="STUDY">Arroyave 1999</LINK>; <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>; <LINK REF="STD-Mora-2010a" TYPE="STUDY">Mora 2010a</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<SUMMARY_OF_RESULTS MODIFIED="2011-04-21 12:17:59 +1000" MODIFIED_BY="Liz Dooley">
<P>This review shows that IS reduce the incidence of ARTIs by about 40% on average (from 35 trials with a total of 4060 participants). However, due to the poor quality of the included trials this may be an overestimate of the true effect of IS. Most of the trials reported a low incidence of adverse events or no adverse events. The most frequent adverse events were gastrointestinal complaints such as nausea, vomiting, abdominal pain and diarrhea; and skin disorders such as rash, urticaria and pruritus.</P>
<P>The possible beneficial effects of immunostimulants in the prevention of ARTIs, cancers, AIDS/HIV infections, tuberculosis etc. have been awaited expectantly by many clinicians and medical researchers. One of the main indications of registered IS is the prevention of ARTIs in children, as they are more susceptible to ARTIs. IS use is common in some countries in Europe and in the Americas as result of the demand to reduce the incidence of ARTIs in children.</P>
<P>While the use of IS is currently controversial and is viewed with skepticism by many physicians, there have been several clinical trials supporting their use as ancillary treatment and in the prevention of ARTIs. Yet their mechanism of action and possible benefits and risks are not well known. The aim of this review was to synthesise all the evidence currently available from trials on this topic to enable a more robust, unbiased assessment of the role of efficacy and safety of IS to prevent ARTIs in children.</P>
<P>After reviewing all available IS studies on the prevention of ARTIs in children, we empathise with the skepticism of many physicians. This review has a number of limitations due to the quality and reporting of the trials on this topic, the heterogeneity of the included trials and the possibility of publication bias. Few papers complied with standards for methodological quality and reporting of clinical trials, with the majority having significant deviations from these standards. In addition, the lack of detail in many of the trial publications limited the quality of this review.</P>
<P>The most common problems with the included trials were that they:</P>
<UL>
<LI>did not report data on ARTIs sufficient to reproduce parametric and non-parametric statistical tests or carry out meta-analysis;</LI>
<LI>did not establish the normal incidence of ARTIs in the local population and the number of infections in susceptible children, therefore, endpoint changes were not properly established;</LI>
<LI>did not identify the possible causes of recurrent ARTIs;</LI>
<LI>did not try to isolate or identify the causative pathogen;</LI>
<LI>did not calculate the sample size required;</LI>
<LI>used small sample sizes;</LI>
<LI>did not include a clinical definition of ARTI and other end points or used non validated scales;</LI>
<LI>misused statistical tests, especially the use of Student's t test for data under suspicion of non-normal distribution (SD &gt; mean/2 or mean - SD &lt; 0);</LI>
<LI>under reported adverse events or did not report them at all;</LI>
<LI>did not report the power of the statistical tests in trials without significant difference;</LI>
<LI>did not report or explain the flow chart and attrition of the participants and the statistical methods did not consider the data from missing participants (censored data);</LI>
<LI>published articles in low impact journals;</LI>
<LI>included heterogeneous groups of children comprising infants, toddlers, schoolboys and girls and adolescents without considering the incidence of ARTIs in each group;</LI>
<LI>did not control for or report on confounding factors (that is to say, age groups, concomitant asthma or allergy, number of siblings, smokers at home, birth weight, seasons during the study, time and timing of attendance at daycare centre or school).</LI>
<LI>did not report the quality and standardisation of the herbal supplements (<LINK REF="REF-Wolsko-2005" TYPE="REFERENCE">Wolsko 2005</LINK>) and bacterial extracts.</LI>
</UL>
<P>All the trials were conducted in populations of highly susceptible children (secondary prevention) except <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK> and <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>, which studied children over-exposed to ARTIs due to the fact that they attended daycare centres and an orphanage, respectively, and <LINK REF="STD-Martin-du-Pan-1982" TYPE="STUDY">Martin du Pan 1982</LINK> which included a subgroup from daycare centres. In contrast, the echinacea trials were carried out in populations without a history of recurrent ARTIs (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>).</P>
<P>The lack of significance of the findings of some trials could be ascribed to small sample size, duration of the intervention, season of intervention, broad participant selection criteria (mainly diverse age groups) and low incidence of ARTIs in the studied population (caused by an over-reporting of previous ARTIs or reduction of incidence as children grew older).</P>
<P>Thymic extracts have been withdrawn from sale in several countries, due to the possible prion contamination and consequent risk of bovine spongiform encephalopathy (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). The use of levamisole is restricted because of the risk of agranulocytosis, neurologic disease (<LINK REF="REF-Symoens-1978" TYPE="REFERENCE">Symoens 1978</LINK>) and leukoencephalopathy (<LINK REF="REF-Xu-2009" TYPE="REFERENCE">Xu 2009</LINK>).</P>
<P>The overall effect of IS was a reduction in the total number of ARTIs (MD -1.24; 95% CI -1.54 to -0.94) but the individual size of the effect in each trial depended on the number of ARTIs in the control group. The size of the effect could seem small but expressing the reduction of ARTIs as a percentage indicates a good effect, about 40% (MD -38.84%; 95% CI -46.37 to -31.31). The results indicate that the reduction in the incidence of ARTIs is a real possibility but as the net effect depends on the background rate of ARTIs the effect would only be noticeable when the number of infections to be reduced is higher than the normal incidence for a given age group. Therefore, the use of IS for the prevention of ARTIs must be limited to children with proven high susceptibility to ARTIs or over-exposed children who are over-exposed to ARTIs because they are in daycare centres, orphanages, kindergarten or elementary school.</P>
<P>Sub-analysis of studies with available databases (<LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="STD-Jara_x002d_P_x00e9_rez-2000" TYPE="STUDY">Jara-Pérez 2000</LINK>) have shown that IS are not very effective in the prevention of one ARTI but are in the prevention of recurrent infections (that is, two or three). This may be the reason why echinacea trials fail to show protection to the first infection but had some effect on the second infection. In addition, the participants had no history of increased incidence of ARTI. In a re-analysis of one study (<LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>) it was found that 69.2% of the children treated with placebo had a second ARTI while only 55.8% of children on echinacea had a second infection (P = 0.01). However, this effect could not be explored in this review.</P>
<P>In all meta-analyses it is important to consider the presence and possible effect of publication bias; that is, the selective publication of trials with positive results. The funnel plot demonstrated considerable asymmetry, indicating possible publication bias. Other types of bias that could affect the funnel plot are the language bias (publication in languages other than English and publication in non-indexed, small, local journals), poor methodological design, inadequate analysis and inadequate presentation of the results. In only one study (<LINK REF="STD-Saracho_x002d_Weber-2001" TYPE="STUDY">Saracho-Weber 2001</LINK>) the treated group had an increase in ARTIs and, therefore, a positive difference.</P>
<P>The high heterogeneity limits the external validity of the analyses with all the studies. However, when we selected only the studies on bacterial IS (particularly those of D53 and OM-85 BV), and used percentage of ARTIs, the heterogeneity could be regarded as acceptable. It is important to note that the size of the effects is similar in the different sub-analyses, supporting the external validity of the conclusions.</P>
<P>On the basis of the asymmetry shown in the funnel plot, the heterogeneity of the trials and the low quality of many included trials, the possibility of bias (resulting in an overestimation of the true effects of IS on ARTIs) should be considered as high. Therefore, caution needs to be applied when interpreting the possible advantages of IS shown in this review. However, the results of this review provide a reference to the probable effect of IS in the prevention of ARTIs in children and point to the need for further clinical trials.</P>
<P>Further trials on IS must follow the established guidelines (<LINK REF="REF-Collet-1992" TYPE="REFERENCE">Collet 1992</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>; <LINK REF="REF-Valleron-1992" TYPE="REFERENCE">Valleron 1992</LINK>), estimate sample size according to realistic incidence of ARTI and control for confounding factors. Multivariable analysis should be used when confounding factors are identified. Reports of such trials must include enough data to replicate non-parametric statistical tests (for instance, frequency of ARTIs at the end point) and include statistical analysis dealing with censored data (<LINK REF="REF-Mahe-1999" TYPE="REFERENCE">Mahe 1999</LINK>). Registration of all the protocols and ongoing trials would be desirable to obtain all the possible outcomes. It would be necessary to conduct trials on otitis and lower ARTIs with large numbers of highly susceptible children.</P>
<P>Considering the present review, the prevention of ARTIs using IS may be possible. Larger clinical trials, adequately powered for important population groups, sponsored by health authorities, would be desirable to establish the true effects of IS and the effect of individual IS preparations.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-04-18 07:40:48 +1000" MODIFIED_BY="[Empty name]">
<P>According to the funnel plots, it is possible that some trials with negative results have not been published (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-02-21 15:16:40 +1000" MODIFIED_BY="[Empty name]">
<P>Although the global quality of the trials was poor, a group of studies comply with the quality standards (<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Collet-1993" TYPE="STUDY">Collet 1993</LINK>; <LINK REF="STD-Del_x002d_Rio_x002d_Navarro-2003" TYPE="STUDY">Del-Rio-Navarro 2003</LINK>; <LINK REF="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TYPE="STUDY">Gutiérrez-Tarango 2001</LINK>; <LINK REF="REF-Jara_x002d_Perez-2000" TYPE="REFERENCE">Jara-Perez 2000</LINK>; <LINK REF="STD-Taylor-2003" TYPE="STUDY">Taylor 2003</LINK>). </P>
<P>Due to the above and the classification of the studies with the GRADEpro tool, the global quality of the evidence on the effect of immunostimulants to reduce the incidence of ARTIs is regarded as moderate. Additional research is likely to have an impact on our confidence in the estimate of effect and may change the estimate. Meanwhile, the evidence of the incidence of adverse events is considered as low. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate, as the incidence of adverse events was not properly reported in most of the studies. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-11-04 20:24:19 +1000" MODIFIED_BY="[Empty name]">
<P>We consider the risk of biases in the review process minimal, as the plausible sources of information have been consulted and the authors and manufactures were contacted. Additionally, no external funding was provided for this review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-02-21 15:19:28 +1000" MODIFIED_BY="[Empty name]">
<P>The present review is in agreement with a previous meta-analysis on the effect of IS showing a percent decrease in ARTIs of -42.64% (95% CI -45.19% to -40.08%) (<LINK REF="REF-Berber-2001" TYPE="REFERENCE">Berber 2001</LINK>).</P>
<P>Another review on the effect of D53 in the incidence of ARTIs showed a reduction of child ear, nose and throat (ENT) infections of 27% to 68%, and a decrease in child ENT and bronchopulmonary infections of 32% to 61% compared with placebo (<LINK REF="REF-Bellanti-2003" TYPE="REFERENCE">Bellanti 2003</LINK>). This concurs with the effect of D53 shown in this review.</P>
<P>Other meta-analyses on the effect of individual IS report an effect as a percent reduction of -31.86% (95% CI -34.32 to -29.40) for D53, and a corresponding reduction of -39.28% (95% CI -52.58 to -25.98) for OM-85 (<LINK REF="REF-De_x002d_La_x002d_Torre_x002d_Gonzalez-2005" TYPE="REFERENCE">De-La-Torre-Gonzalez 2005</LINK>). Both CIs are in agreement with those in this review.</P>
<P>Schaad (<LINK REF="REF-Schaad-2010" TYPE="REFERENCE">Schaad 2010</LINK>) in a meta-analysis reported that in an OM-85 BV-treated population, 32% had three or more ARTIs in six months, against 58.2% in the placebo-treated population. The reduction with OM-85 was -1.21 (95% CI -1.39 to -1.03), which is similar to the findings in this review.</P>
<P>The results of this review do not agree with the review by Steurer-Stey (<LINK REF="REF-Steurer_x002d_Stey-2007" TYPE="REFERENCE">Steurer-Stey 2007</LINK>) which pooled two OM-85 studies to calculate the risk of fewer than three infections over six months of follow up in children not in daycare (RR 0.82; 95% CI 0.65 to 1.02).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-11 10:56:07 +1000" MODIFIED_BY="Liz Dooley">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-11 10:56:07 +1000" MODIFIED_BY="Liz Dooley">
<P>This review indicates that IS reduce the incidence of ARTIs by 40% on average in susceptible children. The trials have shown benefits of IS in toddlers (two to five years), school boys (six to 12 years) and children with a high incidence of ARTIs, for example children attending daycare and children living in orphanages. Studies in healthy children are not available. Although the safety profile in the studies was good, some IS may be unsafe. For instance, levamisole has been related to agranulocytosis and neurologic disease, and thymic extracts introduce the risk of prion contamination and therefore the risk of bovine spongiform encephalopathy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-28 10:40:16 +1000" MODIFIED_BY="[Empty name]">
<P>Further high-quality trials are required to confirm the true effect of IS and individual IS preparations in the prevention of ARTIs. We encourage national health authorities to conduct large, multicentre, double-blind, placebo-controlled studies to establish the precise benefits and risks for using IS to prevent ARTIs. It is necessary to conduct more studies on the number and frequency of ARTIs and the physiological and immunological basis of recurrent ARTIs.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-04 20:27:34 +1000" MODIFIED_BY="[Empty name]">
<P>We especially acknowledged the great editorial work of Liz Dooley. We thank Arturo Berber for his contribution to the protocol. The authors also wish to thank the following people for commenting on the draft review of the first version: Chanpen Choprapawon, Ville Peltola, Richard Shoemaker and Ludovic Reveiz; and to Anne Lyddiatt, Ville Peltola, Sree Nair and Ludovic Reveiz for the comments on the updated draft review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-11-04 20:28:20 +1000" MODIFIED_BY="[Empty name]">
<P>Dr Arturo Berber was the medical manager for OM-85 BV (Broncho-Vaxom) in Mexico for BASF Pharma Mexico (Química Knoll de México) from 1995 to 2001. He was also the contact author of the initial protocol until he graciously stepped down because of a potential conflict of interest.</P>
<P>Dr Blanca Del Rio-Navarro and Dr Sienra-Monge were involved in the following IS trial: Del-Rio-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcantara S, Avila-Castanon L, Gomez-Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergologia et Immunopathologia (Madrid) 2003 Jan-Feb;31(1):7-13.</P>
<P>Dr Blanca Del Rio-Navarro was involved in the following IS trials: Field J, Gomez-Barreto D, Del-Rio-Navarro BE, Berber A. Use of OM-85 BV in primary prevention of acute respiratory tract infections in children in orphanages Current Therapeutics Research, Clinical and Experimental 1998 59:6 (407-18); Berber AC, Del-Rio-Navarro BE. Use of Broncho-Vaxom in private practice: phase IV trial in 587 children. Clinical Therapeutics 1996 Nov-Dec;18(6):1068-79.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-04-21 12:18:00 +1000" MODIFIED_BY="Liz Dooley">
<P>Dr Blanca Estela Del-Rio-Navarro (BN) searched for papers, extracted the relevant data, analyzed data and co-wrote the review.<BR/>Dr Juan JL Sienra-Monge (JSM) searched for papers, extracted the relevant data and co-wrote the review.<BR/>Dr Francisco Espinosa-Rosales (FER) searched for papers, analyzed data and co-wrote the review.<BR/>Vicki Flenady (VF) co-wrote and made corrections to the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-04-17 01:37:42 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-03-14 07:27:17 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-03-14 07:27:06 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahrens-1984" MODIFIED="2010-04-25 00:45:13 +1000" MODIFIED_BY="[Empty name]" NAME="Ahrens 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-04-25 00:45:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahrens J</AU>
<TI>Multicentre double-blind clinical trial with broncho-vaxom in children</TI>
<SO>Therapiewoche</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>3469-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrianova--2003" MODIFIED="2010-04-25 00:46:53 +1000" MODIFIED_BY="[Empty name]" NAME="Andrianova  2003" YEAR="2003">
<REFERENCE MODIFIED="2010-04-25 00:46:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrianova IV, Sobenin IA, Sereda EV, Borodina LI, Studenikin MI</AU>
<TI>Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2003</YR>
<VL>75</VL>
<NO>3</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arroyave-1999" NAME="Arroyave 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arroyave CM</AU>
<TI>Klebsiella pneumoniae glycoproteins as coadjuvants in the prevention of recurrent respiratory infections in children 1 to 6 years of age</TI>
<TO>Glicoproteínas de Klebsiella pneumoniae como coadyuvantes en la prevención de infecciones recurrentes respiratorias en niños de 1 a 6 años de edad</TO>
<SO>Revista Alergia México</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>3</NO>
<PG>66-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10425883"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-1994" MODIFIED="2010-04-28 10:54:15 +1000" MODIFIED_BY="[Empty name]" NAME="Burgio 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-28 10:54:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio GR, Marseglia GL, Severi F, De Benedetti F, Masarone M, Ottolenghi A, et al</AU>
<TI>Immunoactivation by pidotimod in children with recurrent respiratory infections</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>Suppl 12A</NO>
<PG>152-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857357"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caramia-1994" MODIFIED="2010-04-28 10:54:24 +1000" MODIFIED_BY="[Empty name]" NAME="Caramia 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-28 10:54:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V, et al</AU>
<TI>Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>Suppl 12A</NO>
<PG>1480-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Careddu-1994a" NAME="Careddu 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Careddu P, Biolchini A, Alfano S, Zavattini G</AU>
<TI>Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood</TI>
<SO>Advances in Oto-Rhino-Laryngology</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>328-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1456157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Careddu P</AU>
<TI>Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>Suppl 12A</NO>
<PG>1506-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857353"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Careddu-1994b" NAME="Careddu 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Careddu P, Alfano S, Zavattini G</AU>
<TI>Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood</TI>
<SO>Advances in Therapy</SO>
<YR>1992</YR>
<VL>9</VL>
<NO>3</NO>
<PG>174-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Careddu P, Mei V, Venturoli V, Corsini A</AU>
<TI>Pidotimod in the treatment of recurrent respiratory infections in paediatric patients</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>Suppl 12A</NO>
<PG>1485-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857348"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" MODIFIED="2010-11-04 20:57:29 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-04 20:57:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen AH, Chen RC, Zhang CQ, Chen D, Huang S, Lin Y, et al</AU>
<TI>Efficacy of sublingual polyvalent bacterial vaccine (Lantigen B) in children with recurrent respiratory infection: a randomized double-blind controlled clinical trial</TI>
<SO>Zhonghua Er Ke Za Zhi [Chinese Journal of Pediatrics]</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>6</NO>
<PG>463-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clerici-1988" MODIFIED="2010-11-04 20:57:17 +1000" MODIFIED_BY="[Empty name]" NAME="Clerici 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-04 20:57:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clerici-Schoeller M, Careddu P, Sandri MT, Cazzola P</AU>
<TI>Recurrent respiratory infections in children: prevention of acute episodes by oral administration of thymomodulin</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1988</YR>
<VL>44</VL>
<NO>4</NO>
<PG>503-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2004" NAME="Cohen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y</AU>
<TI>Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<NO>3</NO>
<PG>217-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collet-1993" MODIFIED="2010-04-28 10:55:33 +1000" MODIFIED_BY="[Empty name]" NAME="Collet 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-04-28 10:55:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aymard M, Chomel JJ, Allard JP, Thouvenot D, Honegger D, Floret D, et al</AU>
<TI>Epidemiology of viral infections and evaluation of the potential benefit of OM-85 BV on the virologic status of children attending day-care centers</TI>
<SO>Respiration</SO>
<YR>1994</YR>
<VL>61</VL>
<NO>Suppl 1</NO>
<PG>24-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7800968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-28 10:55:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collet JP, Ducruet T, Kramer MS, Haggerty J, Floret D, Chomel JJ, et al</AU>
<TI>Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>8</NO>
<PG>648-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8414777"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Loore-1979" NAME="De Loore 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Loore F, Heck E, Van Eygen M, Casneuf J</AU>
<TI>Levamisole (R 12564) in the prevention of recurrent upper respiratory tract infections in children: a double-blind, placebo-controlled study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1979</YR>
<VL>6</VL>
<NO>2</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Del_x002d_Rio_x002d_Navarro-2003" NAME="Del-Rio-Navarro 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Río Navarro BE, Luis Sienra Monge JJ, Berber A, Torres Alcantara S, Avila Castañón L, Gómez Barreto D</AU>
<TI>Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dils-1979" NAME="Dils 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dils F</AU>
<TI>A placebo controlled, double-blind evaluation of levamisole in the reduction of the frequency, duration and severity of attacks in children suffering from recurrent upper respiratory tract infections</TI>
<SO>Journal of International Medical Research</SO>
<YR>1979</YR>
<VL>7</VL>
<NO>4</NO>
<PG>302-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiocchi-1986" MODIFIED="2010-11-04 20:57:38 +1000" MODIFIED_BY="[Empty name]" NAME="Fiocchi 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-04 20:57:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiocchi A, Borella E, Riva E, Arensi D, Travaglini P, Cazzola P, et al</AU>
<TI>A double-blind clinical trial for the evaluation of the therapeutical effectiveness of a calf thymus derivative (thymomodulin) in children with recurrent respiratory infections</TI>
<SO>Thymus</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>6</NO>
<PG>331-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3544353"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiocchi-1988" MODIFIED="2010-04-28 10:56:19 +1000" MODIFIED_BY="[Empty name]" NAME="Fiocchi 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-04-28 10:56:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiocchi A, Zuccotti G, Rottoli A, Grasso U, Pogliani L, Vimercati E, et al</AU>
<TI>Treatment with immucytal in recidivant respiratory infection in the pediatric age</TI>
<TO>Trattamento con immucytal nele infezioni respiratorie recidivanti in eta pediatrica</TO>
<SO>Rivista di Pediatria Preventiva e Sociale</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>4</NO>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiocchi-1989" MODIFIED="2010-04-28 10:56:38 +1000" MODIFIED_BY="[Empty name]" NAME="Fiocchi 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-04-28 10:56:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiocchi A, Arancio R, Cinquepalmi P, Sala M, Zuccotti GV, Riva E, et al</AU>
<TI>Recurrent respiratory infections in childhood: experience with a bacterial extract plus bacterial ribosomes (immucytal)</TI>
<SO>Journal of International Medical Research</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>1</NO>
<PG>50-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2185964"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-28 10:56:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fiocchi A, Vignati B, Cinquepalmi P, Machado E, Peano L, Pulejo R, et al</AU>
<TI>Treatment using immucytal in children with recurrent respiratory infections: an Italian multicenter experience</TI>
<TO>Terapia con immucytal di bambini affetti da infezioni respiratorie recidivanti: esperienza italina policentrica</TO>
<SO>La Pediatria Medica e Chirurgica</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>3</NO>
<PG>285-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2687818"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuda-1999" MODIFIED="2010-11-04 20:57:52 +1000" MODIFIED_BY="[Empty name]" NAME="Fukuda 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-04 20:57:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda Y, Jordão-Neves BM, da-Cunha J, Mangabeira Albernaz PL</AU>
<TI>Assessment of efficacy and safety of thymomodulin (Leucogen®) in the prevention of recurrent otitis media and recurrent tonsillitis</TI>
<TO>Estudo clínico-imunológico da eficácia de timomodulina (Leucogen®) na otite média aguda recorrente e na amigdalite de repetição</TO>
<SO>Pediatria Moderna</SO>
<YR>1999</YR>
<VL>XXV</VL>
<NO>10</NO>
<PG>828-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="www.moerirajr.com.br/pediatriamoderna/ped1099/pedleuco.htm"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garabedian-1990" MODIFIED="2010-11-04 21:15:36 +1000" MODIFIED_BY="[Empty name]" NAME="Garabedian 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:15:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyle P, Bellantu JA, Robertson C</AU>
<TI>Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>389-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:15:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Garabedian EN, Dubreuil C, Triglia JC</AU>
<TI>Effectiveness and tolerance of Ribomunyl tablets in preventing middle ear infections in children affected by S.O.M</TI>
<SO>International Congress on Prevention of Infection, Nice, France</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giovannini-2000" MODIFIED="2010-11-04 20:58:03 +1000" MODIFIED_BY="[Empty name]" NAME="Giovannini 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-04 20:58:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giovannini M, Fiocchi A, Sala M, Fontana P, Fiori L, Silano M, et al</AU>
<TI>Immucytal(R) in the prevention and treatment of recurrent upper respiratory tract infections in children: a randomized, placebo-controlled, double-blind study</TI>
<SO>International Journal of Immunotherapy</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>3-4</NO>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" MODIFIED="2010-04-28 10:57:53 +1000" MODIFIED_BY="[Empty name]" NAME="Gutiérrez-Tarango 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-25 00:58:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gutiérrez-Tarango MD, Berber A</AU>
<TI>Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract Infections in children during 12 months</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1742-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-G_x00f3_mez_x002d_Barreto-1998" MODIFIED="2010-04-25 04:24:29 +1000" MODIFIED_BY="[Empty name]" NAME="Gómez-Barreto 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-25 04:24:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez Barreto D, De la Torre C, Alvarez A, Faure A, Berber A</AU>
<TI>Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children</TI>
<TO>Seguridad y eficacia de OM-85-BV más amoxicilina/clavulanato en el tratamiento de la sinusitis subaguda y prevención de infecciones recurrentes en niños</TO>
<SO>Allergologia et Immunopathologia</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9585823"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauguenauer-1987" NAME="Hauguenauer 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyle P, Bellantu JA, Robertson C</AU>
<TI>Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>389-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haguernauer JP</AU>
<TI>Prevention of the ENT repeating infectious episodes by D53 tablets in children of less than 5 years</TI>
<TO>Prévention des épisodes infectieux récidivants de la sphére ORL par D53 comimés chez lénfant de moins de 5 ans</TO>
<SO>Immunologie Medicale</SO>
<YR>1987</YR>
<VL>18</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-H_x00fc_ls-1995" NAME="Hüls 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hüls P, Welbers P, Lindemann H</AU>
<TI>Immunotherapy of children with the help of a multibacterial ribosomal preparation</TI>
<TO>Immuntherapie bei kindern mit hilfe eines multibakteriellen ribosomenpräparates</TO>
<SO>Der Kinderartz</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1018-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iuldashev-1988" MODIFIED="2010-11-04 20:58:16 +1000" MODIFIED_BY="[Empty name]" NAME="Iuldashev 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-04 20:58:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iuldashev AK, Slepushkin AN, Khodzhaeva MA, Schastnyi EI, Kamilov FK</AU>
<TI>Prophylactic efficacy of reaferon in viral hepatitis A and acute respiratory infections in children</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>1988</YR>
<VL>5</VL>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jara_x002d_P_x00e9_rez-2000" NAME="Jara-Pérez 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jara-Perez JV, Berber A</AU>
<TI>Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>6</NO>
<PG>748-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10929921"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karam_x002d_Bechara-1995" MODIFIED="2010-04-25 04:25:45 +1000" MODIFIED_BY="[Empty name]" NAME="Karam-Bechara 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-25 04:25:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karam-Bechara J, Rodríguez-Suárez R, Fuare-Fontela A, Posada-Maldonado EE, Rivera-Gutiérrez SM, Sánchez-Díaz R</AU>
<TI>Thymomodulin in the prevention of recurrent infectious episodes of chronic bronchitis in pediatric patients. Double blind trial</TI>
<TO>Timomodulina en la prevención de los episodios infecciosos recurrentes de la bronquitis crónica en pacientes pediátricos. Estudio doble ciego</TO>
<SO>Investigación Médica Internacional</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>43</NO>
<PG>43-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacomme-1985" MODIFIED="2010-11-04 21:15:56 +1000" MODIFIED_BY="[Empty name]" NAME="Lacomme 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:15:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyle P, Bellantu JA, Robertson C</AU>
<TI>Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl R) in prevention of respiratory infections</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>389-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lacomme Y, Narcy P</AU>
<TI>Prevention of the repeating episodes of ENT superinfection by ribosomal immunotherapy in the child. Clinical results of a multicenter study</TI>
<TO>Prévention par immunothérapie ribosomale des épisodes de superinfection récidivantes de la sphére ORL chez l'enfant. Résultats cliniques d'une étude multicentrique</TO>
<SO>Immunologie Medicale</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>73-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Litzman-1999" NAME="Litzman 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litzman J, Lokaj J, Krejci M, Pesak S, Morgan G</AU>
<TI>Isoprinosine does not protect against frequent respiratory tract infections in childhood</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>158</VL>
<NO>1</NO>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longo-1988" NAME="Longo 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longo F, Lepore L, Agosti E, Panizon F</AU>
<TI>Evaluation of the effectiveness of thymomodulin in children with recurrent respiratory infections</TI>
<SO>La Pediatria Medica e Chirurgica</SO>
<YR>1988</YR>
<VL>10</VL>
<NO>6</NO>
<PG>603-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3244540"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maestroni-1984" NAME="Maestroni 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Losa GA, Maestroni GJ</AU>
<TI>Clinical and immunobiological action of an orally administered bacterial extract</TI>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1984</YR>
<VL>114</VL>
<NO>25</NO>
<PG>930-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6235582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maestroni GJ, Losa GA</AU>
<TI>Clinical and immunobiological effects of an orally administered bacterial extract</TI>
<SO>International Journal of Immunopharmacology</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>2</NO>
<PG>111-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-du-Pan-1982" NAME="Martin du Pan 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin du Pan RE, Martin du Pan RC</AU>
<TI>Clinical study concerning the prevention of infections of the upper respiratory tract of preschool children</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1982</YR>
<VL>71</VL>
<NO>36</NO>
<PG>1385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora-2002" NAME="Mora 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mora R, Barbieri M, Passali GC, Sovatzis A, Mora F, Cordone MP</AU>
<TI>A preventive measure for otitis media in children with upper respiratory tract infections</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>2</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora-2007" MODIFIED="2010-11-04 20:58:29 +1000" MODIFIED_BY="[Empty name]" NAME="Mora 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-25 01:03:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mora R, Dellepiane M, Crippa B, Salami A</AU>
<TI>Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2007</YR>
<VL>71</VL>
<NO>2</NO>
<PG>257-61</PG>
<IDENTIFIERS MODIFIED="2010-03-08 08:36:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-08 08:36:49 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17126918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-04 20:58:29 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora-2010a" MODIFIED="2011-03-14 07:27:06 +1000" MODIFIED_BY="[Empty name]" NAME="Mora 2010a" YEAR="2010">
<REFERENCE MODIFIED="2010-11-04 20:58:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Mora R, Dellepiane M, Crippa B, Guastini L, Santomauro V, Salami A</AU>
<TI>Ribosomal therapy in the treatment of recurrent acute adenoiditis</TI>
<SO>European Archives of Oto-Rhino-Laryngology</SO>
<YR>2010 (in press (pending))</YR>
<IDENTIFIERS MODIFIED="2010-03-10 13:10:13 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-10 13:10:13 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20052587"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motta-1994" MODIFIED="2010-04-28 11:00:59 +1000" MODIFIED_BY="[Empty name]" NAME="Motta 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-28 11:00:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motta G, De Campora E, De Vita C, Esposito S, Galletti C, Incutti V, et al</AU>
<TI>Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>Suppl 12A</NO>
<PG>1521-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passali-1994a" NAME="Passali 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passali D, Calearo C, Conticello S, Ferri P, Zavattini G</AU>
<TI>Recurrent pharingo-tonsillar infections in infants. Treatment with pidotimod</TI>
<TO>Le infezioni ricorrenti faringo-tonsillari dell'infanzia: tattamento con pidotimod</TO>
<SO>Otorinolaringologia Pediatrica</SO>
<YR>1994</YR>
<VL>V</VL>
<NO>3</NO>
<PG>231-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Passali D, Calearo C, Conticello S</AU>
<TI>Pidotimod in the management of recurrent pharyngotonsillar infections in childhood</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>12A</NO>
<PG>1511-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857354"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paupe-1986" NAME="Paupe 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paupe J, Paupe G</AU>
<TI>Biostim prevention of recurrent respiratory infections in children. A double-blind versus placebo study</TI>
<TO>Prévention par le biostim des infections respiratoiresá répétition chez l'enfant</TO>
<SO>Annales de Pediatrie</SO>
<YR>1986</YR>
<VL>33</VL>
<NO>9</NO>
<PG>843-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paupe-1991" MODIFIED="2010-04-25 01:08:23 +1000" MODIFIED_BY="[Empty name]" NAME="Paupe 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paupe J</AU>
<TI>Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections</TI>
<SO>Respiration</SO>
<YR>1991</YR>
<VL>58</VL>
<NO>3-4</NO>
<PG>150-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1745846"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-25 01:08:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paupe J</AU>
<TI>Value of Imocur in the prevention of recurrent infections in children under six years of age. Results of a multicenter, placebo-controlled trial</TI>
<TO>Interet d'imocur(r) dans la prevention des infections recidivantes del'enfant de moins de six ans. Resultats d'une etude multicentrique contre placebo</TO>
<SO>Annales de Pediatrie</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>7</NO>
<PG>475-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2256645"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pech-1987" MODIFIED="2010-11-04 21:16:34 +1000" MODIFIED_BY="[Empty name]" NAME="Pech 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-04-25 01:15:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pech A, Zanaret M</AU>
<TI>Double blind trial of biostim versus placebo in children repeating rhinopharyngities</TI>
<TO>Etude du biostim double aveugle contre placebo dans les rhinopharyngities récidivantes del'enfant</TO>
<SO>Les Cahiers d'ORL</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:16:34 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Reinert P, Morales M, Brin S, Fagnani F. Evaluation d&amp;#8217;un traitement preventif par RU 41740 (Biostim) des infections rhinopharyngees recidivantes de l&amp;#8217;enfant.&lt;br&gt;Annales de Pediatrie 1995;42:454-60&lt;br&gt;Evaluation of RU 41740 for the prevention of recurrent nasopahringeal infections in pediatric patients&lt;/p&gt;" NOTES_MODIFIED="2010-11-04 21:16:34 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reinert P, Morales M, Brin S, Fagnani</AU>
<TI>Evaluation of RU 41740 for the prevention of recurrent nasopharyngeal infections in pediatric patients</TI>
<TO>Evaluation d&#8217;un traitement preventif par RU 41740 (biostim) des infections rhinopharyngees recidivantes de l&#8217;enfant</TO>
<SO>Annales de Pediatrie</SO>
<YR>1995</YR>
<VL>42</VL>
<PG>454-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piquett-1986" MODIFIED="2010-11-04 21:16:24 +1000" MODIFIED_BY="[Empty name]" NAME="Piquett 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-04-25 01:16:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piquet JJ, Piedro P</AU>
<TI>Bisotim investigation in the treatment of recurrent ENT infections in children</TI>
<TO>Intéret du biostim dans le traitement des infections ORL récidivantes de l'enfant</TO>
<SO>Les Cahiers d'ORL</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:16:24 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Reinert P, Morales M, Brin S, Fagnani F. Evaluation d&amp;#8217;un traitement preventif par RU 41740 (Biostim) des infections rhinopharyngees recidivantes de l&amp;#8217;enfant.&lt;br&gt;Annales de Pediatrie 1995;42:454-60&lt;br&gt;Evaluation of RU 41740 for the prevention of recurrent nasopahringeal infections in pediatric patients&lt;/p&gt;" NOTES_MODIFIED="2010-11-04 21:16:24 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reinert P, Morales M, Brin S, Fagnani</AU>
<TI>Evaluation of RU 41740 for the prevention of recurrent nasopharyngeal infections in pediatric patients</TI>
<TO>Evaluation d&#8217;un traitement preventif par RU 41740 (biostim) des infections rhinopharyngees recidivantes de l&#8217;enfant</TO>
<SO>Annales de Pediatrie</SO>
<YR>1995</YR>
<VL>42</VL>
<PG>454-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pozzi-2004" MODIFIED="2010-11-04 20:59:12 +1000" MODIFIED_BY="[Empty name]" NAME="Pozzi 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-04 20:59:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pozzi E, Serra C</AU>
<TI>Efficacy of Lantigen B in the prevention of bacterial respiratory infections</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>1</NO>
<PG>19-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB10-1994" NAME="RB10 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB17-1988" NAME="RB17 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB21-1988" MODIFIED="2010-04-25 01:18:49 +1000" MODIFIED_BY="[Empty name]" NAME="RB21 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB22-1990" NAME="RB22 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB24-1990" NAME="RB24 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RB25-1990" NAME="RB25 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renzo-2004" MODIFIED="2010-04-28 11:03:00 +1000" MODIFIED_BY="[Empty name]" NAME="Renzo 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-28 11:03:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renzo M, Giovanni R, Maria PF, Barbara C, Stefano O, Francesco M, et al</AU>
<TI>Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media in children</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2004</YR>
<VL>68</VL>
<NO>1</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedl_x002d_Seifert-1995" NAME="Riedl-Seifert 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedl-Seifert RJ, van Aubel A, Kammereit A, Elsasser U</AU>
<TI>Reduction of the number and severity of respiratory tract infections in children by oral immunostimulation</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1995</YR>
<VL>371B</VL>
<PG>799-802</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7502900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutishauser-1998" NAME="Rutishauser 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rutishauser M, Pitzke P, Grevers G, van Aubel A, Elsasser U, Kammereit A</AU>
<TI>Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study</TI>
<SO>Advances in Therapy</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>6</NO>
<PG>330-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saracho_x002d_Weber-2001" MODIFIED="2010-11-04 21:16:54 +1000" MODIFIED_BY="[Empty name]" NAME="Saracho-Weber 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-04 21:16:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saracho-Weber F, Vázquez-Ramos V, Ayala-Barajas C</AU>
<TI>Evaluation of glycoprotein of Klebsiella pneumoniae efficacy in recurrent infections</TI>
<TO>Evaluación de la eficacia de glucoproteínas de Klebsiella pneumoniae en infecciones recurrentes</TO>
<SO>Alergia Asma e Inmunología Pediátrica</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>2</NO>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaad-1986" NAME="Schaad 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaad UB, Farine JC, Fux T</AU>
<TI>Prospective placebo-controlled double-blind study using a bacterial lysate in infections of the respiratory tract and ENT region in children</TI>
<TO>Prospective placebo-kontrollierte Doppelblindstudie mit einem Bakterienlysat bei Infektionen der Atemwege und des ORL-Bereiches im Kindesalter</TO>
<SO>Helvetica Paediatrica Acta</SO>
<YR>1986</YR>
<VL>41</VL>
<NO>1-2</NO>
<PG>7-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schaad-2002" MODIFIED="2010-04-28 11:03:29 +1000" MODIFIED_BY="[Empty name]" NAME="Schaad 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-04-28 11:03:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaad UB, Mutterlein R, Goffin H, BV-Child Study Group</AU>
<TI>Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>2042-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramek-1986" MODIFIED="2010-04-28 11:03:37 +1000" MODIFIED_BY="[Empty name]" NAME="Sramek 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-04-28 11:03:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sramek J, Josifko M, Helcl J, Holoubkova E, Janout V, Kozesnik B, et al</AU>
<TI>Bacterial lysate (I.R.S. 19) applied intranasally in the prevention of acute respiratory diseases in children: A randomized double-blind study</TI>
<SO>Journal of Hygiene, Epidemiology, Microbiology, and Immunology</SO>
<YR>1986</YR>
<VL>30</VL>
<NO>4</NO>
<PG>377-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3805711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-2003" MODIFIED="2010-04-28 11:04:01 +1000" MODIFIED_BY="[Empty name]" NAME="Taylor 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barret B</AU>
<TI>Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2004</YR>
<VL>145</VL>
<NO>1</NO>
<PG>135-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-28 11:03:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, et al</AU>
<TI>Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>21</NO>
<PG>2824-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-28 11:04:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C</AU>
<TI>Echinacea purpurea for prevention of upper respiratory tract infections in children</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>1021-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber WJ, Taylor JA, Vander Stoep A, Weiss N, Standish LJ, Calabrese C</AU>
<TI>The effect of echinacea purpurea treatment on prevention of upper respiratory tract infections in children</TI>
<SO>Journal of Investigative Medicine</SO>
<YR>2004</YR>
<VL>52</VL>
<NO>Suppl 2</NO>
<PG>392</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Eygen-1976" NAME="Van Eygen 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Eygen M, Znamensky PY, Heck E, Raymaekers I</AU>
<TI>Levamisole in prevention of recurrent upper-respiratory-tract infections in children</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>7956</NO>
<PG>382-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Eygen-1979" NAME="Van Eygen 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Eygen M, Dils F, Gillerot J, Verschueren E</AU>
<TI>A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1979</YR>
<VL>131</VL>
<NO>3</NO>
<PG>147-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vautel-1993" MODIFIED="2010-11-04 21:17:13 +1000" MODIFIED_BY="[Empty name]" NAME="Vautel 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti J, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 21:17:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vautel JM, Cauquil J, Perruchet AM, Thomas AM</AU>
<TI>Prevention of recurrent ear, nose, and throat infections in young children with Ribomunyl, double-blind, placebo-controlled study</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>6</NO>
<PG>722-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wahl-2008" MODIFIED="2010-11-04 20:59:35 +1000" MODIFIED_BY="[Empty name]" NAME="Wahl 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-28 11:04:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wahl RA, Aldous MB, Worden KA, Grant KL</AU>
<TI>Echinacea purpurea and osteopathic manipulative treatment in children with recurrent otitis media: a randomized controlled trial</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>56</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2010-03-08 07:44:57 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-08 07:44:57 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18831749"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-04 20:59:35 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zagar-1988" MODIFIED="2010-04-25 01:30:37 +1000" MODIFIED_BY="[Empty name]" NAME="Zagar 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-04-25 01:30:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zagar S, Lofler-Badzek D</AU>
<TI>Broncho-vaxom in children with rhinosinusitis: a double-blind clinical trial</TI>
<SO>Journal for Oto-Rhino-Laryngology and its Related Specialties</SO>
<YR>1988</YR>
<VL>50</VL>
<NO>6</NO>
<PG>397-404</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3068610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-03-14 07:27:17 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Almeida-1999" MODIFIED="2010-04-25 04:28:07 +1000" MODIFIED_BY="[Empty name]" NAME="Almeida 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-25 04:28:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almeida VM, Matta JJ, Hernández DD, Campos MG</AU>
<TI>Immunomodulatory effect of a glycoprotein from klebsiella versus levamisole in asthmatic patients with phagocytic deficiency</TI>
<SO>Alergia, Asma e Inmunología Pediátricas</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>3</NO>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aymard-1994" MODIFIED="2010-04-28 11:06:08 +1000" MODIFIED_BY="[Empty name]" NAME="Aymard 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-28 11:06:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aymard M, Chomel JJ, Allard JP, Thouvenot D, Honegger D, Floret D, et al</AU>
<TI>Epidemiology of viral infections and evaluation of the potential benefit of OM-85 BV on the virologic status of children attending day-care centers</TI>
<SO>Respiration</SO>
<YR>1994</YR>
<VL>61</VL>
<NO>Suppl 1</NO>
<PG>24-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1965" MODIFIED="2010-04-28 11:06:19 +1000" MODIFIED_BY="[Empty name]" NAME="Barr 1965" YEAR="1965">
<REFERENCE MODIFIED="2010-04-28 11:06:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr SE, Brown H, Fuchs M, Orvis H, Connor A, Murray FJ, et al</AU>
<TI>A double-blind study of the effects of bacterial vaccine on infective asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1965</YR>
<VL>36</VL>
<PG>47-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00e1_novein-1992" MODIFIED="2010-04-25 01:32:17 +1000" MODIFIED_BY="[Empty name]" NAME="Bánovein 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-04-25 01:32:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banovcin P, Minarik M, Rosslerova V, Miklerova M, Cap J, Pullmann R</AU>
<TI>Broncho-vaxom and IRS 19 in the treatment of recurrent respiratory tract inflammation in children</TI>
<TO>Broncho-vaxom a IRS 19 vliebe recidivujucich zapalov dychacich ciest u deti</TO>
<SO>Ceskoslovenska Pediatrie</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>11</NO>
<PG>666-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1483278"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Das-2000" NAME="Das 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Das GC</AU>
<TI>Evaluation of immunomodulatory effects of bacterial vaccine in patients with recurrent respiratory tract infections</TI>
<SO>XVII International Congress of Allergology and Clinical Immunology (ICACI)</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiocchi-1990" MODIFIED="2010-11-04 20:59:50 +1000" MODIFIED_BY="[Empty name]" NAME="Fiocchi 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-04 20:59:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiocchi A, Arancio R, Cinquepalmi P, Sala M, Zuccotti GV, Riva E, et al</AU>
<TI>Recurrent respiratory infections in childhood: experience with a bacterial extract plus bacterial ribosomes (immucytal)</TI>
<SO>Journal of International Medical Research</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>1</NO>
<PG>50-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontana-1965" NAME="Fontana 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fontana VJ, Salanitro AS, Wolfe HI, Moreno F</AU>
<TI>Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study</TI>
<SO>JAMA</SO>
<YR>1965</YR>
<VL>193</VL>
<PG>895-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimfeld-2004" MODIFIED="2010-04-28 11:07:04 +1000" MODIFIED_BY="[Empty name]" NAME="Grimfeld 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-28 11:07:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimfeld A, Holgate ST, Canonica GW, Bonini S, Borres MP, Adam D, et al</AU>
<TI>Prophylactic management of children at risk for recurrent upper respiratory infections: the preventia I study</TI>
<SO>Clinical &amp; Experimental Allergy</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1665-72</PG>
<IDENTIFIERS MODIFIED="2010-03-08 08:47:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-08 08:47:01 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15544588"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimm-1999" NAME="Grimm 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimm W, Muller HH</AU>
<TI>A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>2</NO>
<PG>138-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heinz-2010" MODIFIED="2011-02-28 09:46:53 +1000" MODIFIED_BY="[Empty name]" NAME="Heinz 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-02-28 09:46:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC</AU>
<TI>Quercetin supplementation and upper respiratory tract infection: a randomized community clinical trial</TI>
<SO>Pharmacological Research</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3</NO>
<PG>237-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-02-25 11:10:10 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera_x002d_Basto-1998" NAME="Herrera-Basto 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera-Basto E, Hernández-Guerra R, Escamilla G, Robledo JL</AU>
<TI>Pidotimod in the treatment of recurrent respiratory infection</TI>
<TO>Pidotimod en el tratamiento de la infección respiratoria recurrente</TO>
<SO>Investigación Médica Internacional</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>8</NO>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kozhukharova-1987" MODIFIED="2010-11-04 20:59:58 +1000" MODIFIED_BY="[Empty name]" NAME="Kozhukharova 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-04 20:59:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kozhukharova MS, Slepushkin AN, Radeva KhT, Lavrukhina LA, Demidova SA</AU>
<TI>Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases</TI>
<SO>Voprosy Virusologii</SO>
<YR>1987</YR>
<VL>32</VL>
<NO>3</NO>
<PG>294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauriello-1990" NAME="Lauriello 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauriello G, Giella D, Berra A, Matonti V</AU>
<TI>Combination of oral bacterial vaccines and antibiotics in acute recurrent respiratory infections</TI>
<TO>Sull'associazione vaccino batterico orale e antibiotici in corso di infezioni respiratorie acute ricorrenti</TO>
<SO>Clinica Terapeutica</SO>
<YR>1990</YR>
<VL>133</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luchikhin-2000" MODIFIED="2010-11-04 21:00:03 +1000" MODIFIED_BY="[Empty name]" NAME="Luchikhin 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-04 21:00:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luchikhin LA, Beliakova LV, Gurov AV</AU>
<TI>Prevention and treatment of upper respiratory tract infections with IRS-19 and polydex with phenylephrine</TI>
<SO>Vestnik Otorinolaringologii</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-1994" MODIFIED="2010-11-04 21:00:08 +1000" MODIFIED_BY="[Empty name]" NAME="Ma 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-04 21:00:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma R, Zhang XL, Tian J</AU>
<TI>Clinical study on repeated infantile respiratory tract infection treated by kanggan zhibao oral liquor</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>10</NO>
<PG>586-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macchi-2005" NAME="Macchi 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macchi A, Vecchia LD</AU>
<TI>Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections</TI>
<SO>Arzneimittelforschung</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>5</NO>
<PG>276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makovetskaya-2001" MODIFIED="2010-11-04 21:17:28 +1000" MODIFIED_BY="[Empty name]" NAME="Makovetskaya 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-04 21:17:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makovetskaya GA, Zhestkova VV, Kuznetsova TL</AU>
<TI>Efficiency of the IRS-19 aerosol vaccine in children with relapsing diseases of upper respiratory tract</TI>
<SO>Kazanskii Meditsinskii Zhurnal</SO>
<YR>2001</YR>
<VL>82</VL>
<NO>1</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora-2010b" MODIFIED="2011-03-14 07:27:17 +1000" MODIFIED_BY="[Empty name]" NAME="Mora 2010b" YEAR="2010">
<REFERENCE MODIFIED="2011-02-28 09:47:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mora R, Dellepiane M, Crippa B, Guastini L, Santomauro V, Salami A</AU>
<TI>Ribosomal therapy in the treatment of recurrent acute adenoiditis</TI>
<SO>European Archives of Oto-Rhino-Laryngology</SO>
<YR>2010</YR>
<VL>267</VL>
<NO>8</NO>
<PG>1313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1969" NAME="Mueller 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mueller HL, Lanz M</AU>
<TI>Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study</TI>
<SO>JAMA</SO>
<YR>1969</YR>
<VL>208</VL>
<PG>1379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nespoli-1992" MODIFIED="2010-11-04 21:00:29 +1000" MODIFIED_BY="[Empty name]" NAME="Nespoli 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-04 21:00:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nespoli L</AU>
<TI>Action of thymomodulin in the prevention of respiratory infection in the child entering to elementary school</TI>
<TO>Attivita della timomodulina nella prevenzione delle infezioni respiratorie del bambino ala prima scolarizzazione</TO>
<SO>Rivista di Pediatria Preventiva e Sociale</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>2</NO>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obrosova_x002d_Serova-1972" MODIFIED="2010-11-04 21:00:21 +1000" MODIFIED_BY="[Empty name]" NAME="Obrosova-Serova 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-11-04 21:00:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obrosova-Serova NP, Fedorova GI, Glukhov PI, Shal'nov MI, Litvinov VG</AU>
<TI>Effectiveness of midantan and interferon inducers as means of non-specific prevention of influenza</TI>
<SO>Antibiotiki</SO>
<YR>1972</YR>
<VL>17</VL>
<NO>8</NO>
<PG>734-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oggiano-1985" MODIFIED="2010-04-28 11:08:08 +1000" MODIFIED_BY="[Empty name]" NAME="Oggiano 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-04-28 11:08:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oggiano N, Di Girolamo F, Salvucci C, Marinelli M, Gentili A, Pecora R, et al</AU>
<TI>Oral polyvalent bacterial vaccine in children with recurrent respiratory infections</TI>
<TO>Vaccino batterico orale polivalente in bambini con infezioni respiratoire ricorrenti (I.R.R.)</TO>
<SO>Minerva Pediatrica</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>741-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldini-1990" MODIFIED="2010-11-04 21:00:42 +1000" MODIFIED_BY="[Empty name]" NAME="Oldini 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-04 21:00:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldini C, De Berti G, Vecchi E</AU>
<TI>The employment of the Immucytal spray in nasopharyngeal pathology</TI>
<TO>L'Impiego dell'Immucytal spray nella patologia nasofaringea</TO>
<SO>Otorinolarongologia</SO>
<YR>1990</YR>
<VL>40</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-del-2005" NAME="Ortega del 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega del Alamo P, Rivera Rodriguez T, Sanz Fernandez R</AU>
<TI>The effect of AM3 in the resolution of otitis media with effusion (OME) in paediatric patients</TI>
<TO>Efecto de AM3 sobre la resolución de la otitis media serosa (OMS) en pacientes pediátricos</TO>
<SO>Acta Otorrinolaringologica Espanola</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Predy-2005" NAME="Predy 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK</AU>
<TI>Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2005</YR>
<VL>173</VL>
<PG>1043-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prusek-1987" NAME="Prusek 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prusek W, Jankowski A, Radomska G, Wieczorek E, Podwysocka M</AU>
<TI>Immunostimulation in recurrent respiratory tract infections therapy in children</TI>
<SO>Archivum Immunologiae et Therapiae Experimentalis</SO>
<YR>1987</YR>
<VL>35</VL>
<NO>3</NO>
<PG>289-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3502238"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Razi-2010" MODIFIED="2011-02-28 09:48:16 +1000" MODIFIED_BY="[Empty name]" NAME="Razi 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-02-28 09:48:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Razi CH, Harmanci K, Abaci A, Özdemir O, Hizli S, Renda R, et al</AU>
<TI>The immunostimulant OM-85 BV prevents wheezing attacks in preschool children</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>4</NO>
<PG>763-9</PG>
<IDENTIFIERS MODIFIED="2011-02-25 11:12:49 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-02-25 11:13:09 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedl_x002d_Seifert-1993" MODIFIED="2010-11-04 21:02:41 +1000" MODIFIED_BY="[Empty name]" NAME="Riedl-Seifert 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-04 21:02:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedl-Seifert RD, van Aubel A, Kämmereit A, Elsasser U</AU>
<TI>Infection recurrence in children - still a crux medicorum? Results of a double-blind placebo-controlled with an oral bacterial lysate to infections in children</TI>
<TO>Infektrezidive im Kindesalter - noch immer iene Crux medicorum? Ergebnisse einer plazebokontrollierten Doppelblindstudie mit einem oralen Bakterienlysat bei infektanfälligen Kindern</TO>
<SO>Journal of Pharmacoloy and Therapy</SO>
<YR>1993</YR>
<VL>3</VL>
<PG>108-17</PG>
<IDENTIFIERS MODIFIED="2010-11-04 21:02:41 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-04-24 23:55:24 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosaschino-2004" MODIFIED="2010-04-25 01:38:02 +1000" MODIFIED_BY="[Empty name]" NAME="Rosaschino 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-25 01:38:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosaschino F, Cattaneo L</AU>
<TI>Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered polyvalent mechanical bacterial Lysates (PMBL)</TI>
<SO>Acta Bio Medica Ateneo Parmense</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>3</NO>
<PG>171-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-2004" NAME="Rossi 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi S, Tazza R</AU>
<TI>Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infections. A randomised, open, controlled clinical trial</TI>
<SO>Arzneimittelforschung</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>1</NO>
<PG>50-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruah-2001" NAME="Ruah 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruah SB, Ruah C, van Aubel A, Abel S, Elsasser U</AU>
<TI>Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections</TI>
<SO>Advances in Therapy</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>4</NO>
<PG>151-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rytel-1974" NAME="Rytel 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rytel MW, Ferstenfeld JE, Rose HD, Balay J, Pierce WE, Lynch KL</AU>
<TI>Efficacy of a "mixed bacterial vaccine" in prophylaxis of acute respiratory infections: possible role of interferon</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1974</YR>
<VL>99</VL>
<PG>347-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scotti-1987" NAME="Scotti 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scotti L, Biondelli G, Borzani M</AU>
<TI>Use of a polyvalent oral bacterial vaccine in recurrent respiratory infections in children</TI>
<TO>Impiego di un vaccino batterico orale polivalente nelle infezioni respiratorie recidivanti del bambino</TO>
<SO>Minerva Pediatrica</SO>
<YR>1987</YR>
<VL>39</VL>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinsbekk-2005" MODIFIED="2010-04-28 11:09:32 +1000" MODIFIED_BY="[Empty name]" NAME="Steinsbekk 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-28 11:09:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinsbekk A, Bentzen N, Fønnebø V, Lewith G</AU>
<TI>Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>4</NO>
<PG>447-55</PG>
<IDENTIFIERS MODIFIED="2010-03-08 08:53:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-08 08:53:42 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15801940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vascotto-1985" NAME="Vascotto 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vascotto M, Fossi E, Mancini E, Guerrini L</AU>
<TI>Efficacy of a polyvalent bacterial vaccine administered by aerosol in the treatment of children with respiratory infections</TI>
<TO>Efficacia di un vaccino batterico polivalente somministrato per via aerosolica nel trattamento del bambino catarrale</TO>
<SO>Minerva Pediatrica</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>409-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yale-2004" NAME="Yale 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yale SH, Liu K</AU>
<TI>Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>11</NO>
<PG>1237-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-04-17 01:37:42 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-04-17 01:37:42 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aggarwal-2007" MODIFIED="2010-04-28 11:10:12 +1000" MODIFIED_BY="[Empty name]" NAME="Aggarwal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Aggarwal R, Sentz J, Miller MA</AU>
<TI>Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1120-30</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:04:45 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:04:45 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17545379"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alyanakian-2006" MODIFIED="2010-04-28 11:10:21 +1000" MODIFIED_BY="[Empty name]" NAME="Alyanakian 2006" TYPE="JOURNAL_ARTICLE">
<AU>Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, et al</AU>
<TI>Transforming growth factor-{beta} and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes</TI>
<SO>Diabetes</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>1</NO>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barreto-1994" MODIFIED="2010-04-28 11:10:41 +1000" MODIFIED_BY="[Empty name]" NAME="Barreto 1994" TYPE="JOURNAL_ARTICLE">
<AU>Barreto ML, Santos LM, Assis AM, Araújo MPN, Farenzena GG, Santos PAB, et al</AU>
<TI>Effect of vitamin A supplementation on diarrhoea and acute lower-respiratory-tract infections in young children in Brazil</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8917</NO>
<PG>228-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7913157"/>
<IDENTIFIER TYPE="OTHER" VALUE="94301083 94301083"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bell-1989" MODIFIED="2010-11-04 21:02:57 +1000" MODIFIED_BY="[Empty name]" NAME="Bell 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bell DM, Gleiber DW, Mercer AA, Phifer R, Guinter RH, Cohen AJ, et al</AU>
<TI>Illness associated with child day care: a study of incidence and cost</TI>
<SO>American Journal of Public Health</SO>
<YR>1989</YR>
<VL>79</VL>
<NO>4</NO>
<PG>479-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2929808"/>
<IDENTIFIER TYPE="OTHER" VALUE="89191073"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bellanti-2003" MODIFIED="2010-11-04 21:03:04 +1000" MODIFIED_BY="[Empty name]" NAME="Bellanti 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bellanti JA, Olivieri D, Serrano E</AU>
<TI>Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults</TI>
<SO>BioDrugs</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>5</NO>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berber-1996" NAME="Berber 1996" TYPE="JOURNAL_ARTICLE">
<AU>Berber AC, Del-Rio-Navarro BE</AU>
<TI>Use of broncho-vaxom in private practice: phase IV trial in 587 children</TI>
<SO>Clinical Therapeutics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1068-79</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9001824"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berber-2001" MODIFIED="2010-04-25 01:43:11 +1000" MODIFIED_BY="[Empty name]" NAME="Berber 2001" TYPE="JOURNAL_ARTICLE">
<AU>Berber A, Del-Rio-Navarro B</AU>
<TI>Compilation and meta-analysis of randomized placebo-controlled clinical trials on the prevention of respiratory tract infections in children using immunostimulants</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>4</NO>
<PG>235-46</PG>
<IDENTIFIERS MODIFIED="2010-04-03 06:53:50 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-03 06:53:50 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11908811"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Campbell-1995" NAME="Campbell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Campbell H</AU>
<TI>Acute respiratory infection: a global challenges</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>4</NO>
<PG>281-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7492188"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDCIDSG-1984" NAME="CDCIDSG 1984" TYPE="JOURNAL_ARTICLE">
<AU>The Child Day Care Infectious Disease Study Group</AU>
<TI>Public health considerations of infectious diseases in child day care centres</TI>
<SO>Journal of Pediatrics</SO>
<YR>1984</YR>
<VL>105</VL>
<PG>683-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2008a" MODIFIED="2010-04-28 11:14:48 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2008a" TYPE="COCHRANE_REVIEW">
<AU>Chen H, Zhuo Q, Yuan W, Wang J, Wu T</AU>
<TI>Vitamin A for preventing acute lower respiratory tract infections in children up to seven years of age</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-04-28 11:14:29 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-28 11:14:29 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006090.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2008b" MODIFIED="2010-11-04 21:03:31 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Chen LY, Lin YL, Chiang BL</AU>
<TI>Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells</TI>
<SO>Clinical &amp; Experimental Allergy</SO>
<YR>2008</YR>
<VL>151</VL>
<NO>1</NO>
<PG>174-81</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:12:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:12:03 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18005262"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collet-1992" NAME="Collet 1992" TYPE="JOURNAL_ARTICLE">
<AU>Collet JP</AU>
<TI>Immunomodulators and primary prevention of respiratory infections: methodological considerations</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1992</YR>
<VL>77</VL>
<PG>159-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1426657"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahan-1986" NAME="Dahan 1986" TYPE="JOURNAL_ARTICLE">
<AU>Dahan R, Constantini D, Caulin C, Yagello M</AU>
<TI>Clinical trials with C 1740, an immunomodulator compound proposed for prevention of acute infectious exacerbations in chronic bronchitis</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>1</NO>
<PG>41-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3517520"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dajani-1995" NAME="Dajani 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dajani A, Taubert K, Frrieri P, Peter G, Shulman S</AU>
<TI>Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<NO>4 Pt 1</NO>
<PG>758-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7567345"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Mattia-1993" MODIFIED="2010-04-28 11:16:13 +1000" MODIFIED_BY="[Empty name]" NAME="De Mattia 1993" TYPE="JOURNAL_ARTICLE">
<AU>De Mattia D, Decandia P, Ferrante P, Pace D, Martire B, Ciccarelli M, et al</AU>
<TI>Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections</TI>
<SO>Immunopharmacology and Immunotoxicology</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>4</NO>
<PG>447-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8227971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De_x002d_La_x002d_Torre_x002d_Gonzalez-2005" MODIFIED="2010-11-04 21:18:04 +1000" MODIFIED_BY="[Empty name]" NAME="De-La-Torre-Gonzalez 2005" TYPE="JOURNAL_ARTICLE">
<AU>De-la-Torre-Gonzalez C, Pacheco-Rios A, Escalante-Dominguez AJ, del-Rio-Navarro BE</AU>
<TI>Comparative meta-analysis of immunostimulant agents used in pediatric patients in Mexico</TI>
<TO>Metaanalisis comparativo de los inmunoestimulantes utilizados enpediatría en México</TO>
<SO>Revista Alergia Mexico</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>1</NO>
<PG>25-38</PG>
<IDENTIFIERS MODIFIED="2010-04-03 07:03:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-03 07:03:20 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15957470"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Denny-1986" NAME="Denny 1986" TYPE="JOURNAL_ARTICLE">
<AU>Denny FW, Collier AM, Henderson FW</AU>
<TI>Acute respiratory infections in day care</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>4</NO>
<PG>527-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3529308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fendrick-2003" NAME="Fendrick 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fendrick AM, Monto AS, Nightengale B, Sarnes M</AU>
<TI>The economic burden of non-influenza-related viral respiratory tract infection in the United States</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>487-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flores_x002d_Hernandez1999" NAME="Flores-Hernandez1999" TYPE="JOURNAL_ARTICLE">
<AU>Flores-Hernandez S, Reyes-Morales H, Perez-Cuevas R, Guiscafre-Gallardo H</AU>
<TI>The day care center as a risk factor for acute respiratory infections</TI>
<SO>Archives of Medical Research</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>3</NO>
<PG>216-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gr_x00fc_ber-2008" MODIFIED="2010-11-04 21:03:49 +1000" MODIFIED_BY="[Empty name]" NAME="Grüber 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grüber C, Keil T, Kulig M, Roll S, Wahn U, Wahn V; MAS-90 Study Group</AU>
<TI>History of respiratory infections in the first 12 yr among children from a birth cohort</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>6</NO>
<PG>505-12</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:18:35 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:18:35 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18167154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hament-1999" NAME="Hament 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hament JM, Kimpen JL, Fleer A, Wolfs TF</AU>
<TI>Respiratory viral infection predisposing for bacterial disease: a concise review</TI>
<SO>FEMS Immunology and Medical Microbiology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>3-4</NO>
<PG>189-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10575129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haskins-1986" NAME="Haskins 1986" TYPE="JOURNAL_ARTICLE">
<AU>Haskins R, Kotch J</AU>
<TI>Day care and illness: evidence, costs, and public policy</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>6 Pt 2</NO>
<PG>951-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3012455"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-1998" NAME="Heikkinen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen T, Ruohola A, Ruuskanen O, Waris M, Uhari M, Hammarström L</AU>
<TI>Intranasally administered immunoglobulin for the prevention of rhinitis in children</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>5</NO>
<PG>367-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9613647"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-1999" NAME="Heikkinen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen T, Thint M, Chonmaitree T</AU>
<TI>Prevalence of various respiratory viruses in the middle ear during acute otitis media</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>4</NO>
<PG>260-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9920949"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemila-1997" NAME="Hemila 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hemila H</AU>
<TI>Vitamin C intake and susceptibility to the common cold</TI>
<SO>British Journal of Nutrition</SO>
<YR>1997</YR>
<VL>77</VL>
<NO>1</NO>
<PG>59-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9059230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemil_x00e4_-2010" MODIFIED="2010-04-28 11:18:09 +1000" MODIFIED_BY="[Empty name]" NAME="Hemilä 2010" TYPE="COCHRANE_REVIEW">
<AU>Hemilä H, Chalker E, Douglas B</AU>
<TI>Vitamin C for preventing and treating the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-04-28 11:18:09 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-28 11:18:09 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000980.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hemmi-2002" MODIFIED="2010-04-28 11:18:22 +1000" MODIFIED_BY="[Empty name]" NAME="Hemmi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al</AU>
<TI>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway</TI>
<SO>Nature Immunology</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>196-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-1982" MODIFIED="2010-04-28 11:18:32 +1000" MODIFIED_BY="[Empty name]" NAME="Henderson 1982" TYPE="JOURNAL_ARTICLE">
<AU>Henderson FW, Collier AM, Sanyal MA, Watkins JM, Fairclough DL, Clyde WA Jr, et al</AU>
<TI>A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>306</VL>
<NO>23</NO>
<PG>1377-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6281639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-04-17 01:37:42 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. <I> </I>
</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffmann-1999" NAME="Hoffmann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA</AU>
<TI>Phylogenetic perspectives in innate immunity</TI>
<SO>Science</SO>
<YR>1999</YR>
<VL>284</VL>
<PG>1313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-2009" MODIFIED="2010-04-28 11:18:51 +1000" MODIFIED_BY="[Empty name]" NAME="Hsu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al</AU>
<TI>Effect of pneumococcal conjugate vaccine on pneumococcal meningitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>3</NO>
<PG>244-56</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:25:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:25:22 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19144940"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huang-2009" MODIFIED="2010-04-28 11:19:04 +1000" MODIFIED_BY="[Empty name]" NAME="Huang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, et al</AU>
<TI>Continued impact of pneumococcal conjugate vaccine on carriage in young children</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>1</NO>
<PG>e1-11</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:23:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:23:41 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19564254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jara_x002d_Perez-2000" NAME="Jara-Perez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jara-Perez JV, Berber A</AU>
<TI>Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<PG>748-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2001" MODIFIED="2008-04-21 14:09:48 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2001" NOTES="&lt;p&gt;Jefferson TO, Tyrrell D. Antivirals for the common cold (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-21 14:09:48 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Jefferson TO, Tyrrell D</AU>
<TI>Antivirals for the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-04-21 14:09:48 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-04-21 14:09:48 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002743.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2009" MODIFIED="2010-04-28 11:19:48 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al</AU>
<TI>Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<NO>b3675. doi</NO>
<PG>10.1136/bmj.b3675</PG>
<IDENTIFIERS MODIFIED="2010-01-13 12:36:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-13 12:36:21 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19773323"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jin-1993" NAME="Jin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jin C, MacKay-Rossignol A</AU>
<TI>Effects of passive smoking on respiratory illness from birth to age eighteen months, in Shanghai, People's Republic of China</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>123</VL>
<NO>4</NO>
<PG>553-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8410506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krieg-2003" MODIFIED="2010-04-28 11:20:06 +1000" MODIFIED_BY="[Empty name]" NAME="Krieg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Krieg 2003</AU>
<TI>CpG motifs: the active ingredient in bacterial extracts?</TI>
<SO>Nature Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>7</NO>
<PG>831-5</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:07:10 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:07:10 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12835699"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2005" MODIFIED="2010-04-28 11:20:11 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lee T, Jordan NN, Sanchez JL, Gaydos JC</AU>
<TI>Selected nonvaccine interventions to prevent infectious acute respiratory disease</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>3</NO>
<PG>305-16</PG>
<IDENTIFIERS MODIFIED="2010-01-13 12:50:28 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-13 12:50:28 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15766621"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2009" MODIFIED="2010-05-18 17:00:56 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2009" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 (updated September 2009). The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2009</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahe-1999" NAME="Mahe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mahe C, Chevret S</AU>
<TI>Estimation of the treatment effect in a clinical trial when recurrent events define the endpoint</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>14</NO>
<PG>1821-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mera-2009" MODIFIED="2010-04-28 11:20:22 +1000" MODIFIED_BY="[Empty name]" NAME="Mera 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mera RM, Miller LA, Amrine-Madsen H, Sahm DF</AU>
<TI>The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics</TI>
<SO>Microbial Drug Resistance</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>261-8</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:27:04 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:27:04 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19857132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2010-04-25 01:51:35 +1000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molinari-2007" MODIFIED="2010-07-17 15:28:16 +1000" MODIFIED_BY="[Empty name]" NAME="Molinari 2007" TYPE="JOURNAL_ARTICLE">
<AU>Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al</AU>
<TI>The annual impact of seasonal influenza in the US: measuring disease burden and costs</TI>
<SO>Vaccine</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>7</NO>
<PG>5086-96</PG>
<IDENTIFIERS MODIFIED="2010-07-17 02:29:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-17 02:29:03 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17544181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monto-1974" NAME="Monto 1974" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS, Ulman BM</AU>
<TI>Acute respiratory illness in an American community. The Tecumseh study</TI>
<SO>JAMA</SO>
<YR>1974</YR>
<VL>227</VL>
<PG>164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monto-1993" NAME="Monto 1993" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS, Sullivan KM</AU>
<TI>Acute respiratory illness in the community. Frequency of illness and the agents involved</TI>
<SO>Epidemiology and Infection</SO>
<YR>1993</YR>
<VL>110</VL>
<NO>1</NO>
<PG>145-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8432318"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monto-2002" NAME="Monto 2002" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS</AU>
<TI>Epidemiology of viral respiratory infections</TI>
<SO>American Journal of Medicine</SO>
<YR>2002</YR>
<VL>112</VL>
<NO>Suppl 6A</NO>
<PG>4-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nikolova-2009" MODIFIED="2010-04-28 11:20:42 +1000" MODIFIED_BY="[Empty name]" NAME="Nikolova 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nikolova M, Stankulova D, Taskov H, Nenkov P, Maximov V, Petrunov B</AU>
<TI>Polybacterial immunomodulator respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections</TI>
<SO>International Immunopharmacology</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>4</NO>
<PG>425-32</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:09:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:09:14 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19186221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nydahl_x002d_Persson-1995" NAME="Nydahl-Persson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Nydahl-Persson K, Petterson A, Fasth A</AU>
<TI>A prospective, double-blind, placebo-controlled trial of i.v. immunoglobulin and trimethoprim-sulfamethoxazole in children with recurrent respiratory tract infections</TI>
<SO>Acta Paediatrica</SO>
<YR>1995</YR>
<VL>84</VL>
<NO>9</NO>
<PG>1007-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8652950"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Passali-1994" NAME="Passali 1994" TYPE="JOURNAL_ARTICLE">
<AU>Passali D, Calearo C, Conticello S, a multicenter trial group</AU>
<TI>Pidotimod in the management of recurrent pharyngotonsillar infections in childhood</TI>
<SO>Arzneimittelforschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>12A</NO>
<PG>1511-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7857354"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-11-04 21:18:30 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhodes-1995" MODIFIED="2010-04-28 11:20:58 +1000" MODIFIED_BY="[Empty name]" NAME="Rhodes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes J, Chen H, Hall SR, Beesley JE, Jenkins DC, Collins P, et al</AU>
<TI>Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs</TI>
<SO>Nature</SO>
<YR>1995</YR>
<VL>377</VL>
<PG>71-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovers-2006" MODIFIED="2010-04-28 11:21:08 +1000" MODIFIED_BY="[Empty name]" NAME="Rovers 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Balemans WA, Sanders EA, van der Ent CK, Zielhuis GA, Schilder AG</AU>
<TI>Persistence of upper respiratory tract infections in a cohort followed from childhood to adulthood</TI>
<SO>Family Practice</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>3</NO>
<PG>286-90</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:20:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:20:21 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16517546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sazawal-1998" MODIFIED="2010-11-04 21:04:10 +1000" MODIFIED_BY="[Empty name]" NAME="Sazawal 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sazawal S, Black RE, Jalla S, Mazumdar S, Sinha A, Bhan MK</AU>
<TI>Zinc supplementation reduces the incidence of acute lower respiratory infections in infants and preschool children: a double-blind, controlled trial</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>1 Pt 1</NO>
<PG>1-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9651405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schaad-2010" MODIFIED="2010-04-28 11:21:21 +1000" MODIFIED_BY="[Empty name]" NAME="Schaad 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schaad UB</AU>
<TI>OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review</TI>
<SO>World Journal Of Pediatrics</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>1</NO>
<PG>5-12</PG>
<IDENTIFIERS MODIFIED="2010-04-03 07:13:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-03 07:13:26 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20143206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schnare-2001" NAME="Schnare 2001" TYPE="JOURNAL_ARTICLE">
<AU>Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R</AU>
<TI>Toll-like receptors control activation of adaptive immune responses</TI>
<SO>Nature Immunology</SO>
<YR>2001</YR>
<VL>2</VL>
<PG>947-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1994" NAME="Schwartz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz B, Giebink GS, Henderson FW, Reichler MR, Jereb J, Collet JP</AU>
<TI>Respiratory infections in day care</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<NO>6 Pt 2</NO>
<PG>1018-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7971043"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Selwyn-1990" MODIFIED="2010-11-04 21:04:19 +1000" MODIFIED_BY="[Empty name]" NAME="Selwyn 1990" TYPE="JOURNAL_ARTICLE">
<AU>Selwyn BJ</AU>
<TI>The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries</TI>
<SO>Reviews of Infectious Disease</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>Suppl 8</NO>
<PG>870-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2270410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Steurer_x002d_Stey-2007" MODIFIED="2010-04-28 11:21:42 +1000" MODIFIED_BY="[Empty name]" NAME="Steurer-Stey 2007" TYPE="JOURNAL_ARTICLE">
<AU>Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM</AU>
<TI>Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>166</VL>
<NO>4</NO>
<PG>365-76</PG>
<IDENTIFIERS MODIFIED="2010-04-03 07:07:16 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-03 07:07:16 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17115184"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Symoens-1978" NAME="Symoens 1978" TYPE="JOURNAL_ARTICLE">
<AU>Symoens J, Veys E, Mielants M, Pinals R</AU>
<TI>Adverse reactions to levamisole</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<NO>11</NO>
<PG>1721-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takeuchi-2001" NAME="Takeuchi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi O, Akira S</AU>
<TI>Toll-like receptors; their physiological role and signal transduction system</TI>
<SO>International Immunopharmacology</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>625-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uhari-1998" NAME="Uhari 1998" TYPE="JOURNAL_ARTICLE">
<AU>Uhari M, Kontiokari T, Niemelä M</AU>
<TI>A novel use of xylitol sugar in preventing acute otitis media</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>4 Pt 1</NO>
<PG>879-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9755259"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valleron-1992" NAME="Valleron 1992" TYPE="JOURNAL_ARTICLE">
<AU>Valleron AJ, Grimfield A</AU>
<TI>Evaluation of clinical trials of immunomodulators for prevention of recurrent respiratory infections in children</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1992</YR>
<VL>77</VL>
<PG>149-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1426656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>WHO</AU>
<TI>Acute respiratory infections: the forgotten pandemic</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>1</NO>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9615503"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2010-11-04 21:04:35 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Fact Sheet 113. Bovine spongiform encephalopathy</TI>
<SO>http://www.who.int/mediacentre/factsheets/fs113/en/print.html (accessed 20 July 2005)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2002" NAME="Williams 2002" TYPE="JOURNAL_ARTICLE">
<AU>Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C</AU>
<TI>Estimates of world-wide distribution of child deaths from acute respiratory infections</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolsko-2005" MODIFIED="2010-04-28 11:22:19 +1000" MODIFIED_BY="[Empty name]" NAME="Wolsko 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wolsko PM, Solondz DK, Phillips RS, Schachter SC, Eisenberg DM</AU>
<TI>Lack of herbal supplement characterization in published randomized controlled trials</TI>
<SO>American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118</VL>
<NO>10</NO>
<PG>1087-93</PG>
<IDENTIFIERS MODIFIED="2010-03-28 13:29:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 13:29:22 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16194636"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wright-1989" NAME="Wright 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wright AL, Holberg CJ, Martinez FD, Morgan WJ, Taussig LM</AU>
<TI>Breast feeding and lower respiratory tract illness in the first year of life</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>299</VL>
<NO>6705</NO>
<PG>946-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2508946"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xu-2009" MODIFIED="2010-04-28 11:22:29 +1000" MODIFIED_BY="[Empty name]" NAME="Xu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xu N, Zhou W, Li S, Zhou G, Zhang N, Liang J</AU>
<TI>Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients</TI>
<SO>Journal of Neuroimaging</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>4</NO>
<PG>326-31</PG>
<IDENTIFIERS MODIFIED="2010-04-03 07:24:45 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-03 07:24:45 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19187474"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yamshchikov-2009" MODIFIED="2010-04-28 11:22:36 +1000" MODIFIED_BY="[Empty name]" NAME="Yamshchikov 2009" TYPE="JOURNAL_ARTICLE">
<AU>Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V</AU>
<TI>Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials</TI>
<SO>Endocrine Practice</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>5</NO>
<PG>438-49</PG>
<IDENTIFIERS MODIFIED="2010-03-28 12:57:29 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-28 12:57:29 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19491064"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-04-28 11:24:31 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Del_x002d_Rio_x002d_Navarro-2006" MODIFIED="2010-04-28 11:24:31 +1000" MODIFIED_BY="[Empty name]" NAME="Del-Rio-Navarro 2006" TYPE="COCHRANE_REVIEW">
<AU>Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJL</AU>
<TI>Immunostimulants for preventing respiratory tract infection in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-04-28 11:24:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-28 11:24:31 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004974.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:00 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Ahrens-1984">
<CHAR_METHODS MODIFIED="2010-11-04 20:31:41 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:33:33 +1000" MODIFIED_BY="[Empty name]">
<P>Paediatric participants (1 to 19 years) suffering from chronic obstructive disease of respiratory tract, or those who received treatment for at least 1 ARTI during the autumn and winter seasons in the last year. 87 participants received OM-85 BV and 77 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:33:35 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months<BR/>Participants were followed for another 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-21 12:18:00 +1000" MODIFIED_BY="Liz Dooley">
<P>During the study 83 participants with OM-85 BV had 3.75 ± 3.42 (mean ± SD) ARTIs and 72 participants with placebo had 5.04 ± 4.04 ARTIs<BR/>Two participants in the OM-85 BV had adverse events, 1 presented abdominal pain and diarrhea and the other gastrointestinal distress. Six placebo participants had adverse events with 2 cases of folliculitis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:00 +1000" MODIFIED_BY="Liz Dooley">
<P>It is not stated that the trial is randomized<BR/>Selection criteria of the participants allows the inclusion of non-susceptible participants<BR/>The reason for excluding participants from the analysis are given<BR/>The trial was conducted in Germany<BR/>The trial took place over the 4 seasons of the year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:01 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Andrianova--2003">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-09 14:22:35 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants from 6 to 11 years attending school</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:56 +1000" MODIFIED_BY="[Empty name]">
<P>In the first part of the study 172 students received Allicor (300 mg of garlic extract) and 468 students received placebo once a day for 5 months<BR/>In the second part of the study, 42 students had Allicor, 41 students had placebo and 73 students had dibazol for 5 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:38:57 +1000" MODIFIED_BY="[Empty name]">
<P>In the first part of the study Allicor diminished the rate of ARTIs from 28.5% to 9.5%. During this phase there was a case of atopy<BR/>In the second phase of the study Allicor subjects had 1.7 fewer infections than those in the placebo group and 2.4 fewer infections than those in the dibazol group<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:01 +1000" MODIFIED_BY="Liz Dooley">
<P>It is not stated that the trial is randomized<BR/>Selection criteria of the participants allows the inclusion of non-susceptible participants<BR/>The trial was conducted in Russia<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Arroyave-1999">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 1 to 6 years with history of more than 6 ARTIs during the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One capsule with 1 mg of Klebsiella products (RU41740) or placebo once a day for 8 days per month for 3 months, plus a follow up for 15 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:42:28 +1000" MODIFIED_BY="[Empty name]">
<P>During 12 months of the trial 42 RU41740 participants had 2.8 ± 1.3 (mean ± SD) ARTIs and 44 placebo participants had 8.4 ± 1.9 ARTIs<BR/>No adverse events related to the trial medications were reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>It is not stated that the trial was randomized<BR/>Flow of patient numbers and drop-outs were not clear<BR/>SD was obtained from the reported variance<BR/>This is the greatest reduction in the treatment group regarding the placebo group<BR/>The trial was conducted in Mexico<BR/>The trial was run over the 4 seasons of the year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Burgio-1994">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Children from 2 to 13 years with history of recurrent ARTIs. 101 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Pidotimod 400 mg or placebo by mouth once a day by 60 days plus a follow up of 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:35:18 +1000" MODIFIED_BY="[Empty name]">
<P>After the treatment, during the follow up, 18% of 50 participants treated with pidotimod suffered respiratory symptoms and this happened in 62.5% of 40 placebo participants<BR/>There was no adverse events in the pidotimod group while 2 adverse events were reported in the placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:39:36 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of patient numbers and drop-outs are given. Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Caramia-1994">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:14 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants from 2 to 8 years with history of 6 ARTIs in the 6 months before the trial with at least 3 antibiotic courses with current hospitalization because of relapse of ARTI (active infection) and deficit of at least 1 parameter of immune system<BR/>120 children were randomized<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:39:57 +1000" MODIFIED_BY="[Empty name]">
<P>Pidotimod 400 mg or placebo twice a day for 15 days; followed by pidotimod 400 mg or placebo once a day by 60 days plus a follow-up period of 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:40:08 +1000" MODIFIED_BY="[Empty name]">
<P>During the follow up 60 pidotimod participants had 40 relapses and 60 placebo participants had 149 relapses<BR/>5 pidotimod participants and 7 placebo participants suffered from adverse events, mainly gastrointestinal complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:40:23 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs were not reported. Only total numbers of relapses were reported. Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Careddu-1994a">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:17 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:40:33 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 3 to 14 years who had suffered more than 6 ARTIs in the autumn-winter period before the trial, with at least 3 courses of antibiotics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:40:37 +1000" MODIFIED_BY="[Empty name]">
<P>Pidotimod 400 mg daily or placebo for 60 days and a follow-up period of 90 days for a total study period of 150 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 12:25:09 +1000" MODIFIED_BY="[Empty name]">
<P>329 pidotimod participants had 0.75 ± 0.99 (mean ± SD) ARTIs during the trial period, and 342 placebo participants had 1.03 ± 1.0 ARTIs<BR/>There were 22 adverse events in the pidotimod group and 15 in the placebo group, mainly gastrointestinal complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Number of screened participants and analyzed participants are given but there is no report of drop-outs during the trial. The mean number of ARTIs in the placebo group is rather low. Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Careddu-1994b">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Children with mean age of 4.8 years with history of recurrent ARTI in the fall-winter period before the trial. 50 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:40:57 +1000" MODIFIED_BY="[Empty name]">
<P>Pidotimod 400 mg or placebo per os twice a day by 20 days and an additional follow-up period of 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:41:01 +1000" MODIFIED_BY="[Empty name]">
<P>After the treatment during the follow up 100% of 25 pidotimod participants were without infection, while 4.35% of 24 placebo participants were without infection.<BR/>Only 3 participants in the pidotimod group presented skin rash</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:41:17 +1000" MODIFIED_BY="[Empty name]">
<P>The reason for 1 drop-out is given. Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:41:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 2 to 12 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:41:28 +1000" MODIFIED_BY="[Empty name]">
<P>43 children had sublingual Lantigen B (bacterial antigen suspension) and there were 43 placebo participants in periods of 4 and 2 weeks with an interval of 2 weeks. They were followed up for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:43:01 +1000" MODIFIED_BY="[Empty name]">
<P>Children with Lantigen B had 3 (1 to 5) (mean and interval) ARTIs and children with placebo had 4 (1 to 10) ARTIs<BR/>Six participants in the Lantigen B group and 6 in the control group were lost to follow up<BR/>No adverse events were observed<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The study was conducted in China. No information on the seasons during the trial was provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Clerici-1988">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children aged 4.7 ± 1.1 years (mean ± SD) with history of 6 ARTIs in the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:41:36 +1000" MODIFIED_BY="[Empty name]">
<P>A vial (liquid form) with thymomodulin 60 mg or placebo twice a day for 3 months. There was not additional follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:43:03 +1000" MODIFIED_BY="[Empty name]">
<P>During the trial 20 thymomodulin participants had 2.55 ± 0.6 (mean ± SD) ARTIs and 20 placebo participants had 4.60 ± 0.6 ARTIs<BR/>The adverse events were not reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Flow diagram of participants and drop-outs is not given. It is not stated that the trial is randomized<BR/>The trial was conducted in Italy in autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:54:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2004">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 1 to 5 years, without clinical alterations</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:54:45 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received Chizukit (preparation of <I>Echinacea purpurea</I>, propolis and vitamin C) or placebo for 12 weeks. Children from 1 to 3 years had 5 ml twice a day and those from 4 to 5 years had 7.5 ml twice a day. During ARTIs participants had the respective dosage 4 times a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:43:09 +1000" MODIFIED_BY="[Empty name]">
<P>160 Chizukit participants had 0.9 ± 1.1 (mean ± SD) ARTIs and 168 placebo participants had 1.8 ±1.3 ARTIs. Nine participants in the verum group and 7 in the placebo group had adverse events, all gastrointestinal and palatability symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-28 11:43:10 +1000" MODIFIED_BY="[Empty name]">
<P>A flow diagram of the participants was provided. Trial was conducted in winter in Israel</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Collet-1993">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:24 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Children older than 6 months attending daycare centres<BR/>423 children were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:33:41 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months. Participants were followed up after 4.5 months for a total study period of 7.5 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:43:14 +1000" MODIFIED_BY="[Empty name]">
<P>26.7% of 210 participants with OM-85 BV and 33.8% of 213 with placebo had more than 4 infections in the 7.5 month period<BR/>OM-85 BV participants had 17 adverse events the most frequent were eczema (n = 3) and adenoidectomy (n = 2); placebo participants had 19 adverse event the most frequent were tympanocentesis (n = 3) and adenoidectomy (n = 2)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:42:06 +1000" MODIFIED_BY="[Empty name]">
<P>Flow diagram and drop-outs are given. Sub-analysis for different age groups and for the treatment period are given<BR/>The trial was conducted in France during boreal autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:36:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Loore-1979">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children suffering from chronic or recurrent upper ARTIs with history of 4 ARTIs the last winter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:35:20 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had levamisole tablets (50 mg) or placebo tablets<BR/>Dosage: participants under 15 kg had half a tablet; participants from 15 to 30 kg had a tablet; participants over 30 kg had 2 tablets. Participants were given a weekly dose for 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:36:21 +1000" MODIFIED_BY="[Empty name]">
<P>After 4 months, 15 levamisole participants had 1.3 ± 1.2 (mean ± SD) ARTIs; 17 placebo participants had 2.3 ± 1.7. Authors reported that no adverse event occurred</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>A levamisole drop-out is explained. The trial was conducted in Belgium during autumn and winter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:04 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants from 3 to 6 years with at least 3 ARTIs during the previous 6 months. 54 children were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:33:42 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months<BR/>Participants were followed up for 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:14 +1000" MODIFIED_BY="[Empty name]">
<P>After 6 months participants in the OM-85 group (n = 20) had 2.8 ± 1.4 (mean ± SD) ARTIs, while participants in the placebo group (n = 20) had 5.2 ± 1.5 ARTIs. Eight participants in the OM-85 BV group had 10 adverse events; only 3 gastrointestinal events were related to drug administration. Nine participants with placebo had 10 adverse events; 4 were related to the administration of placebo</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:36:24 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of patient numbers and drop-outs are given. The trial was conducted in Mexico<BR/>The trial was conducted over the 4 seasons. Changes in the levels of IgG subclasses were investigated; only the OM-85 BV group presented significant reduction in the IgG4 levels</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:42:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dils-1979">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 2.5 to 17 years suffering chronic or recurrent RTIs with at least 4 infections from October to February in the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had levamisole tablets (50 mg) or placebo tablets<BR/>Dosage: participants under 15 kg had half a tablet; participants from 15 to 30 kg had 1 tablet; participants over 30 kg had 2 tablets. Participants had 1 dose 1 day per week after supper</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>After 4 months, 45 children in levamisole group had 44 episodes of infection while 41 children in placebo group had 79 ARTIs<BR/>Author claimed that no side effects were reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:42:56 +1000" MODIFIED_BY="[Empty name]">
<P>No flow diagram nor drop-outs are provided<BR/>There are no data on the dispersion of ARTIs<BR/>The study was conducted in Belgium during autumn and winter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Fiocchi-1986">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:08 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 4 to 14 years with more than 6 ARTIs in the last fall-winter period with at least 3 antibiotic courses. 16 participants were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Thymomodulin 3 mg/kg/day or placebo by 3 months. There was no additional follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:42:29 +1000" MODIFIED_BY="[Empty name]">
<P>During the 3-month period, 8 thymomodulin participants had 0.53 ± 0.11 (mean ± SD) ARTIs, and 8 placebo participants had 0.82 ± 0.12 ARTIs<BR/>The adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>The sample size is clearly insufficient<BR/>The number of ARTIs in the placebo group was rather low<BR/>It is not stated that the trial is randomized<BR/>The trial was conducted in Italy during boreal autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 21:13:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiocchi-1988">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:04 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:09 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 3 to 12 years with a clinical score more than 30 in a clinical scale for ARTIs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:37:15 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received ribosomal extract spray (D53) or placebo, 1 puff in the nose and 1 in pharynx 3 times a day by 2 weeks; this schedule was repeated another 2 times with intervals of 1 week between the puff administrations. Additionally participants had 1 subcutaneous injection in the weeks 2, 5 and 8<BR/>Participants were followed up for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:16 +1000" MODIFIED_BY="[Empty name]">
<P>After 6 months 30 participants in the D53 group had 36 upper ARTIs and 45 lower ARTIs, while 30 participants in the placebo group had 43 upper ARTIs and 51 lower ARTIs<BR/>Adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 21:13:31 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of participants is not reported. The number of lower ARTIs is extremely high. Trial was conducted in Italy during autumn-winter seasons<BR/>It was not possible to identify this study in the Bellanti review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 21:13:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiocchi-1989">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:04 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:43:33 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 2 to 15 years suffering recurrent ARTIs defined as 30 points in a clinical scale and more than 5 ARTIs in the last 6 months<BR/>120 participants were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:27 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo or ribosomal extract spray (D53); 1 puff in each nostril plus 1 puff in the oropharyngeal cavity 3 times a day according to the following schedule; 2 weeks treatment, 1 week washout and 1 week treatment in the first month; 2 week treatment and 2 week washout in the second, third and fourth months. Total duration of the study was 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:33:56 +1000" MODIFIED_BY="[Empty name]">
<P>Monthly clinical score by month 4 was 4.2 ± 2.6 in 60 D53 participants and 8.0 ± 4.3 in 58 placebo participants. One child in the placebo group had a headache and was withdrawn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 21:13:35 +1000" MODIFIED_BY="[Empty name]">
<P>Two drop-outs in the placebo group are explained<BR/>The main outcome is a non-validated clinical score<BR/>The trial was conducted during boreal winter-spring seasons in Italy<BR/>It was not possible to identify this study in the Bellanti review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Fukuda-1999">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:37:45 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 8 months to 7 years with recurrent acute otitis and repetitive tonsillitis. At baseline, there were 18 participants in the thymomodulin group and 17 in the placebo group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:35:50 +1000" MODIFIED_BY="[Empty name]">
<P>Thymomodulin 4 mg/kg/day divided in 2 doses a day for 3 months or the corresponding placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 12:29:18 +1000" MODIFIED_BY="[Empty name]">
<P>55.5% of children on thymomodulin group (n = 9) and only 20% of children on placebo (n = 10) group were free from infections after the end of medication<BR/>One patient in the thymomodulin group had nausea and vomiting</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>The sample size is clearly insufficient<BR/>It is not stated that the trial is randomized<BR/>The trial was conducted in Brazil<BR/>There is no indication of the season during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:43:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garabedian-1990">
<CHAR_METHODS MODIFIED="2010-11-04 20:43:20 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, multicentre clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:11 +1000" MODIFIED_BY="[Empty name]">
<P>Participants with a mean age of 3.8 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:46:11 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had D53 or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:35:51 +1000" MODIFIED_BY="[Empty name]">
<P>In a period of 3 months 75 D53 participants had 0.73 ± 0.1 (mean ± SE) ARTIs and 69 placebo participants had 1.5 ± 0.2 ARTIs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The trial was conducted in France<BR/>Data were obtained from Boyle 2000 and Bellanti 2003 (trial RB13)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:43:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giovannini-2000">
<CHAR_METHODS MODIFIED="2010-11-04 20:43:36 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 3 to 14 years with recurrent ARTI symptoms in the last 2 years who had also suffered from at least 5 ARTIs requiring medical care in the last winter. 114 children were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:33:59 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had a tablets of 0.525 mg of ribosomal extracts (D53) or placebo daily by 4 days per week for the first 3 weeks and then 1 tablet 4 consecutive days per month for the following 5 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>45 in D53 group and 42 in placebo group finished the trial. A clinical score for upper ARTIs was 0.46 in the D53 group and 0.76 in the placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:43:46 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs are explained, but adverse event description is not clear. Primary endpoint is a non-validated clinical score. There are no data on the dispersion of the variable. Trial was conducted in autumn, winter and spring in Italy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants from 1 to 12 years with at least 3 ARTIs during the previous 6 months. 54 children were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:37:18 +1000" MODIFIED_BY="[Empty name]">
<P>At the beginning participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months. The treatment was repeated 6 months after the beginning<BR/>Participants were followed for a total study period of 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:20 +1000" MODIFIED_BY="[Empty name]">
<P>During the trial the OM-85 BV group (n = 26) had 5.04 ± 1.99 (mean ± SD) ARTIs while the placebo group (n = 28) had 8.0 ± 2.55<BR/>Four OM-85 BV participants had 5 adverse events and 6 placebo participants had 6 adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:36:30 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of patient numbers and drop-outs are given<BR/>The trial was conducted in Mexico<BR/>The trial was conducted during the 4 seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:44:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:13 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 1.5 to 9 years suffering subacute sinusitis (lasting more than 60 days and less than 90 days)<BR/>26 participants with OM-85 BV and 30 with placebo were included<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:44:09 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months<BR/>Both groups received amoxicillin/ clavulanate at entry; 40/10 mg/kg a day, divided in 3 doses, by 21 days<BR/>Participants were followed up for 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:44:16 +1000" MODIFIED_BY="[Empty name]">
<P>During the study 26 participants with OM-85 BV had 1.56 ± 1.55 ARTIs and 30 participants with placebo had 2.22 ± 2.37 ARTIs<BR/>A patient in the OM-85 BV presented rash and withdrew from the trial</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:44:20 +1000" MODIFIED_BY="[Empty name]">
<P>Definitions of subacute sinus and its cure are given. A sub-analysis for children under 6 years was included<BR/>Drop-outs are reported. But the flow of participants is not clear<BR/>The trial was conducted over the 4 seasons in Mexico</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:37:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hauguenauer-1987">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:15 +1000" MODIFIED_BY="[Empty name]">
<P>Participants aged less than 5 years with at least 3 ARTI treated with antibiotics in the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:57 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had D53 or placebo. During the first month they had 3 weeks with 3 tablets per day for 4 days per week. The next 5 months they had a week per month with 3 tablets a day for 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:22 +1000" MODIFIED_BY="[Empty name]">
<P>In a period of 6 months 45 D53 participants had 3.24 ± 2.1 (mean ± SD) ARTIs and 42 placebo participants had 4.9 ± 4.3 ARTIs<BR/>There were no adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The trial was conducted in France<BR/>Flow of patient numbers is not clear. The trial was conducted from January to June<BR/>ARTIs data were obtained from Boyle 2000 and Bellanti 2003 (trial RB12)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:44:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-H_x00fc_ls-1995">
<CHAR_METHODS MODIFIED="2010-11-04 20:44:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:35:56 +1000" MODIFIED_BY="[Empty name]">
<P>Participants with a mean age from 3 to 12 years with at least 3 severe ARTIs in the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:58 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had 3 tablets of 0.25 mg of D53 or placebo in the morning for 4 consecutive days a week for 3 consecutive weeks. The following 5 months they had a 1 week cycle per month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:22 +1000" MODIFIED_BY="[Empty name]">
<P>In a period of 6 months 78 D53 participants had 1.7 ± 0.16 (mean ± SE) ARTIs and 78 placebo participants had 2.5 ± 0.2 ARTIs<BR/>Three participants in the D53 group had aggressiveness, cough and headache respectively; 2 placebo participants presented fever and exudative erythema respectively</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>It was conducted in Germany during boreal autumn-winter seasons<BR/>This study is cited by Boyle, and it corresponds to RB14 in Bellanti's review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Iuldashev-1988">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Healthy children from 2 to 6 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 21:13:46 +1000" MODIFIED_BY="[Empty name]">
<P>1100 children received Reaferon (an analogue of human interferon 2 obtained by genetic engineering) 1106 IU in 0.5 ml of water orally twice a week for 2 months. 1078 received 0.5 ml of water as placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Children from 2 to 3 years treated with Reaferon had 1.3 less ARTIs than the placebo group. Children &gt; 3 years did not have statistically significant improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>It is not stated that the trial is randomized<BR/>Selection criteria of the participants allows the inclusion of non-susceptible participants<BR/>The study was conducted from September to October in the former USSR<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:34:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Girls from 6 to 13 years suffering more than 3 ARTI during fall and winter seasons before the trial, living in an orphanage<BR/>200 girls entered the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:03 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo once daily for 10 days per month for 3 months<BR/>Participants were followed up for 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:43:55 +1000" MODIFIED_BY="[Empty name]">
<P>During the study period 99 OM-85 BV participants had 1.43 ± 0.94 (mean ± SD) ARTIs and 100 placebo participants had 2.99 ± 0.81 ARTIs. No adverse events related to the trial medications were reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:34:04 +1000" MODIFIED_BY="[Empty name]">
<P>The reason for excluding 1 participants from the analysis is given<BR/>Confounders are well controlled as all the participants had the same background and lived in the same place under the same conditions<BR/>The trial was conducted in Mexico<BR/>The trial was conducted during the boreal autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Children from 3 to 12 years suffering recurrent bronchitis with 6 episodes probed by the physician prescriptions in the last year with 3 antibiotic courses.<BR/>80 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A vial (liquid form) with thymomodulin 3 mg/kg or placebo once a day by 3 months. There was no additional follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:46:16 +1000" MODIFIED_BY="[Empty name]">
<P>During the trial 33 thymomodulin participants had 1.59 ± 1.98 (mean ± SD) ARTIs and 39 placebo participants had 2.61 ± 3.04 ARTIs<BR/>Participants did not present adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:44:50 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs are explained<BR/>The trial was conducted in Mexico<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:45:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacomme-1985">
<CHAR_METHODS MODIFIED="2010-11-04 20:45:00 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, multicentre clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:17 +1000" MODIFIED_BY="[Empty name]">
<P>Participants aged from 2 to 15 years with 5 to 7 ARTIs and 5 antibiotic courses during the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:59 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had D53 or placebo. During the first month they had 3 weeks of 3 tablets a day for 4 days per week. The next 5 months they had a week per month with 3 tablets a day for 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:25 +1000" MODIFIED_BY="[Empty name]">
<P>In a period of 6 months 47 D53 participants had 4.04 ± 4.2 (mean ± SD) ARTIs and 40 placebo participants had 5.38 ± 3.7 ARTIs<BR/>There was no adverse event in the D53 group, while there were 6 cases of digestive adverse events in the placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The trial was conducted in France. There are no data about the seasons during the trial<BR/>ARTIs data were obtained from Boyle 2000 and Bellanti 2003 (trial RB11)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:38:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Litzman-1999">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 4 to 8 years with at least 5 documented respiratory tract infections during the last autumn-winter seasons</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:46:18 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had placebo or isoprinosine, 50 mg/kg per day divided in 4 to 6 doses for a period of 6 weeks and then 50 mg/kg per day twice a week during 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:34:12 +1000" MODIFIED_BY="[Empty name]">
<P>During the 6-month study period, 43 isoprinosine participants had 3.3 ± 1.9 (mean ± SD) ARTIs and 41 placebo participants had 3.9 ± 2.0 ARTIs<BR/>A isoprinosine patient and a placebo patient had transit increase in antinuclear antibodies and 1 placebo participant had an increase in the rheumatoid factor</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:38:25 +1000" MODIFIED_BY="[Empty name]">
<P>Reasons for drop-out are provided. Trial was conducted during autumn and winter in the Czech Republic</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:36:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Longo-1988">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:34:18 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 3.5 to 9 years with history of recurrent ARTI in the last fall-winter period with more than 1 fever episode by month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:20 +1000" MODIFIED_BY="[Empty name]">
<P>Participants were followed by 1 year before the beginning of study medication<BR/>Participants took thymomodulin 30 mg or placebo twice a day by 4 months plus a follow up of 8 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:06 +1000" MODIFIED_BY="[Empty name]">
<P>During 12 months the total number of infections was 26 in 21 participants treated with thymomodulin and 72 in the 19 placebo participants<BR/>The adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:36:37 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of patient numbers and drop-outs are not given<BR/>The trial was conducted in Italy<BR/>The trial was conducted during the 4 seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Maestroni-1984">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:44:07 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 1 to 16 years who were susceptible to upper ARTIs<BR/>20 participants were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:21 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months<BR/>Participants were followed up for 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:08 +1000" MODIFIED_BY="[Empty name]">
<P>During the study 11 participants receiving OM-85 BV had 2.0 ± 2.05 (mean ± SD) ARTIs and 9 participants with placebo had 5.55 ± 5.36 ARTIs<BR/>The adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Inclusion criteria are not clear<BR/>It is not stated that the trial is randomized; the sample size is clearly insufficient<BR/>The trial was conducted in Switzerland<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Martin-du-Pan-1982">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-09 14:23:50 +1000" MODIFIED_BY="Liz Dooley">
<P>Children from 8 months to 5 years attending to daycare centres or those highly susceptible to ARTI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:46:19 +1000" MODIFIED_BY="[Empty name]">
<P>One capsule of 3.5 mg of OM-85 BV or placebo once a day for 10 days per month for 3 months<BR/>Participants were followed for a further 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-21 12:18:02 +1000" MODIFIED_BY="Liz Dooley">
<P>During the 6-month study period 36 participants with OM-85 BV had 265/3660 days (7.24%) suffering from purulent rhinorrhea, while 34 placebo participants had 569/3530 days (16.12%) suffering from purulent rhinorrhea<BR/>The adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:45:31 +1000" MODIFIED_BY="[Empty name]">
<P>The participants participated in a previous trial 1 year before comparing the effect of a syrup with yeast extract versus a placebo syrup<BR/>Flow of patient numbers and drop-outs are not given. Sub-analyses for the children attending the daycare centres and private practice are provided<BR/>The trial was conducted in Switzerland during autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Mora-2002">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 4 to 14 years with history of otitis and recurrent ARTIs by more than 2 years, with 3 ARTIs requiring medical care the last winter. 84 children were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:24 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had a tablets of ribosomal extracts (D53) or placebo daily for 4 days per week for the first 3 weeks and then 1 tablet for 4 consecutive days per month for the following 5 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:45:42 +1000" MODIFIED_BY="[Empty name]">
<P>41 children in the D53 group and 40 in placebo group finished the 6-month trial. There were greater improvements in D53 group regarding incidence of infections, otitis, fever and duration of antibiotic and ancillary treatments. One D53 patient has dysuria and another 2 heartburn; 1 placebo patient had somnolence and another 1 had heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>It was not established if trial was randomized. Drop-outs are explained. There is no clinical definition of otitis. Primary end points are a non-validated clinical scores given as ranks. To express a significant difference "P &gt;" is used; for instance "P &gt; 0.02".<BR/>Trial was conducted in autumn, winter and spring in Italy<BR/>It is not possible to establish if this trial corresponds to any study cited by Bellanti in his review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:46:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mora-2007">
<CHAR_METHODS MODIFIED="2010-03-08 06:48:09 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:44:10 +1000" MODIFIED_BY="[Empty name]">
<P>160 participants from 5 to 14 years with recurrent pharyngotonsillitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:46:03 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had D53 or placebo 1 tablet a day, 8 days a month for 3 months plus 3 months of follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:45:58 +1000" MODIFIED_BY="[Empty name]">
<P>The number of ARTIs was reported as an ordinal categorical scale (1, 2 or &gt; 2). By the end of trial D53 score was 1 and placebo 2 (no dispersion is reported). A clinical scale score was 1.9 in D53 group and 3.1 in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-09 14:26:11 +1000" MODIFIED_BY="Liz Dooley">
<P>The clinical scale was not described. The study was conducted in Italy. The flow diagram of the number of participants is not included. Authors claimed that no participant experienced side effects from the treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:46:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mora-2010a">
<CHAR_METHODS MODIFIED="2010-09-28 10:14:09 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 12:32:27 +1000" MODIFIED_BY="[Empty name]">
<P>80 children aged between 6 and 14 years with recurrent acute adenoiditis defined as more than 4 episodes of acute adenoiditis during a 6-month period. Acute adenoiditis was defined as mouth breathing, nasal obstruction, body temperature higher than 38 C, mucoid anterior nasal discharge, postnasal drip, otitis media and snoring</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 12:32:30 +1000" MODIFIED_BY="[Empty name]">
<P>Group A children had D53 (Immucytal) 1 tablet daily, 8 days a month for 3 months; group B children had placebo in the same way. Both groups were followed 3 extra months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:34:31 +1000" MODIFIED_BY="[Empty name]">
<P>After 3 months 2/30 in the D53 group and 12/30 in the placebo group had more than 1 acute episode of adenoiditis. After 6 months 2/30 in the D53 group and 18/30 in the placebo group had more than 1 acute episode of adenoiditis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:46:18 +1000" MODIFIED_BY="[Empty name]">
<P>Levels of IgE, IgA, IgG, and IgM were investigated, as well as tympanometry, rhinomanometry, and symptom visual analogue scale by the parents. Only 60 participants completed the trial, the lost of participants are explained</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:46:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motta-1994">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:40 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 3 to 14 years with history of recurrent tonsillitis with at least 8 episodes in the last 2 years, who had suffered tonsillitis 10 days before the enrolment to the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:46:28 +1000" MODIFIED_BY="[Empty name]">
<P>Pidotimod 400 mg (liquid form) or placebo twice a day by 15 days; then pidotimod 400 mg or placebo once a day by 45 days. Participants were followed up for another 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:14 +1000" MODIFIED_BY="[Empty name]">
<P>During the trial 117 pidotimod participants had 1.96 ± 1.80 (mean ± SD) ARTIs and the 118 placebo participants had 3.12 ± 2.45 ARTIs<BR/>11 pidotimod participants had 15 adverse events, while 12 placebo participants had 18 adverse events, mainly gastrointestinal complaints<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:46:35 +1000" MODIFIED_BY="[Empty name]">
<P>Flow diagram of participants and drop-outs are not given. Number of infections per group was reconstructed from the reported frequencies<BR/>Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Passali-1994a">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Children from 3 to 14 years with history of tonsillitis or pharyngitis in the previous autumn-winter seasons<BR/>429 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:46:41 +1000" MODIFIED_BY="[Empty name]">
<P>Pidotimod 400 mg or placebo once a day for 2 months plus a follow-up period of 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:15 +1000" MODIFIED_BY="[Empty name]">
<P>Total number of infections during the treatment period of 2 months and the follow up period of 3 months were 186 and 129 in the 205 pidotimod participants, while for the same periods the number of ARTIs were 278 and 276 in 216 placebo participants<BR/>There were 5 adverse events in the pidotimod group and 10 in the placebo group, mainly gastrointestinal complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:46:55 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of patient numbers and drop-outs are given<BR/>Only the total number of ARTIs per group is reported<BR/>Most of the pidotimod papers were published in a single supplement issue of a German magazine<BR/>The trial was conducted in Italy<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Paupe-1986">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-25 04:21:41 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 1 to 13 years with history of recurrent rhinopharyngeal infection with at least 3 infections of this kind during the year before the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:32 +1000" MODIFIED_BY="[Empty name]">
<P>2 capsules with 1 mg of Klebsiella products (RU41740) or placebo once a day for 8 days; 3 weeks without treatment; then 1 capsule a day for 8 days per month for 2 months; plus an additional follow up period of 21 weeks<BR/>The total period of the study was 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>During the study period 21 participants with RU41740 had 1.57 ± 1.60 (mean ± SD) ARTIs and 22 placebo participants had 2.41 ± 2.59 ARTIs. There was 1 case of diarrhea and 1 of urticaria in the RU41740 group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:47:05 +1000" MODIFIED_BY="[Empty name]">
<P>ARTI data were obtained from a paper by Reinert 1995 as he reported the data as mean ± SD. Safety data are from Paupe<BR/>The trial was conducted in France<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Paupe-1991">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants from 0.5 to 19 years, with history of more than 3 ARTIS in the last 6 months. 127 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:36 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo a day for 10 days per month for 3 months<BR/>Participants were followed for another 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>During the study 34% of 61 participants with OM-85 BV and 3.5% of 55 participants with placebo had no infection<BR/>One patient with OM-85 BV, 2 with placebo had diarrhea</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:47:15 +1000" MODIFIED_BY="[Empty name]">
<P>The reasons for excluding participants from the analysis are given<BR/>The trial was conducted in France<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:47:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pech-1987">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-25 04:21:46 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 1 to 12 years with history of recurrent rhinopharyngeal infection with at least 3 infections of this kind during the year before the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:47:21 +1000" MODIFIED_BY="[Empty name]">
<P>2 capsules with 1 mg of Klebsiella products (RU41740) or placebo once a day by 8 days; 3 weeks without treatment; then a capsule once a day for 8 days per month for 2 months; plus an additional follow-up period of 21 weeks<BR/>The total period of the study was 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:34:38 +1000" MODIFIED_BY="[Empty name]">
<P>During the study period 35 participants with RU41740 had 1.11 ± 1.16 (mean ± SD) ARTIs and 34 placebo participants had 1.88 ± 1.43 ARTIs<BR/>In RU41740 group 1 patient presented dry cough and another had difficulties in swallowing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:47:30 +1000" MODIFIED_BY="[Empty name]">
<P>ARTI data were obtained from a paper by Reinert 1995<BR/>The number of ARTIs in the placebo group is low<BR/>The trial was conducted in France<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:47:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piquett-1986">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-25 04:21:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 1 to 12 years with history of recurrent rhinopharyngeal infection with at least 3 infections of this kind during the year before the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:47:38 +1000" MODIFIED_BY="[Empty name]">
<P>2 capsules with 1 mg of Klebsiella products (RU41740) or placebo once a day by 8 days; 3 weeks without treatment; then a capsule a day by 8 days per month by 2 months; plus an additional follow-up period of 21 weeks<BR/>The total period of the study was 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:18 +1000" MODIFIED_BY="[Empty name]">
<P>During the study period 17 participants with RU41740 had 1.35 ± 1.41 (mean ± SD) ARTIs and 20 placebo participants had 1.35 ± 1.46 ARTIs<BR/>Adverse events report is not available<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:47:47 +1000" MODIFIED_BY="[Empty name]">
<P>ARTI data were obtained from a paper by Reinert 1995<BR/>The number of ARTIs in the placebo group is low<BR/>The trial was conducted in France<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 21:14:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pozzi-2004">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:48 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children with recurrent ARTIs from 1.5 to 15.2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 21:14:11 +1000" MODIFIED_BY="[Empty name]">
<P>The participants had bacterial lysate (Lantigen B) or placebo. Participants received 7 to 8 drops twice a day during: weeks 1, 2, 3 and 4 of the second month; weeks 3 and 4 of the third month; weeks 3 and 4 of the fourth month; weeks 1 and 2 of the sixth month; weeks 1 and 2 of the seventh month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 21:14:13 +1000" MODIFIED_BY="[Empty name]">
<P>During the 6-month period 47 Lantigen B participants had a mean number of ARTIS of 1.211 while 47 placebo participants had 1.643. The number but not the kind of adverse events are reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:06 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs are explained<BR/>Dispersion of the mean number of ARTIs (SD) is not provided<BR/>A group of adults was also included in the trial<BR/>There were no data on the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB10-1994">
<CHAR_METHODS MODIFIED="2010-09-28 10:14:10 +1000" MODIFIED_BY="[Empty name]">
<P>Double blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:19 +1000" MODIFIED_BY="[Empty name]">
<P>153 D53 participants had 1.13 ± 1.2 (mean ± SD) ARTIs and 161 placebo participants had 1.32 ± 1.4 ARTIs. No adverse event report is provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:13 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB17-1988">
<CHAR_METHODS MODIFIED="2010-09-28 10:14:11 +1000" MODIFIED_BY="[Empty name]">
<P>Double blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:20 +1000" MODIFIED_BY="[Empty name]">
<P>By the third month, 15 D53 participants had 1.2 ± 0.86 (mean ± SD) ARTIs and 15 placebo participants had 3.73 ± 2.05 ARTIs. No adverse event report was provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:18 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial<BR/>The number of ARTIs is extremely high</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB21-1988">
<CHAR_METHODS MODIFIED="2010-11-04 20:48:27 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:20 +1000" MODIFIED_BY="[Empty name]">
<P>45 D53 participants had 0.54 ± 0.6 (mean ± SD) ARTIs and 42 placebo participants had 0.95 ± 0.5 ARTIs. No adverse event report is provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:29 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB22-1990">
<CHAR_METHODS MODIFIED="2010-09-28 10:14:15 +1000" MODIFIED_BY="[Empty name]">
<P>Double blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:20 +1000" MODIFIED_BY="[Empty name]">
<P>20 D53 participants had 3.0 ± 1.0 (mean ± SD) ARTIs and 20 placebo participants had 6.2 ± 1.4 ARTIs. No adverse event report is provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:35 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial<BR/>The number of ARTIs is extremely high</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB24-1990">
<CHAR_METHODS MODIFIED="2010-11-04 20:48:45 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:21 +1000" MODIFIED_BY="[Empty name]">
<P>16 D53 participants had 0.36 ± 0.5 (mean ± SD) ARTIs and 17 placebo participants had 0.92 ± 0.8 ARTIs. No adverse event report is provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:51 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:48:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RB25-1990">
<CHAR_METHODS MODIFIED="2010-11-04 20:48:55 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D53 or placebo for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:21 +1000" MODIFIED_BY="[Empty name]">
<P>13 D53 participants had 1.31 ± 0.2 (mean ± SD) ARTIs and 12 placebo participants had 3.25 ± 0.6 ARTIs. No adverse event report is provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:48:59 +1000" MODIFIED_BY="[Empty name]">
<P>Available data are from the Bellanti review. It was not possible to establish if this trial corresponds to any other published trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:49:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Renzo-2004">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 6 to 14 years with history of recurrent or chronic ARTIs for more than 2 years and at least 5 ARTIs in the last years or suffering otitis media by more than 3 months. 72 children were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:39 +1000" MODIFIED_BY="[Empty name]">
<P>Ribosomal extracts (D53) or placebo, 1 tablet daily in the morning 8 days per month for 3 consecutive months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:33 +1000" MODIFIED_BY="[Empty name]">
<P>36 children in each group finished the 6-month trial. There were greater improvements in D53 group regarding incidence of infections, otitis, fever, and duration of antibiotic and ancillary treatments. According to the authors there was no adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:49:11 +1000" MODIFIED_BY="[Empty name]">
<P>Drop-outs are explained. There is no clinical definition of otitis. Primary endpoints are a non-validated clinical scores given as ranks. To express a significant difference "P &gt;" is used; for instance "P &gt; 0.02"<BR/>Trial was conducted in autumn, winter and spring in Italy<BR/>It is not possible to establish if this trial correspond to any study cited by Bellanti in his review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:49:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<CHAR_METHODS MODIFIED="2010-09-28 10:44:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 4 to 9 years, with history of 10 ARTIs in the last year<BR/>Children from 4 to 6 years must have 8 severe ARTIs lasting more than 2 weeks in this period<BR/>Children from 7 to 9 years must have 4 severe ARTIs lasting more than 2 weeks in this period<BR/>115 children had LW50020 and 118 had placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dosage is not specified. Total follow up of 14 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:22 +1000" MODIFIED_BY="[Empty name]">
<P>During the study period 99 participants with LW50020 had 15 ARTIs and 108 participants with placebo had 29 ARTIs data dispersion is not specified<BR/>10.4% of participants with LW50020 experienced adverse events versus 5.1% in the placebo group. The adverse events were mainly gastrointestinal complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:49:17 +1000" MODIFIED_BY="[Empty name]">
<P>The reasons for participants' exclusion from analysis are given. The intervention is not well defined<BR/>The trial was conducted in Germany<BR/>There were no data about the seasons during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:49:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rutishauser-1998">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:53 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:21 +1000" MODIFIED_BY="[Empty name]">
<P>Children from 4 to 11 years with history of recurrent ARTIs; children from 4 to 6 years with more than 10 ARTIs in the last year, those from 7 to 11 with more than 8 ARTIs in the last year. 200 children were included<BR/>Participants suffering 4 ARTIs lasting more than 2 weeks were included too<BR/>124 children had LW50020 and 76 had placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:49:31 +1000" MODIFIED_BY="[Empty name]">
<P>The total duration of the trial was 16 weeks: 4-week treatment (a tablet with 3 mg of bacterial lysates or placebo once a day); 4-week follow up; 4-week treatment (same schedule); and 4-week follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:23 +1000" MODIFIED_BY="[Empty name]">
<P>Considering only children. During the study period 75% of 117 participants with LW50020 had no infection and 54% of 72 placebo participants had no infection<BR/>Considering children and adults, 62 participants had 101 adverse events in the LW50020 group, while 26 participants had 38 adverse events in the placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:36:39 +1000" MODIFIED_BY="[Empty name]">
<P>The reason for excluding participants from the analysis are not given<BR/>Beside the children group, the trial included a group of adolescents and adults<BR/>The trial was conducted in Switzerland<BR/>The trial was conducted during the 4 seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:34:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<CHAR_METHODS MODIFIED="2010-11-04 20:32:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children older than 2 years and younger than 18 years currently suffering acute or chronic ARTIs and history of 3 ARTIs the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:40 +1000" MODIFIED_BY="[Empty name]">
<P>135 participants had RU 41740 (1 mg of klebsiella glycoproteins by tablet) and 117 placebo. Participants had 1 tablet OD for 8 consecutive days per month, for 3 consecutive months<BR/>The total period of the study was 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:46:21 +1000" MODIFIED_BY="[Empty name]">
<P>Participants with RU 41740 had 8.0 ± 3.4 (mean ± SD) ARTIs and placebo participants 7.2 ± 3.2. Yet authors claimed that RU 41740 participants experienced clinical improvement<BR/>Authors did not describe the adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-28 11:44:24 +1000" MODIFIED_BY="[Empty name]">
<P>There is no flow diagram of the study, nor explanation of drop-outs. This is the only study where the active treatment participants had a higher ARTIs number, probably a clerical mistake</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Schaad-1986">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:21 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 8 months to 12 years with who had recurrent ARTIs during fall and winter seasons in the last year<BR/>45 participants received OM-85 BV and 49 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:46:22 +1000" MODIFIED_BY="[Empty name]">
<P>One capsule of 3.5 mg of OM-85 BV or placebo a day by 10 days per month during 3 months<BR/>Participants were followed up for 3 months for a total study period of 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:34:42 +1000" MODIFIED_BY="[Empty name]">
<P>During the study 45 OM-85 BV participants had 2.89 ± 1.77 (mean ± SD) ARTIs and 49 placebo participants had 2.98 ± 1.56 ARTIs<BR/>Only 1 patient in the placebo group had urticaria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>It is not stated that the trial is randomized. Flow diagram of participants is not provided<BR/>The trial was conducted in Germany during autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Schaad-2002">
<CHAR_METHODS MODIFIED="2010-11-04 20:33:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-28 11:46:22 +1000" MODIFIED_BY="[Empty name]">
<P>Participants from 36 to 96 months with a history of recurrent ARTIs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:46:22 +1000" MODIFIED_BY="[Empty name]">
<P>One capsule of 3.5 mg of OM-85 BV or placebo once a day for 10 days per month for 3 months<BR/>Participants were followed for another 3 months for a total study period of 6 months<BR/>120 participants had OM-85 BV and 100 placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>The mean cumulative difference of ARTIs between the groups was -0.4 or a reduction of 16%, favorable to OM-85 BV. 88 participants with OM-85 BV had 456 adverse events and 76 placebo participants had 379 events. Most of the adverse events were gastrointestinal and respiratory</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:50:28 +1000" MODIFIED_BY="[Empty name]">
<P>There is no flow diagram of the study, nor explanation of drop-outs. This trial was conducted in Germany and Switzerland during summer and autumn. There are no data on the dispersion of ARTIs (SD)</P>
<P>A later review by the same author reported ARTIs; 2.12 ± 1.44 for OM-85 and 2.48 ± 1.63</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:50:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sramek-1986">
<CHAR_METHODS MODIFIED="2010-11-04 20:50:33 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 3 to 6 years attending school or maternal school<BR/>1203 entered the trial, only 1152 completed the trial and their data were used for analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 11:44:26 +1000" MODIFIED_BY="[Empty name]">
<P>Spray application of IRS19 (n = 416) or placebo (n = 409) during 20 days, a group of participants (327) did not receive any medication, the total duration of the follow up is variable (about 6 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The number of ARTIs as cases per 1000 persons days was IRS19 7.79, placebo 7.43, and no-treatment 8.04<BR/>Adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:35:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomisation was unblinded ascribing children to 1 of 2 medication batches or left without treatment<BR/>Reasons for drop-outs are not specified<BR/>Only ARTIs associated with school absenteeism were considered. Tonsillitis, sinusitis and otitis media were not considered. There is a bias to consider only severe infections<BR/>The trial was conducted in the former Czechoslovakia<BR/>The trial was conducted during autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:54:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-2003">
<CHAR_METHODS MODIFIED="2010-11-04 20:33:08 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 2 to 11 years without significant health problems</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:54:55 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had a preparation of <I>Echinacea purpurea</I> or placebo. Children from 2 to 5 years had 3.75 ml twice a day and children from 6 to 11 years had 5 ml twice a day during ARTIs (up to 3 ARTIs, during a maximum of 10 days each). The study period was 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:50:49 +1000" MODIFIED_BY="[Empty name]">
<P>200 children with echinacea had 337 ARTIs and 207 with placebo had 370 ARTIs. 52.3% of the children with echinacea and 64.4% of the children with placebo had more than 1 ARTI<BR/>Echinacea and placebo. Participants had 152 and 146 adverse events respectively. Most of the adverse events were cutaneous and gastrointestinal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Flow diagram of participants is provided. Subject did not have history of recurrent ARTIs. The trial was conducted in the USA during autumn, winter and spring</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:37:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Eygen-1976">
<CHAR_METHODS MODIFIED="2010-11-04 20:33:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children aged 1.8 to 14.5 years with history of relapsing upper ARTIs in winter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:37:34 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had placebo or levamisole 1.25 mg/kg twice a day for 2 consecutive days every week for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:44:26 +1000" MODIFIED_BY="[Empty name]">
<P>38 levamisole participants had 1.6 ± 1.5 (mean ± SD) ARTIs while 32 placebo participants had 3.8 ± 2.0 ARTIs<BR/>Authors claim that no adverse event were observed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Apparently, there were no drop-outs. The trial was conducted in Belgium during autumn and winter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:37:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Eygen-1979">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children from 0.6 to 16 years suffering recurrent ARTIs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:35:32 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had syrup with placebo or 5 mg of levamisole per ml. Participants had 5 ml of syrup per 5 kg twice a day for 2 consecutive days every week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:37:35 +1000" MODIFIED_BY="[Empty name]">
<P>After 6 months 53 levamisole participants had 1.28 ± 1.49 (mean ± SD) ARTIs and the placebo group 3.07 ±1.89 ARTIs<BR/>Only 1 patient with levamisole had stomach complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Apparently, there were no drop-outs. The trial was conducted in Belgium during autumn and winter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:51:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vautel-1993">
<CHAR_METHODS MODIFIED="2010-09-28 10:14:17 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children aged 2.98 ± 0.17 years (mean ± SE) with history of 5 ARTIs during the last 12 months or with 3 ARTIs during the last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:36:04 +1000" MODIFIED_BY="[Empty name]">
<P>D53 or placebo 3 tablets daily taken as a single dose 4 days per week for the first 3 weeks and then 4 consecutive days per month for the following 5 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:51:12 +1000" MODIFIED_BY="[Empty name]">
<P>During the 6-month period 32 D53 participants had 3.39 ± 0.38 (mean ± SE) ARTIs and 32 placebo participants had 5.56 ± 0.39 ARTIs<BR/>Regarding adverse events D53 participants had 3 cases of rhinitis and placebo participants had 3 cases of rhinitis, 1 of pharyngitis, and 1 with abdominal pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 20:51:27 +1000" MODIFIED_BY="[Empty name]">
<P>Flow of number of participants and drop-out are not reported. The trial was conducted in the private practice<BR/>Potential ARTIs were reported as adverse events<BR/>The trial was conducted in France<BR/>There were no data about the seasons during the trial. This trial corresponds to the study RB 15 in the Bellanti review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 20:55:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahl-2008">
<CHAR_METHODS MODIFIED="2010-11-04 20:51:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, two-by-two factorial trial with 6-month follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 20:36:07 +1000" MODIFIED_BY="[Empty name]">
<P>90 children aged 12 to 60 months with recurrent otitis media, defined as 3 or more separate episodes of acute otitis media (AOM) within 6 months, or at least 4 episodes in 1 year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:55:05 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly assigned to 1 of 4 protocol groups: double placebo, echinacea plus sham osteopathic manipulative treatment (OMT), true OMT (including cranial manipulation) plus placebo echinacea, or true echinacea plus OMT. An alcohol extract of <I>Echinacea purpurea</I> roots and seeds (or placebo) was administered for 10 days at the first sign of each common cold. Five OMT visits (or sham treatments) were offered over 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 20:51:54 +1000" MODIFIED_BY="[Empty name]">
<P>As no interaction was found between echinacea and OMT, the results of echinacea versus placebo were presented; 65% of children assigned to echinacea experienced AOM compared to 41% of children taking placebo (RR 1.59; 95% CI 1.04 to 2.42).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-25 04:22:14 +1000" MODIFIED_BY="[Empty name]">
<P>Only 62% of the participants completed the follow-up period of 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Zagar-1988">
<CHAR_METHODS MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Children from 4 to 12 years, suffering from chronic rhino-sinusitis during a symptomatic episode of the disease<BR/>55 participants were randomized</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-04 20:34:59 +1000" MODIFIED_BY="[Empty name]">
<P>Participants received either 1 capsule of 3.5 mg of OM-85 BV or placebo once a day by 30 days. After 1 month 1 capsule 1 day for 10 days per month for 3 months. Participants received antibiotics at the beginning of the trial. The total period of the trial was 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-28 11:46:24 +1000" MODIFIED_BY="[Empty name]">
<P>During the study period 29 with OM-85 BV had 0.38 ± 0.26 (mean ± SD) ARTIs and 22 participants with placebo had 1.09 ± 0.65 ARTIs<BR/>Participants did not present adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-28 11:44:28 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical definitions of chronic sinusitis and its cure are not provided<BR/>The reasons for excluding participants from the analysis are not given. The number of ARTIs is rather low<BR/>The trial was conducted in the former Yugoslavia<BR/>The trial was conducted during autumn-winter seasons</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ARTI = acute respiratory tract infection<BR/>RTIs = respiratory tract infections<BR/>SD = standard deviation<BR/>COPD = chronic obstructive airways disease<BR/>iv = intravenously<BR/>n = number<BR/>IgG = immunoglobulin G<BR/>OD = daily</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-28 12:37:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almeida-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 12:37:08 +1000" MODIFIED_BY="[Empty name]">
<P>Only included participants with asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 20:35:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aymard-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 20:35:03 +1000" MODIFIED_BY="[Empty name]">
<P>The trial was part of the Collet's study. Yet, it is a good paper and it is the only one showing prevention of viral ARTIs proved with viral test</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was a trial on asthmatic children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 20:52:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-B_x00e1_novein-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 20:52:20 +1000" MODIFIED_BY="[Empty name]">
<P>Comparison between IS without placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 11:44:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Das-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 11:44:28 +1000" MODIFIED_BY="[Empty name]">
<P>The age of the participants is not specified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 20:52:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiocchi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 20:52:23 +1000" MODIFIED_BY="[Empty name]">
<P>Unable to ascertain whether this was a subgroup of an included study <LINK REF="STD-Fiocchi-1989" TYPE="STUDY">Fiocchi 1989</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fontana-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was a trial on asthmatic children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grimfeld-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]">
<P>The trial used an antihistaminic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grimm-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Results of children and adults are not separated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 09:44:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heinz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 09:44:56 +1000" MODIFIED_BY="[Empty name]">
<P>The trial was on adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herrera_x002d_Basto-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>The results only compare the effect of pidotimod during the acute phase of ARTIs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kozhukharova-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Trial was not double-blind, placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lauriello-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was a trial during the acute phase of respiratory infection in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luchikhin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Trial was not double-blind, placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Trial was not double-blind, placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macchi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open trial in adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Makovetskaya-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Trial was not double-blind, placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 09:46:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mora-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 09:46:11 +1000" MODIFIED_BY="[Empty name]">
<P>Trial on acute adenoiditis not on prevention of acute respiratory tract infections</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 11:44:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mueller-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 11:44:29 +1000" MODIFIED_BY="[Empty name]">
<P>It was a study on asthmatic participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Nespoli-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-21 12:18:03 +1000" MODIFIED_BY="Liz Dooley">
<P>It was a randomized, multicentre trial - it did not include a placebo group but a group without treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Obrosova_x002d_Serova-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 09:22:06 +1000" MODIFIED_BY="[Empty name]">
<P>Trial was not double-blind, placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oggiano-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was an open trial on children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oldini-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was a Ribomunyl trial including adults and children without a separate analysis for each group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ortega-del-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was an acute phase trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 12:37:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Predy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 12:37:21 +1000" MODIFIED_BY="[Empty name]">
<P>It is a trial in adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 20:53:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prusek-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 20:53:09 +1000" MODIFIED_BY="[Empty name]">
<P>Comparison between IS without placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 09:45:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Razi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 09:45:49 +1000" MODIFIED_BY="[Empty name]">
<P>The trial included children with asthma symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-09 14:31:49 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Riedl_x002d_Seifert-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-09 14:31:49 +1000" MODIFIED_BY="Liz Dooley">
<P>The report duplicates the results of <LINK REF="STD-Riedl_x002d_Seifert-1995" TYPE="STUDY">Riedl-Seifert 1995</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 12:41:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosaschino-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 12:41:38 +1000" MODIFIED_BY="[Empty name]">
<P>It was an open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was an open trial in adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruah-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Both study groups had immunostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rytel-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]">
<P>It was a trial in an adult population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-09 14:32:09 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Scotti-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-09 14:32:09 +1000" MODIFIED_BY="Liz Dooley">
<P>It was an open trial in children without a control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinsbekk-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-04 07:13:11 +1000" MODIFIED_BY="[Empty name]">
<P>The trial used a homeopathic medicine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-09 14:32:26 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Vascotto-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-09 14:32:26 +1000" MODIFIED_BY="Liz Dooley">
<P>It was an open trial in children without a control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yale-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was an acute phase trial in adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IS = immunostimulants</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-04-17 04:51:27 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-04-17 04:48:47 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:48:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:36:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:38:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:37:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:45:07 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:45:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-04-17 04:51:27 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:32:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:34:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:34:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:35:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:36:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:36:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:37:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:38:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:38:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:51:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:39:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:51:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:40:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:40:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:40:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:40:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:42:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:43:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:44:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:44:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:44:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:44:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:44:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:45:05 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:46:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:46:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:46:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:47:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:47:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:47:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-17 04:45:32 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:32:37 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:36:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:36:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:37:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:39:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:41:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:45:09 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 04:45:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-04-17 04:45:39 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:32:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:36:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:36:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:38:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:40:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:41:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:45:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-17 04:45:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-04-17 04:45:48 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:32:43 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2011-04-17 04:32:49 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:36:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2011-04-17 04:37:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:36:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2011-04-17 04:36:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:41:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:45:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2011-04-17 04:45:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-17 04:45:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2011-04-17 04:45:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-04-17 04:45:50 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:36:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:36:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:38:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:40:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:41:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:44:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:45:19 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-17 04:45:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-04-17 04:45:56 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:32:59 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahrens-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andrianova--2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Arroyave-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Caramia-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Careddu-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clerici-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:36:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:36:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collet-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-De-Loore-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:38:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dils-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiocchi-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fukuda-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garabedian-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Giovannini-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:40:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hauguenauer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ls-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iuldashev-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:41:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karam_x002d_Bechara-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lacomme-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Litzman-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Longo-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Maestroni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martin-du-Pan-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mora-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Motta-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Passali-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paupe-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pech-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piquett-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pozzi-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB10-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB17-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB21-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB22-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB24-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RB25-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Renzo-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Riedl_x002d_Seifert-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rutishauser-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saracho_x002d_Weber-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schaad-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schaad-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:45:23 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 04:45:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1976">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vautel-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wahl-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zagar-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-04-21 12:18:06 +1000" MODIFIED_BY="Liz Dooley">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-04-21 12:18:06 +1000" MODIFIED_BY="Liz Dooley" NO="1">
<TITLE MODIFIED="2011-02-18 12:14:32 +1000" MODIFIED_BY="[Empty name]">Summary of findings table</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6">
<P>
<B>Any immunostimulant (IS) compared with placebo for preventing respiratory tract infection in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>children (age &lt; 18 years) susceptible to acute respiratory tract infections (ARTIs)<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> any IS</P>
<P>
<B>Comparison:</B> placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2">
<P>Illustrative comparative risks' (95% CI)</P>
</TH>
<TH ROWSPAN="3">
<P>No of participants (studies)</P>
</TH>
<TH ROWSPAN="3">
<P>Quality of the evidence (GRADE)</P>
</TH>
<TH ROWSPAN="3">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH>
<P>Assumed risk</P>
</TH>
<TH>
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Any IS</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Number of ARTIs</B>
</P>
</TD>
<TD>
<P>The range of ARTIs in the control group was 0.92 to 6.2</P>
</TD>
<TD>
<P>The mean Number of ARTIs in the intervention groups was</P>
<P>1.24 lower (0.94 to 1.54 lower)</P>
<P>
<BR/>
</P>
</TD>
<TD>
<P>4060<BR/>(35 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;</P>
<P>
<B>moderate<SUP>1</SUP>
</B>
</P>
</TD>
<TD>
<P>The effect depends on the number of ARTIs in the control group</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Percent difference in ARTIs</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>The mean Percent difference in ARTIs in the intervention groups was<BR/>
<B>39 lower </B>(31.31 to 46.37 lower)<BR/>
<BR/>
</P>
</TD>
<TD>
<P>4060<BR/>(35 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;</P>
<P>
<B>moderate<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of gastrointestinal adverse events</B>
</P>
</TD>
<TD>
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>30 per 1000 </B>(11 to 50 per 1000)<BR/>
</P>
</TD>
<TD>
<P>1457<BR/>(10 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8854;&#8854;</P>
<P>
<B>low<SUP>1,3</SUP>
</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of skin adverse events</B>
</P>
</TD>
<TD>
<P>
<B>3 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>7 per 1000 </B>(-8 to 14 per 1000)</P>
</TD>
<TD>
<P>1469<BR/>(10 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8854;&#8854;</P>
<P>
<B>low<SUP>1,3</SUP>
</B>
<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
<P>
<B>CI: </B>confidence interval; <B>RR:</B> risk ratio; <B>OR:</B> odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>1</SUP>Funnel plot shows possible publication bias, risk of bias in the studies moderate, and high heterogeneity among studies. A group of six studies with good quality point to the benefit of IS.</P>
<P>
<SUP>2</SUP> Heterogenity decreased with calculation of percent difference ARTIs.<BR/>
<SUP>3</SUP> Adverse events were reported only in 10 trials; selective outcome reporting</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-04-18 07:31:29 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-04-18 07:31:29 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Trade and common names of IS used for prevention of ARIs</TITLE>
<TABLE COLS="3" ROWS="25">
<TR>
<TH>
<P>Trade name</P>
</TH>
<TH>
<P>Common name</P>
</TH>
<TH>
<P>Active ingredient</P>
</TH>
</TR>
<TR>
<TD>
<P>Adimod</P>
</TD>
<TD>
<P>Pidotimod</P>
</TD>
<TD>
<P>Pidotimod</P>
</TD>
</TR>
<TR>
<TD>
<P>Allicor</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Garlic extract</P>
</TD>
</TR>
<TR>
<TD>
<P>Biostim</P>
</TD>
<TD>
<P>RU41740</P>
</TD>
<TD>
<P>Glycoprotein and membranes of <I>Klebsiella pneumoniae</I>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Broncho-Vaxom, Broncho-Munal, Ommunal</P>
</TD>
<TD>
<P>OM-85 or OM-85 BV</P>
</TD>
<TD>
<P>Lyophilised bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Chizukit</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Preparation of <I>Echinacea purpurea</I>, propolis and vitamin C</P>
</TD>
</TR>
<TR>
<TD>
<P>Decaris</P>
</TD>
<TD>
<P>Levamisole</P>
</TD>
<TD>
<P>Levamisole</P>
</TD>
</TR>
<TR>
<TD>
<P>Echinacea</P>
</TD>
<TD>
<P>
<I>Echinacea purpurea</I>
</P>
</TD>
<TD>
<P>Extract of <I>Echinacea purpurea</I>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Immunoferon, Inmunol</P>
</TD>
<TD>
<P>AM3</P>
</TD>
<TD>
<P>Glycophosphopeptical</P>
</TD>
</TR>
<TR>
<TD>
<P>IRS 19</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Ismigen</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Lantigen B</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial antigens</P>
</TD>
</TR>
<TR>
<TD>
<P>Leucotrofina, Leucogen</P>
</TD>
<TD>
<P>Thymomodulin</P>
</TD>
<TD>
<P>Thymus extract</P>
</TD>
</TR>
<TR>
<TD>
<P>Luivac</P>
</TD>
<TD>
<P>LW50020</P>
</TD>
<TD>
<P>Bacterial antigens</P>
</TD>
</TR>
<TR>
<TD>
<P>Munostin</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial corpses and lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>SL04</P>
</TD>
<TD>
<P>Bacterial extracts</P>
</TD>
</TR>
<TR>
<TD>
<P>Paspat</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Autolysate mixture of bacterial antigens for parenteral application</P>
</TD>
</TR>
<TR>
<TD>
<P>Prasosine</P>
</TD>
<TD>
<P>Isoprinosine</P>
</TD>
<TD>
<P>Isoprinosine</P>
</TD>
</TR>
<TR>
<TD>
<P>Pulmotabs</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Pulmonarom</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Reaferon</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Analogue of human interferon 2 obtained by genetic engineering</P>
</TD>
</TR>
<TR>
<TD>
<P>Respivax</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Bacterial lysates</P>
</TD>
</TR>
<TR>
<TD>
<P>Ribovac, Ribomunyl, Immucithal</P>
</TD>
<TD>
<P>D53</P>
</TD>
<TD>
<P>Proteoglycans of <I>K. pneumoniae</I> plus bacterial ribosomes</P>
</TD>
</TR>
<TR>
<TD>
<P>TFX</P>
</TD>
<TD>
<P>Thymus extract</P>
</TD>
<TD>
<P>Thymus extract</P>
</TD>
</TR>
<TR>
<TD>
<P>Umckaloabo</P>
</TD>
<TD>
<P>
<I>Pelargonium sidoides</I>
</P>
</TD>
<TD>
<P>Alcohol extract from the roots of <I>Pelargonium sidoides</I>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-04-18 07:31:29 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Description of the studies</TITLE>
<TABLE COLS="10" ROWS="16">
<TR>
<TH>
<P>Immunostimulant</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>n analysis data</P>
</TH>
<TH>
<P>Duration &lt; 6 months</P>
</TH>
<TH>
<P>Duration 6 months</P>
</TH>
<TH>
<P>Duration &gt; 6 months</P>
</TH>
<TH>
<P>Quality A</P>
</TH>
<TH>
<P>Quality B</P>
</TH>
<TH>
<P>Quality C</P>
</TH>
<TH>
<P>Quality D</P>
</TH>
</TR>
<TR>
<TD>
<P>D53</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>IRS19</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Lantigen B</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>LW50020</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>OM-85 BV</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>RU41740</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Total bacterial</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Herbal (echinacea/garlic)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Isoprinosine</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Levamisole</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Pidotimod</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Total synthetic</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymic extract</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Synthetic interferon</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Grand total</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-04 21:05:51 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-04 21:05:03 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any IS compared with placebo</NAME>
<CONT_OUTCOME CHI2="582.0183927348079" CI_END="-0.9437910110592945" CI_START="-1.538711145807706" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2412510784335002" ESTIMABLE="YES" I2="94.15826021575715" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2010-04-02 14:34:47 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1102230246251565E-15" P_Q="1.0" P_Z="2.8715660854525296E-16" Q="0.0" RANDOM="YES" SCALE="6.06" SORT_BY="STUDY" STUDIES="35" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.6399837707799916" TOTALS="YES" TOTAL_1="2042" TOTAL_2="2018" UNITS="" WEIGHT="100.00000000000001" Z="8.1786016892166">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1016581888643131" CI_START="-2.478341811135687" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="5.04" ORDER="1947" SD_1="3.42" SD_2="4.04" SE="0.606307983467643" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="2.285998595249939"/>
<CONT_DATA CI_END="-4.914618922830659" CI_START="-6.285381077169342" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="8.4" ORDER="1948" SD_1="1.3" SD_2="1.9" SE="0.3496906486933126" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="3.02171750531089"/>
<CONT_DATA CI_END="-0.12941398921091238" CI_START="-0.43058601078908765" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="1.03" ORDER="1949" SD_1="0.99" SD_2="1.0" SE="0.07683100912919363" STUDY_ID="STD-Careddu-1994a" TOTAL_1="329" TOTAL_2="342" WEIGHT="3.5661923983300827"/>
<CONT_DATA CI_END="-1.6781229806172628" CI_START="-2.4218770193827366" EFFECT_SIZE="-2.05" ESTIMABLE="YES" MEAN_1="2.55" MEAN_2="4.6" ORDER="1950" SD_1="0.6" SD_2="0.6" SE="0.18973665961010275" STUDY_ID="STD-Clerici-1988" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.4074139141173854"/>
<CONT_DATA CI_END="-0.6398187577830079" CI_START="-1.1601812422169921" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.8" ORDER="1951" SD_1="1.1" SD_2="1.3" SE="0.13274797101848226" STUDY_ID="STD-Cohen-2004" TOTAL_1="160" TOTAL_2="168" WEIGHT="3.5026402218840853"/>
<CONT_DATA CI_END="0.010855106483930177" CI_START="-2.0108551064839295" EFFECT_SIZE="-0.9999999999999998" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.3" ORDER="1952" SD_1="1.2" SD_2="1.7" SE="0.5157518783291051" STUDY_ID="STD-De-Loore-1979" TOTAL_1="15" TOTAL_2="17" WEIGHT="2.542381641439608"/>
<CONT_DATA CI_END="-1.5007630558322724" CI_START="-3.2992369441677285" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.2" ORDER="1953" SD_1="1.4" SD_2="1.5" SE="0.45880278987817846" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.708289782132865"/>
<CONT_DATA CI_END="-0.1771956013998155" CI_START="-0.40280439860018435" EFFECT_SIZE="-0.2899999999999999" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.82" ORDER="1954" SD_1="0.11" SD_2="0.12" SE="0.05755432216610669" STUDY_ID="STD-Fiocchi-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.580553177279388"/>
<CONT_DATA CI_END="-0.3316150177586536" CI_START="-1.2083849822413464" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.5" ORDER="1955" SD_1="0.87" SD_2="1.66" SE="0.22366991725321037" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="3.33813976768565"/>
<CONT_DATA CI_END="-1.744595245795114" CI_START="-4.1754047542048855" EFFECT_SIZE="-2.96" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="8.0" ORDER="1956" SD_1="1.99" SD_2="2.55" SE="0.6201158612055342" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="2.2482135559716"/>
<CONT_DATA CI_END="0.37643712055884815" CI_START="-1.6964371205588484" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="2.22" ORDER="1957" SD_1="1.55" SD_2="2.37" SE="0.5288041661653643" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="2.504689409880016"/>
<CONT_DATA CI_END="-0.22207806937025065" CI_START="-3.0979219306297496" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.9" ORDER="1958" SD_1="2.1" SD_2="4.3" SE="0.7336471190143768" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="1.9549429294311893"/>
<CONT_DATA CI_END="-0.2977983010580436" CI_START="-1.3022016989419565" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.5" ORDER="1959" SD_1="1.41" SD_2="1.77" SE="0.2562300648906099" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="3.26422011950257"/>
<CONT_DATA CI_END="-1.3160946877113417" CI_START="-1.8039053122886588" EFFECT_SIZE="-1.5600000000000003" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.99" ORDER="1960" SD_1="0.94" SD_2="0.81" SE="0.1244437725450837" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="3.5140531593778723"/>
<CONT_DATA CI_END="0.14903941331385506" CI_START="-2.1890394133138544" EFFECT_SIZE="-1.0199999999999998" ESTIMABLE="YES" MEAN_1="1.59" MEAN_2="2.61" ORDER="1961" SD_1="1.98" SD_2="3.04" SE="0.5964596403480311" STUDY_ID="STD-Karam_x002d_Bechara-1995" TOTAL_1="33" TOTAL_2="39" WEIGHT="2.3131924937361377"/>
<CONT_DATA CI_END="0.32027477745065713" CI_START="-3.000274777450657" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="5.38" ORDER="1962" SD_1="4.2" SD_2="3.7" SE="0.8470945336479101" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="1.6966973978111055"/>
<CONT_DATA CI_END="0.23503313631654188" CI_START="-1.435033136316542" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.9" ORDER="1963" SD_1="1.9" SD_2="2.0" SE="0.4260451431266986" STUDY_ID="STD-Litzman-1999" TOTAL_1="43" TOTAL_2="41" WEIGHT="2.80384839407603"/>
<CONT_DATA CI_END="0.1554326822839398" CI_START="-7.2554326822839394" EFFECT_SIZE="-3.55" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.55" ORDER="1964" SD_1="2.05" SD_2="5.36" SE="1.8905616182296816" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.5465693793819699"/>
<CONT_DATA CI_END="-0.610647052341595" CI_START="-1.7093529476584053" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="3.12" ORDER="1965" SD_1="1.8" SD_2="2.45" SE="0.28028726649654334" STUDY_ID="STD-Motta-1994" TOTAL_1="117" TOTAL_2="118" WEIGHT="3.205585447946491"/>
<CONT_DATA CI_END="0.4404707340906613" CI_START="-2.1204707340906612" EFFECT_SIZE="-0.8400000000000001" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="2.41" ORDER="1966" SD_1="1.6" SD_2="2.59" SE="0.6533133997312456" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="2.1591224437872327"/>
<CONT_DATA CI_END="-0.15459055945744304" CI_START="-1.3854094405425565" EFFECT_SIZE="-0.7699999999999998" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="1.88" ORDER="1967" SD_1="1.16" SD_2="1.43" SE="0.3139901780832851" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="3.118655334841514"/>
<CONT_DATA CI_END="0.9266444797123985" CI_START="-0.9266444797123985" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.35" MEAN_2="1.35" ORDER="1968" SD_1="1.41" SD_2="1.46" SE="0.47278648333421014" STUDY_ID="STD-Piquett-1986" TOTAL_1="17" TOTAL_2="20" WEIGHT="2.6674321008004744"/>
<CONT_DATA CI_END="0.09795918493936284" CI_START="-0.4779591849393632" EFFECT_SIZE="-0.19000000000000017" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.32" ORDER="1969" SD_1="1.2" SD_2="1.4" SE="0.14692065120111814" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="3.481654891098083"/>
<CONT_DATA CI_END="-1.4049852256450903" CI_START="-3.6550147743549104" EFFECT_SIZE="-2.5300000000000002" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.73" ORDER="1970" SD_1="0.86" SD_2="2.05" SE="0.5739976771149281" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.3759241089681358"/>
<CONT_DATA CI_END="-0.17848866792485393" CI_START="-0.6415113320751459" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.95" ORDER="1971" SD_1="0.6" SD_2="0.5" SE="0.11812019705529174" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="3.5222957167475024"/>
<CONT_DATA CI_END="-2.4459868002065677" CI_START="-3.9540131997934327" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.2" ORDER="1972" SD_1="1.0" SD_2="1.4" SE="0.3847076812334269" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.9231014542257463"/>
<CONT_DATA CI_END="-0.10762579619944795" CI_START="-1.012374203800552" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.92" ORDER="1973" SD_1="0.5" SD_2="0.8" SE="0.2308074063446176" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="3.3225202124742177"/>
<CONT_DATA CI_END="-1.5835401314099058" CI_START="-2.296459868590094" EFFECT_SIZE="-1.94" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="3.25" ORDER="1974" SD_1="0.2" SD_2="0.6" SE="0.18187062180825983" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="3.422212182788598"/>
<CONT_DATA CI_END="1.6155687741188238" CI_START="-0.015568774118824291" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.2" ORDER="1975" SD_1="3.4" SD_2="3.2" SE="0.41611416360296744" STUDY_ID="STD-Saracho_x002d_Weber-2001" TOTAL_1="135" TOTAL_2="117" WEIGHT="2.8326872704436714"/>
<CONT_DATA CI_END="0.5869265775424103" CI_START="-0.76692657754241" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.98" ORDER="1976" SD_1="1.77" SD_2="1.56" SE="0.3453770492120879" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="3.0336498302685935"/>
<CONT_DATA CI_END="0.08872831063952019" CI_START="-0.80872831063952" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.48" MODIFIED="2010-04-02 14:34:47 +1000" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="1.44" SD_2="1.63" SE="0.22894722259134948" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="3.326624068844652"/>
<CONT_DATA CI_END="-1.3587882839733525" CI_START="-3.041211716026647" EFFECT_SIZE="-2.1999999999999997" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.8" ORDER="1977" SD_1="1.5" SD_2="2.0" SE="0.42919753763947605" STUDY_ID="STD-Van-Eygen-1976" TOTAL_1="38" TOTAL_2="32" WEIGHT="2.7946765882627838"/>
<CONT_DATA CI_END="-1.1420642679607083" CI_START="-2.4379357320392914" EFFECT_SIZE="-1.7899999999999998" ESTIMABLE="YES" MEAN_1="1.28" MEAN_2="3.07" ORDER="1978" SD_1="1.49" SD_2="1.89" SE="0.33058552970877325" STUDY_ID="STD-Van-Eygen-1979" TOTAL_1="53" TOTAL_2="53" WEIGHT="3.0741318547670686"/>
<CONT_DATA CI_END="-1.1017184882834778" CI_START="-3.2382815117165213" EFFECT_SIZE="-2.1699999999999995" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="5.56" ORDER="1979" SD_1="2.15" SD_2="2.21" SE="0.5450516030615816" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="2.4580540893053713"/>
<CONT_DATA CI_END="-0.4223751688241779" CI_START="-0.9976248311758222" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.09" ORDER="1980" SD_1="0.26" SD_2="0.65" SE="0.1467500594115862" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="3.4819185618315105"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="195.07099103823714" CI_END="-31.30728453634231" CI_START="-46.3673948333292" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="MD" EFFECT_SIZE="-38.837339684835754" ESTIMABLE="YES" I2="82.5704479076874" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-11-04 21:05:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.1094237467877974E-15" P_Q="1.0" P_Z="5.050136185933995E-24" Q="0.0" RANDOM="YES" SCALE="91.12" SORT_BY="STUDY" STUDIES="35" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="357.14048155976377" TOTALS="YES" TOTAL_1="2042" TOTAL_2="2018" UNITS="" WEIGHT="100.00000000000003" Z="10.10879542533705">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.021178558095105" CI_START="-49.17882144190489" EFFECT_SIZE="-25.599999999999994" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="100.0" ORDER="1981" SD_1="67.86" SD_2="80.16" SE="12.030231998083446" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="2.9411117318479585"/>
<CONT_DATA CI_END="-58.50981003278082" CI_START="-74.83018996721918" EFFECT_SIZE="-66.67" ESTIMABLE="YES" MEAN_1="33.33" MEAN_2="100.0" ORDER="1982" SD_1="15.48" SD_2="22.62" SE="4.163438732336778" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="3.9416462575481117"/>
<CONT_DATA CI_END="-12.559535125800506" CI_START="-41.800464874199506" EFFECT_SIZE="-27.180000000000007" ESTIMABLE="YES" MEAN_1="72.82" MEAN_2="100.0" ORDER="1983" SD_1="96.12" SD_2="97.09" SE="7.459557925310802" STUDY_ID="STD-Careddu-1994a" TOTAL_1="329" TOTAL_2="342" WEIGHT="3.5758205271222914"/>
<CONT_DATA CI_END="-36.48787277874852" CI_START="-52.65212722125148" EFFECT_SIZE="-44.57" ESTIMABLE="YES" MEAN_1="55.43" MEAN_2="100.0" ORDER="1984" SD_1="13.04" SD_2="13.04" SE="4.123610068859566" STUDY_ID="STD-Clerici-1988" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.945123490173378"/>
<CONT_DATA CI_END="-35.545853215728116" CI_START="-64.45414678427188" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="100.0" ORDER="1985" SD_1="61.11" SD_2="72.22" SE="7.374700197699727" STUDY_ID="STD-Cohen-2004" TOTAL_1="160" TOTAL_2="168" WEIGHT="3.586758452122233"/>
<CONT_DATA CI_END="0.5678758119796115" CI_START="-87.32787581197962" EFFECT_SIZE="-43.38" ESTIMABLE="YES" MEAN_1="56.62" MEAN_2="100.0" ORDER="1986" SD_1="52.17" SD_2="73.91" SE="22.4227976425255" STUDY_ID="STD-De-Loore-1979" TOTAL_1="15" TOTAL_2="17" WEIGHT="1.716488516346252"/>
<CONT_DATA CI_END="-28.85666953301901" CI_START="-63.44333046698099" EFFECT_SIZE="-46.15" ESTIMABLE="YES" MEAN_1="53.85" MEAN_2="100.0" ORDER="1987" SD_1="26.92" SD_2="28.85" SE="8.82328991929881" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.393281845701044"/>
<CONT_DATA CI_END="-21.61765393463405" CI_START="-49.12234606536596" EFFECT_SIZE="-35.370000000000005" ESTIMABLE="YES" MEAN_1="64.63" MEAN_2="100.0" ORDER="1988" SD_1="13.41" SD_2="14.63" SE="7.016632026834527" STUDY_ID="STD-Fiocchi-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="3.632240850078058"/>
<CONT_DATA CI_END="-22.10363180167417" CI_START="-80.55636819832583" EFFECT_SIZE="-51.33" ESTIMABLE="YES" MEAN_1="48.67" MEAN_2="100.0" ORDER="1989" SD_1="58.0" SD_2="110.67" SE="14.91168635182059" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="2.5471090401542638"/>
<CONT_DATA CI_END="-21.804791794947036" CI_START="-52.195208205052964" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="100.0" ORDER="1990" SD_1="24.88" SD_2="31.88" SE="7.752799706989939" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="3.5375904206999502"/>
<CONT_DATA CI_END="16.95734624017239" CI_START="-76.4173462401724" EFFECT_SIZE="-29.730000000000004" ESTIMABLE="YES" MEAN_1="70.27" MEAN_2="100.0" ORDER="1991" SD_1="69.82" SD_2="106.76" SE="23.8205123198366" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="1.59649037665659"/>
<CONT_DATA CI_END="-4.532958610129363" CI_START="-63.22704138987063" EFFECT_SIZE="-33.879999999999995" ESTIMABLE="YES" MEAN_1="66.12" MEAN_2="100.0" ORDER="1992" SD_1="42.86" SD_2="87.76" SE="14.973255438036794" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="2.5390472162997026"/>
<CONT_DATA CI_END="-11.911932042321745" CI_START="-52.088067957678255" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="100.0" ORDER="1993" SD_1="56.4" SD_2="70.8" SE="10.249202595624395" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="3.1936163901484895"/>
<CONT_DATA CI_END="-44.01239000956119" CI_START="-60.327609990438816" EFFECT_SIZE="-52.17" ESTIMABLE="YES" MEAN_1="47.83" MEAN_2="100.0" ORDER="1994" SD_1="31.44" SD_2="27.09" SE="4.162122393464879" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="3.941761615912677"/>
<CONT_DATA CI_END="5.7116303880052754" CI_START="-83.87163038800527" EFFECT_SIZE="-39.08" ESTIMABLE="YES" MEAN_1="60.92" MEAN_2="100.0" ORDER="1995" SD_1="75.86" SD_2="116.48" SE="22.853292581555547" STUDY_ID="STD-Karam_x002d_Bechara-1995" TOTAL_1="33" TOTAL_2="39" WEIGHT="1.6784446402153408"/>
<CONT_DATA CI_END="5.950071774408784" CI_START="-55.77007177440878" EFFECT_SIZE="-24.909999999999997" ESTIMABLE="YES" MEAN_1="75.09" MEAN_2="100.0" ORDER="1996" SD_1="78.07" SD_2="68.77" SE="15.745223900964042" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="2.439534874202642"/>
<CONT_DATA CI_END="6.031062721204531" CI_START="-36.791062721204526" EFFECT_SIZE="-15.379999999999995" ESTIMABLE="YES" MEAN_1="84.62" MEAN_2="100.0" ORDER="1997" SD_1="48.72" SD_2="51.28" SE="10.924212327416349" STUDY_ID="STD-Litzman-1999" TOTAL_1="43" TOTAL_2="41" WEIGHT="3.0978220124253837"/>
<CONT_DATA CI_END="2.807258324771361" CI_START="-130.72725832477136" EFFECT_SIZE="-63.96" ESTIMABLE="YES" MEAN_1="36.04" MEAN_2="100.0" ORDER="1998" SD_1="36.94" SD_2="96.58" SE="34.065553679262976" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.9726175880457535"/>
<CONT_DATA CI_END="-19.572149104039628" CI_START="-54.787850895960375" EFFECT_SIZE="-37.18" ESTIMABLE="YES" MEAN_1="62.82" MEAN_2="100.0" ORDER="1999" SD_1="57.69" SD_2="78.53" SE="8.983762474641805" STUDY_ID="STD-Motta-1994" TOTAL_1="117" TOTAL_2="118" WEIGHT="3.371136171715193"/>
<CONT_DATA CI_END="18.28195193183506" CI_START="-87.98195193183506" EFFECT_SIZE="-34.849999999999994" ESTIMABLE="YES" MEAN_1="65.15" MEAN_2="100.0" ORDER="2000" SD_1="66.39" SD_2="107.47" SE="27.108636868296106" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.3516681067089547"/>
<CONT_DATA CI_END="-8.226900920713518" CI_START="-73.69309907928648" EFFECT_SIZE="-40.96" ESTIMABLE="YES" MEAN_1="59.04" MEAN_2="100.0" ORDER="2001" SD_1="61.7" SD_2="76.06" SE="16.70086763709996" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="2.320611363771456"/>
<CONT_DATA CI_END="68.63936411248929" CI_START="-68.63936411248929" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="100.0" MEAN_2="100.0" ORDER="2002" SD_1="104.44" SD_2="108.15" SE="35.02072724494319" STUDY_ID="STD-Piquett-1986" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.9320879263582355"/>
<CONT_DATA CI_END="7.425114582168156" CI_START="-36.20511458216816" EFFECT_SIZE="-14.39" ESTIMABLE="YES" MEAN_1="85.61" MEAN_2="100.0" ORDER="2003" SD_1="90.91" SD_2="106.06" SE="11.130365024175441" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="3.068541672442908"/>
<CONT_DATA CI_END="-37.667921566016204" CI_START="-97.99207843398379" EFFECT_SIZE="-67.83" ESTIMABLE="YES" MEAN_1="32.17" MEAN_2="100.0" ORDER="2004" SD_1="23.06" SD_2="54.96" SE="15.389098305835422" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.4850744421136435"/>
<CONT_DATA CI_END="-18.7902322158218" CI_START="-67.52976778417819" EFFECT_SIZE="-43.16" ESTIMABLE="YES" MEAN_1="56.84" MEAN_2="100.0" ORDER="2005" SD_1="63.16" SD_2="52.63" SE="12.43378346561662" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="2.884371736394937"/>
<CONT_DATA CI_END="-39.44848033239019" CI_START="-63.77151966760981" EFFECT_SIZE="-51.61" ESTIMABLE="YES" MEAN_1="48.39" MEAN_2="100.0" ORDER="2006" SD_1="16.13" SD_2="22.58" SE="6.204970991068371" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.7307623239198002"/>
<CONT_DATA CI_END="-11.696924046879992" CI_START="-110.04307595312" EFFECT_SIZE="-60.87" ESTIMABLE="YES" MEAN_1="39.13" MEAN_2="100.0" ORDER="2007" SD_1="54.35" SD_2="86.96" SE="25.088765069659928" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.4961147787481373"/>
<CONT_DATA CI_END="-48.72347055823274" CI_START="-70.65652944176725" EFFECT_SIZE="-59.69" ESTIMABLE="YES" MEAN_1="40.31" MEAN_2="100.0" ORDER="2008" SD_1="6.15" SD_2="18.46" SE="5.595270896950067" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="3.799861422352075"/>
<CONT_DATA CI_END="22.436507920127063" CI_START="-0.21650792012706432" EFFECT_SIZE="11.11" ESTIMABLE="YES" MEAN_1="111.11" MEAN_2="100.0" ORDER="2009" SD_1="47.22" SD_2="44.44" SE="5.778936760812501" STUDY_ID="STD-Saracho_x002d_Weber-2001" TOTAL_1="135" TOTAL_2="117" WEIGHT="3.779535248980648"/>
<CONT_DATA CI_END="19.6967376881291" CI_START="-25.736737688129093" EFFECT_SIZE="-3.019999999999996" ESTIMABLE="YES" MEAN_1="96.98" MEAN_2="100.0" ORDER="2010" SD_1="59.4" SD_2="52.35" SE="11.590385265910918" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="3.0032845401547728"/>
<CONT_DATA CI_END="3.5723621880353846" CI_START="-32.61236218803538" EFFECT_SIZE="-14.519999999999996" ESTIMABLE="YES" MEAN_1="85.48" MEAN_2="100.0" MODIFIED="2010-04-02 14:37:29 +1000" MODIFIED_BY="[Empty name]" ORDER="479" SD_1="58.06" SD_2="65.72" SE="9.230966655890427" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="3.3368208884090493"/>
<CONT_DATA CI_END="-35.753964332208284" CI_START="-80.02603566779172" EFFECT_SIZE="-57.89" ESTIMABLE="YES" MEAN_1="42.11" MEAN_2="100.0" ORDER="2011" SD_1="39.47" SD_2="52.63" SE="11.294103280671454" STUDY_ID="STD-Van-Eygen-1976" TOTAL_1="38" TOTAL_2="32" WEIGHT="3.0452964457622342"/>
<CONT_DATA CI_END="-37.20604569228265" CI_START="-79.41395430771735" EFFECT_SIZE="-58.31" ESTIMABLE="YES" MEAN_1="41.69" MEAN_2="100.0" ORDER="2012" SD_1="48.53" SD_2="61.56" SE="10.767521482120411" STUDY_ID="STD-Van-Eygen-1979" TOTAL_1="53" TOTAL_2="53" WEIGHT="3.1200786607032667"/>
<CONT_DATA CI_END="-19.815631126216957" CI_START="-58.244368873783046" EFFECT_SIZE="-39.03" ESTIMABLE="YES" MEAN_1="60.97" MEAN_2="100.0" ORDER="2013" SD_1="38.67" SD_2="39.75" SE="9.803429565718316" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.256600689697128"/>
<CONT_DATA CI_END="-38.75397996197093" CI_START="-91.52602003802907" EFFECT_SIZE="-65.14" ESTIMABLE="YES" MEAN_1="34.86" MEAN_2="100.0" ORDER="2014" SD_1="23.85" SD_2="59.63" SE="13.462502498086" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="2.7416477360674745"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-04 21:05:12 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Bacterial IS compared with placebo</NAME>
<CONT_OUTCOME CHI2="371.5042589565854" CI_END="-0.9757164533137581" CI_START="-1.84941447012243" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.412565461718094" ESTIMABLE="YES" I2="93.8089538826289" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-04-02 14:39:11 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.2212453270876722E-15" P_Q="1.0" P_Z="2.3336080618426913E-10" Q="0.0" RANDOM="YES" SCALE="3.98" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.9813436606075994" TOTALS="YES" TOTAL_1="1091" TOTAL_2="1063" UNITS="" WEIGHT="100.00000000000003" Z="6.337607222425315">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1016581888643131" CI_START="-2.478341811135687" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="5.04" MODIFIED="2010-03-31 12:09:26 +1000" MODIFIED_BY="[Empty name]" ORDER="2015" SD_1="3.42" SD_2="4.04" SE="0.606307983467643" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="3.68272845992094"/>
<CONT_DATA CI_END="-4.914618922830659" CI_START="-6.285381077169342" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="8.4" ORDER="2016" SD_1="1.3" SD_2="1.9" SE="0.3496906486933126" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="4.501363932628863"/>
<CONT_DATA CI_END="-1.5007630558322724" CI_START="-3.2992369441677285" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.2" ORDER="2017" SD_1="1.4" SD_2="1.5" SE="0.45880278987817846" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.1681873924554305"/>
<CONT_DATA CI_END="-0.3316150177586536" CI_START="-1.2083849822413464" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.5" ORDER="2018" SD_1="0.87" SD_2="1.66" SE="0.22366991725321037" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="4.816718155776878"/>
<CONT_DATA CI_END="-1.744595245795114" CI_START="-4.1754047542048855" EFFECT_SIZE="-2.96" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="8.0" ORDER="2019" SD_1="1.99" SD_2="2.55" SE="0.6201158612055342" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="3.6370698866837046"/>
<CONT_DATA CI_END="0.37643712055884815" CI_START="-1.6964371205588484" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="2.22" ORDER="2020" SD_1="1.55" SD_2="2.37" SE="0.5288041661653643" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="3.939664025158816"/>
<CONT_DATA CI_END="-0.22207806937025065" CI_START="-3.0979219306297496" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.9" ORDER="2021" SD_1="2.1" SD_2="4.3" SE="0.7336471190143768" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="3.2692072675996124"/>
<CONT_DATA CI_END="-0.2977983010580436" CI_START="-1.3022016989419565" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.5" ORDER="2022" SD_1="1.41" SD_2="1.77" SE="0.2562300648906099" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="4.744832425904168"/>
<CONT_DATA CI_END="-1.3160946877113417" CI_START="-1.8039053122886588" EFFECT_SIZE="-1.5600000000000003" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.99" ORDER="2023" SD_1="0.94" SD_2="0.81" SE="0.1244437725450837" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="4.983626248042218"/>
<CONT_DATA CI_END="0.32027477745065713" CI_START="-3.000274777450657" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="5.38" ORDER="2024" SD_1="4.2" SD_2="3.7" SE="0.8470945336479101" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="2.9241216453342282"/>
<CONT_DATA CI_END="0.1554326822839398" CI_START="-7.2554326822839394" EFFECT_SIZE="-3.55" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.55" ORDER="2025" SD_1="2.05" SD_2="5.36" SE="1.8905616182296816" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="1.0904960538789197"/>
<CONT_DATA CI_END="0.4404707340906613" CI_START="-2.1204707340906612" EFFECT_SIZE="-0.8400000000000001" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="2.41" ORDER="2026" SD_1="1.6" SD_2="2.59" SE="0.6533133997312456" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="3.527880678654181"/>
<CONT_DATA CI_END="-0.15459055945744304" CI_START="-1.3854094405425565" EFFECT_SIZE="-0.7699999999999998" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="1.88" ORDER="2027" SD_1="1.16" SD_2="1.43" SE="0.3139901780832851" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="4.60012376154433"/>
<CONT_DATA CI_END="0.9266444797123985" CI_START="-0.9266444797123985" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.35" MEAN_2="1.35" ORDER="2028" SD_1="1.41" SD_2="1.46" SE="0.47278648333421014" STUDY_ID="STD-Piquett-1986" TOTAL_1="17" TOTAL_2="20" WEIGHT="4.123120962112888"/>
<CONT_DATA CI_END="0.09795918493936284" CI_START="-0.4779591849393632" EFFECT_SIZE="-0.19000000000000017" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.32" ORDER="2029" SD_1="1.2" SD_2="1.4" SE="0.14692065120111814" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="4.953317776166587"/>
<CONT_DATA CI_END="-1.4049852256450903" CI_START="-3.6550147743549104" EFFECT_SIZE="-2.5300000000000002" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.73" ORDER="2030" SD_1="0.86" SD_2="2.05" SE="0.5739976771149281" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.7898713114688087"/>
<CONT_DATA CI_END="-0.17848866792485393" CI_START="-0.6415113320751459" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.95" ORDER="2031" SD_1="0.6" SD_2="0.5" SE="0.11812019705529174" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="4.991306618818843"/>
<CONT_DATA CI_END="-2.4459868002065677" CI_START="-3.9540131997934327" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.2" ORDER="2032" SD_1="1.0" SD_2="1.4" SE="0.3847076812334269" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.398862713985376"/>
<CONT_DATA CI_END="-0.10762579619944795" CI_START="-1.012374203800552" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.92" ORDER="2033" SD_1="0.5" SD_2="0.8" SE="0.2308074063446176" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="4.8016163166881185"/>
<CONT_DATA CI_END="-1.5835401314099058" CI_START="-2.296459868590094" EFFECT_SIZE="-1.94" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="3.25" ORDER="2034" SD_1="0.2" SD_2="0.6" SE="0.18187062180825983" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="4.897207134617335"/>
<CONT_DATA CI_END="0.5869265775424103" CI_START="-0.76692657754241" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.98" ORDER="2035" SD_1="1.77" SD_2="1.56" SE="0.3453770492120879" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="4.513626181111572"/>
<CONT_DATA CI_END="0.08872831063952019" CI_START="-0.80872831063952" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.48" MODIFIED="2010-04-02 14:39:11 +1000" MODIFIED_BY="[Empty name]" ORDER="480" SD_1="1.44" SD_2="1.63" SE="0.22894722259134948" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="4.805588684748004"/>
<CONT_DATA CI_END="-1.1017184882834778" CI_START="-3.2382815117165213" EFFECT_SIZE="-2.1699999999999995" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="5.56" ORDER="2036" SD_1="2.15" SD_2="2.21" SE="0.5450516030615816" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.8858971525839996"/>
<CONT_DATA CI_END="-0.4223751688241779" CI_START="-0.9976248311758222" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.09" ORDER="2037" SD_1="0.26" SD_2="0.65" SE="0.1467500594115862" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="4.953565214116217"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="81.87420476326257" CI_END="-33.30961987313154" CI_START="-49.10446986290543" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="MD" EFFECT_SIZE="-41.207044868018485" ESTIMABLE="YES" I2="71.90812409536802" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-11-04 21:05:12 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.5744960446539835E-8" P_Q="1.0" P_Z="1.5061630018812334E-24" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="222.9047255584853" TOTALS="YES" TOTAL_1="1091" TOTAL_2="1063" UNITS="" WEIGHT="100.00000000000001" Z="10.226665514763587">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.021178558095105" CI_START="-49.17882144190489" EFFECT_SIZE="-25.599999999999994" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="100.0" ORDER="2038" SD_1="67.86" SD_2="80.16" SE="12.030231998083446" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="4.4163396559196295"/>
<CONT_DATA CI_END="-58.50981003278082" CI_START="-74.83018996721918" EFFECT_SIZE="-66.67" ESTIMABLE="YES" MEAN_1="33.33" MEAN_2="100.0" ORDER="2039" SD_1="15.48" SD_2="22.62" SE="4.163438732336778" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="6.758205929340562"/>
<CONT_DATA CI_END="-28.85666953301901" CI_START="-63.44333046698099" EFFECT_SIZE="-46.15" ESTIMABLE="YES" MEAN_1="53.85" MEAN_2="100.0" ORDER="2040" SD_1="26.92" SD_2="28.85" SE="8.82328991929881" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.398358662828643"/>
<CONT_DATA CI_END="-22.10363180167417" CI_START="-80.55636819832583" EFFECT_SIZE="-51.33" ESTIMABLE="YES" MEAN_1="48.67" MEAN_2="100.0" ORDER="2041" SD_1="58.0" SD_2="110.67" SE="14.91168635182059" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="3.646348022487624"/>
<CONT_DATA CI_END="-21.804791794947036" CI_START="-52.195208205052964" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="100.0" ORDER="2042" SD_1="24.88" SD_2="31.88" SE="7.752799706989939" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="5.736831464395861"/>
<CONT_DATA CI_END="16.95734624017239" CI_START="-76.4173462401724" EFFECT_SIZE="-29.730000000000004" ESTIMABLE="YES" MEAN_1="70.27" MEAN_2="100.0" ORDER="2043" SD_1="69.82" SD_2="106.76" SE="23.8205123198366" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="2.0543338541595793"/>
<CONT_DATA CI_END="-4.532958610129363" CI_START="-63.22704138987063" EFFECT_SIZE="-33.879999999999995" ESTIMABLE="YES" MEAN_1="66.12" MEAN_2="100.0" ORDER="2044" SD_1="42.86" SD_2="87.76" SE="14.973255438036794" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="3.6313420013285054"/>
<CONT_DATA CI_END="-11.911932042321745" CI_START="-52.088067957678255" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="100.0" ORDER="2045" SD_1="56.4" SD_2="70.8" SE="10.249202595624395" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="4.950693479835621"/>
<CONT_DATA CI_END="-44.01239000956119" CI_START="-60.327609990438816" EFFECT_SIZE="-52.17" ESTIMABLE="YES" MEAN_1="47.83" MEAN_2="100.0" ORDER="2046" SD_1="31.44" SD_2="27.09" SE="4.162122393464879" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="6.7585142403523575"/>
<CONT_DATA CI_END="5.950071774408784" CI_START="-55.77007177440878" EFFECT_SIZE="-24.909999999999997" ESTIMABLE="YES" MEAN_1="75.09" MEAN_2="100.0" ORDER="2047" SD_1="78.07" SD_2="68.77" SE="15.745223900964042" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="3.4484416785136816"/>
<CONT_DATA CI_END="2.807258324771361" CI_START="-130.72725832477136" EFFECT_SIZE="-63.96" ESTIMABLE="YES" MEAN_1="36.04" MEAN_2="100.0" ORDER="2048" SD_1="36.94" SD_2="96.58" SE="34.065553679262976" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="1.1736470973490785"/>
<CONT_DATA CI_END="18.28195193183506" CI_START="-87.98195193183506" EFFECT_SIZE="-34.849999999999994" ESTIMABLE="YES" MEAN_1="65.15" MEAN_2="100.0" ORDER="2049" SD_1="66.39" SD_2="107.47" SE="27.108636868296106" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.695148503024726"/>
<CONT_DATA CI_END="-8.226900920713518" CI_START="-73.69309907928648" EFFECT_SIZE="-40.96" ESTIMABLE="YES" MEAN_1="59.04" MEAN_2="100.0" ORDER="2050" SD_1="61.7" SD_2="76.06" SE="16.70086763709996" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="3.2353678451912886"/>
<CONT_DATA CI_END="67.27686730540827" CI_START="-67.27686730540827" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="100.0" MEAN_2="100.0" ORDER="2051" SD_1="100.44" SD_2="108.15" SE="34.32556303895358" STUDY_ID="STD-Piquett-1986" TOTAL_1="17" TOTAL_2="20" WEIGHT="1.1587520501528852"/>
<CONT_DATA CI_END="7.425114582168156" CI_START="-36.20511458216816" EFFECT_SIZE="-14.39" ESTIMABLE="YES" MEAN_1="85.61" MEAN_2="100.0" ORDER="2052" SD_1="90.91" SD_2="106.06" SE="11.130365024175441" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="4.681753930400529"/>
<CONT_DATA CI_END="-37.667921566016204" CI_START="-97.99207843398379" EFFECT_SIZE="-67.83" ESTIMABLE="YES" MEAN_1="32.17" MEAN_2="100.0" ORDER="2053" SD_1="23.06" SD_2="54.96" SE="15.389098305835422" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.5316110693555527"/>
<CONT_DATA CI_END="-18.7902322158218" CI_START="-67.52976778417819" EFFECT_SIZE="-43.16" ESTIMABLE="YES" MEAN_1="56.84" MEAN_2="100.0" ORDER="2054" SD_1="63.16" SD_2="52.63" SE="12.43378346561662" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="4.300843393099924"/>
<CONT_DATA CI_END="-39.44848033239019" CI_START="-63.77151966760981" EFFECT_SIZE="-51.61" ESTIMABLE="YES" MEAN_1="48.39" MEAN_2="100.0" ORDER="2055" SD_1="16.13" SD_2="22.58" SE="6.204970991068371" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.210958641470762"/>
<CONT_DATA CI_END="-11.696924046879992" CI_START="-110.04307595312" EFFECT_SIZE="-60.87" ESTIMABLE="YES" MEAN_1="39.13" MEAN_2="100.0" ORDER="2056" SD_1="54.35" SD_2="86.96" SE="25.088765069659928" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.90483093271353"/>
<CONT_DATA CI_END="-48.72347055823274" CI_START="-70.65652944176725" EFFECT_SIZE="-59.69" ESTIMABLE="YES" MEAN_1="40.31" MEAN_2="100.0" ORDER="2057" SD_1="6.15" SD_2="18.46" SE="5.595270896950067" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="6.386738914306275"/>
<CONT_DATA CI_END="19.6967376881291" CI_START="-25.736737688129093" EFFECT_SIZE="-3.019999999999996" ESTIMABLE="YES" MEAN_1="96.98" MEAN_2="100.0" ORDER="2058" SD_1="59.4" SD_2="52.35" SE="11.590385265910918" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="4.544777457646845"/>
<CONT_DATA CI_END="3.5723621880353846" CI_START="-32.61236218803538" EFFECT_SIZE="-14.519999999999996" ESTIMABLE="YES" MEAN_1="85.48" MEAN_2="100.0" MODIFIED="2010-04-02 14:40:47 +1000" MODIFIED_BY="[Empty name]" ORDER="481" SD_1="58.06" SD_2="65.72" SE="9.230966655890427" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="5.269402004751252"/>
<CONT_DATA CI_END="-19.815631126216957" CI_START="-58.244368873783046" EFFECT_SIZE="-39.03" ESTIMABLE="YES" MEAN_1="60.97" MEAN_2="100.0" ORDER="2059" SD_1="38.67" SD_2="39.75" SE="9.803429565718316" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="5.089415132328733"/>
<CONT_DATA CI_END="-38.75397996197093" CI_START="-91.52602003802907" EFFECT_SIZE="-65.14" ESTIMABLE="YES" MEAN_1="34.86" MEAN_2="100.0" ORDER="2060" SD_1="23.85" SD_2="59.63" SE="13.462502498086" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="4.017344039046548"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-04 21:05:19 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Bacterial IS trials with n equal to or greater than 40 compared with placebo</NAME>
<CONT_OUTCOME CHI2="326.8436569062968" CI_END="-0.9262948468798149" CI_START="-1.922400647618234" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4243477472490245" ESTIMABLE="YES" I2="94.49277976804657" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-04-02 14:42:36 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="2.080528046843064E-8" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.0459089126298098" TOTALS="YES" TOTAL_1="1019" TOTAL_2="990" UNITS="" WEIGHT="99.99999999999999" Z="5.605168214057916">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1016581888643131" CI_START="-2.478341811135687" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="5.04" ORDER="2061" SD_1="3.42" SD_2="4.04" SE="0.606307983467643" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="4.568286518957085"/>
<CONT_DATA CI_END="-4.914618922830659" CI_START="-6.285381077169342" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="8.4" ORDER="2062" SD_1="1.3" SD_2="1.9" SE="0.3496906486933126" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="5.527647820314977"/>
<CONT_DATA CI_END="-1.5007630558322724" CI_START="-3.2992369441677285" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.2" ORDER="2063" SD_1="1.4" SD_2="1.5" SE="0.45880278987817846" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.1395341545704225"/>
<CONT_DATA CI_END="-0.3316150177586536" CI_START="-1.2083849822413464" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.5" ORDER="2064" SD_1="0.87" SD_2="1.66" SE="0.22366991725321037" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="5.892086558880095"/>
<CONT_DATA CI_END="-1.744595245795114" CI_START="-4.1754047542048855" EFFECT_SIZE="-2.96" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="8.0" ORDER="2065" SD_1="1.99" SD_2="2.55" SE="0.6201158612055342" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="4.514205186446126"/>
<CONT_DATA CI_END="0.37643712055884815" CI_START="-1.6964371205588484" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="2.22" ORDER="2066" SD_1="1.55" SD_2="2.37" SE="0.5288041661653643" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="4.8714811165299485"/>
<CONT_DATA CI_END="-0.22207806937025065" CI_START="-3.0979219306297496" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.9" ORDER="2067" SD_1="2.1" SD_2="4.3" SE="0.7336471190143768" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="4.076235656473899"/>
<CONT_DATA CI_END="-0.2977983010580436" CI_START="-1.3022016989419565" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.5" ORDER="2068" SD_1="1.41" SD_2="1.77" SE="0.2562300648906099" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="5.809259502030862"/>
<CONT_DATA CI_END="-1.3160946877113417" CI_START="-1.8039053122886588" EFFECT_SIZE="-1.5600000000000003" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.99" ORDER="2069" SD_1="0.94" SD_2="0.81" SE="0.1244437725450837" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="6.083838263597346"/>
<CONT_DATA CI_END="0.32027477745065713" CI_START="-3.000274777450657" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="5.38" ORDER="2070" SD_1="4.2" SD_2="3.7" SE="0.8470945336479101" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="3.6617163883702744"/>
<CONT_DATA CI_END="0.4404707340906613" CI_START="-2.1204707340906612" EFFECT_SIZE="-0.8400000000000001" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="2.41" ORDER="2071" SD_1="1.6" SD_2="2.59" SE="0.6533133997312456" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="4.384624682915188"/>
<CONT_DATA CI_END="-0.15459055945744304" CI_START="-1.3854094405425565" EFFECT_SIZE="-0.7699999999999998" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="1.88" ORDER="2072" SD_1="1.16" SD_2="1.43" SE="0.3139901780832851" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="5.642082657797528"/>
<CONT_DATA CI_END="0.09795918493936284" CI_START="-0.4779591849393632" EFFECT_SIZE="-0.19000000000000017" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.32" ORDER="2073" SD_1="1.2" SD_2="1.4" SE="0.14692065120111814" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="6.049076573094354"/>
<CONT_DATA CI_END="-0.17848866792485393" CI_START="-0.6415113320751459" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.95" ORDER="2074" SD_1="0.6" SD_2="0.5" SE="0.11812019705529174" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="6.092643025713849"/>
<CONT_DATA CI_END="-2.4459868002065677" CI_START="-3.9540131997934327" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.2" ORDER="2075" SD_1="1.0" SD_2="1.4" SE="0.3847076812334269" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.40858389635776"/>
<CONT_DATA CI_END="0.5869265775424103" CI_START="-0.76692657754241" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.98" ORDER="2076" SD_1="1.77" SD_2="1.56" SE="0.3453770492120879" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="5.541871401904494"/>
<CONT_DATA CI_END="0.08872831063952019" CI_START="-0.80872831063952" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.48" MODIFIED="2010-04-02 14:42:36 +1000" MODIFIED_BY="[Empty name]" ORDER="482" SD_1="1.44" SD_2="1.63" SE="0.22894722259134948" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="5.879272663500424"/>
<CONT_DATA CI_END="-1.1017184882834778" CI_START="-3.2382815117165213" EFFECT_SIZE="-2.1699999999999995" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="5.56" ORDER="2077" SD_1="2.15" SD_2="2.21" SE="0.5450516030615816" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="4.808193461315427"/>
<CONT_DATA CI_END="-0.4223751688241779" CI_START="-0.9976248311758222" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.09" ORDER="2078" SD_1="0.26" SD_2="0.65" SE="0.1467500594115862" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="6.049360471229933"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="72.97724118247392" CI_END="-29.63057596524412" CI_START="-47.25292794864794" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="MD" EFFECT_SIZE="-38.44175195694603" ESTIMABLE="YES" I2="75.33477600915003" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-11-04 21:05:19 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.4076448007216413E-8" P_Q="1.0" P_Z="1.220166125870916E-17" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="245.63221593211668" TOTALS="YES" TOTAL_1="1019" TOTAL_2="990" UNITS="" WEIGHT="100.0" Z="8.551009469019052">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.021178558095105" CI_START="-49.17882144190489" EFFECT_SIZE="-25.599999999999994" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="100.0" ORDER="2079" SD_1="67.86" SD_2="80.16" SE="12.030231998083446" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="5.177352189899597"/>
<CONT_DATA CI_END="-58.50981003278082" CI_START="-74.83018996721918" EFFECT_SIZE="-66.67" ESTIMABLE="YES" MEAN_1="33.33" MEAN_2="100.0" ORDER="2080" SD_1="15.48" SD_2="22.62" SE="4.163438732336778" STUDY_ID="STD-Arroyave-1999" TOTAL_1="42" TOTAL_2="44" WEIGHT="7.685484408218589"/>
<CONT_DATA CI_END="-28.85666953301901" CI_START="-63.44333046698099" EFFECT_SIZE="-46.15" ESTIMABLE="YES" MEAN_1="53.85" MEAN_2="100.0" ORDER="2081" SD_1="26.92" SD_2="28.85" SE="8.82328991929881" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.24770568347417"/>
<CONT_DATA CI_END="-22.10363180167417" CI_START="-80.55636819832583" EFFECT_SIZE="-51.33" ESTIMABLE="YES" MEAN_1="48.67" MEAN_2="100.0" ORDER="2082" SD_1="58.0" SD_2="110.67" SE="14.91168635182059" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="4.318515017649649"/>
<CONT_DATA CI_END="-21.804791794947036" CI_START="-52.195208205052964" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="100.0" ORDER="2083" SD_1="24.88" SD_2="31.88" SE="7.752799706989939" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="6.610312329743749"/>
<CONT_DATA CI_END="16.95734624017239" CI_START="-76.4173462401724" EFFECT_SIZE="-29.730000000000004" ESTIMABLE="YES" MEAN_1="70.27" MEAN_2="100.0" ORDER="2084" SD_1="69.82" SD_2="106.76" SE="23.8205123198366" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="2.485735056265501"/>
<CONT_DATA CI_END="-4.5852173037052" CI_START="-63.17478269629479" EFFECT_SIZE="-33.879999999999995" ESTIMABLE="YES" MEAN_1="66.12" MEAN_2="100.0" ORDER="2085" SD_1="42.66" SD_2="87.66" SE="14.946592349333102" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="4.308918890259189"/>
<CONT_DATA CI_END="-11.911932042321745" CI_START="-52.088067957678255" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="100.0" ORDER="2086" SD_1="56.4" SD_2="70.8" SE="10.249202595624395" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="5.763185395463089"/>
<CONT_DATA CI_END="-44.01239000956119" CI_START="-60.327609990438816" EFFECT_SIZE="-52.17" ESTIMABLE="YES" MEAN_1="47.83" MEAN_2="100.0" ORDER="2087" SD_1="31.44" SD_2="27.09" SE="4.162122393464879" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="7.685804718030197"/>
<CONT_DATA CI_END="5.950071774408784" CI_START="-55.77007177440878" EFFECT_SIZE="-24.909999999999997" ESTIMABLE="YES" MEAN_1="75.09" MEAN_2="100.0" ORDER="2088" SD_1="78.07" SD_2="68.77" SE="15.745223900964042" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="4.094920138904649"/>
<CONT_DATA CI_END="18.28195193183506" CI_START="-87.98195193183506" EFFECT_SIZE="-34.849999999999994" ESTIMABLE="YES" MEAN_1="65.15" MEAN_2="100.0" ORDER="2089" SD_1="66.39" SD_2="107.47" SE="27.108636868296106" STUDY_ID="STD-Paupe-1986" TOTAL_1="21" TOTAL_2="22" WEIGHT="2.0611963331490863"/>
<CONT_DATA CI_END="-8.226900920713518" CI_START="-73.69309907928648" EFFECT_SIZE="-40.96" ESTIMABLE="YES" MEAN_1="59.04" MEAN_2="100.0" ORDER="2090" SD_1="61.7" SD_2="76.06" SE="16.70086763709996" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" WEIGHT="3.8528640779612644"/>
<CONT_DATA CI_END="7.425114582168156" CI_START="-36.20511458216816" EFFECT_SIZE="-14.39" ESTIMABLE="YES" MEAN_1="85.61" MEAN_2="100.0" ORDER="2091" SD_1="90.91" SD_2="106.06" SE="11.130365024175441" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="5.469364436115939"/>
<CONT_DATA CI_END="-18.7902322158218" CI_START="-67.52976778417819" EFFECT_SIZE="-43.16" ESTIMABLE="YES" MEAN_1="56.84" MEAN_2="100.0" ORDER="2092" SD_1="63.16" SD_2="52.63" SE="12.43378346561662" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="5.04964261615904"/>
<CONT_DATA CI_END="-39.44848033239019" CI_START="-63.77151966760981" EFFECT_SIZE="-51.61" ESTIMABLE="YES" MEAN_1="48.39" MEAN_2="100.0" ORDER="2093" SD_1="16.13" SD_2="22.58" SE="6.204970991068371" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.112930188335346"/>
<CONT_DATA CI_END="19.6967376881291" CI_START="-25.736737688129093" EFFECT_SIZE="-3.019999999999996" ESTIMABLE="YES" MEAN_1="96.98" MEAN_2="100.0" ORDER="2094" SD_1="59.4" SD_2="52.35" SE="11.590385265910918" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="5.318915879617057"/>
<CONT_DATA CI_END="3.5723621880353846" CI_START="-32.61236218803538" EFFECT_SIZE="-14.519999999999996" ESTIMABLE="YES" MEAN_1="85.48" MEAN_2="100.0" MODIFIED="2010-04-02 14:43:53 +1000" MODIFIED_BY="[Empty name]" ORDER="483" SD_1="58.06" SD_2="65.72" SE="9.230966655890427" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="6.108712275637407"/>
<CONT_DATA CI_END="-19.815631126216957" CI_START="-58.244368873783046" EFFECT_SIZE="-39.03" ESTIMABLE="YES" MEAN_1="60.97" MEAN_2="100.0" ORDER="2095" SD_1="38.67" SD_2="39.75" SE="9.803429565718316" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="5.913933775792372"/>
<CONT_DATA CI_END="-38.75397996197093" CI_START="-91.52602003802907" EFFECT_SIZE="-65.14" ESTIMABLE="YES" MEAN_1="34.86" MEAN_2="100.0" ORDER="2096" SD_1="23.85" SD_2="59.63" SE="13.462502498086" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="4.734506589324134"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-11-04 21:05:28 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Bacterial IS trials with n equal to or greater than 40 only OM-85 and BV D53 compared with placebo</NAME>
<CONT_OUTCOME CHI2="145.40820374377824" CI_END="-0.7823311138932674" CI_START="-1.5641225642677705" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.173226839080519" ESTIMABLE="YES" I2="89.68421339800656" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-04-02 14:45:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="1.0" P_Z="4.0387643096502455E-9" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.4788870774482564" TOTALS="YES" TOTAL_1="921" TOTAL_2="890" UNITS="" WEIGHT="99.99999999999997" Z="5.882597844200166">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1016581888643131" CI_START="-2.478341811135687" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="5.04" ORDER="2097" SD_1="3.42" SD_2="4.04" SE="0.606307983467643" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="4.698946710194627"/>
<CONT_DATA CI_END="-1.5007630558322724" CI_START="-3.2992369441677285" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.2" ORDER="2098" SD_1="1.4" SD_2="1.5" SE="0.45880278987817846" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.769823413993619"/>
<CONT_DATA CI_END="-0.3316150177586536" CI_START="-1.2083849822413464" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.5" ORDER="2099" SD_1="0.87" SD_2="1.66" SE="0.22366991725321037" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="7.520375437396259"/>
<CONT_DATA CI_END="-1.744595245795114" CI_START="-4.1754047542048855" EFFECT_SIZE="-2.96" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="8.0" ORDER="2100" SD_1="1.99" SD_2="2.55" SE="0.6201158612055342" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="4.606787122624676"/>
<CONT_DATA CI_END="0.37643712055884815" CI_START="-1.6964371205588484" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="2.22" ORDER="2101" SD_1="1.55" SD_2="2.37" SE="0.5288041661653643" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="5.243944599281923"/>
<CONT_DATA CI_END="-0.22207806937025065" CI_START="-3.0979219306297496" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.9" ORDER="2102" SD_1="2.1" SD_2="4.3" SE="0.7336471190143768" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="3.910670788198217"/>
<CONT_DATA CI_END="-0.2977983010580436" CI_START="-1.3022016989419565" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.5" ORDER="2103" SD_1="1.41" SD_2="1.77" SE="0.2562300648906099" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="7.3045780920444745"/>
<CONT_DATA CI_END="-1.3160946877113417" CI_START="-1.8039053122886588" EFFECT_SIZE="-1.5600000000000003" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.99" ORDER="2104" SD_1="0.94" SD_2="0.81" SE="0.1244437725450837" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="8.045825815439366"/>
<CONT_DATA CI_END="0.32027477745065713" CI_START="-3.000274777450657" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="5.38" ORDER="2105" SD_1="4.2" SD_2="3.7" SE="0.8470945336479101" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="3.324519203502852"/>
<CONT_DATA CI_END="0.09795918493936284" CI_START="-0.4779591849393632" EFFECT_SIZE="-0.19000000000000017" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.32" ORDER="2106" SD_1="1.2" SD_2="1.4" SE="0.14692065120111814" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="7.947768703602992"/>
<CONT_DATA CI_END="-0.17848866792485393" CI_START="-0.6415113320751459" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.95" ORDER="2107" SD_1="0.6" SD_2="0.5" SE="0.11812019705529174" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="8.070866958733022"/>
<CONT_DATA CI_END="-2.4459868002065677" CI_START="-3.9540131997934327" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.2" ORDER="2108" SD_1="1.0" SD_2="1.4" SE="0.3847076812334269" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.345068902929968"/>
<CONT_DATA CI_END="0.5869265775424103" CI_START="-0.76692657754241" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.98" ORDER="2109" SD_1="1.77" SD_2="1.56" SE="0.3453770492120879" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="6.649657874577247"/>
<CONT_DATA CI_END="0.08872831063952019" CI_START="-0.80872831063952" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.48" MODIFIED="2010-04-02 14:45:32 +1000" MODIFIED_BY="[Empty name]" ORDER="484" SD_1="1.44" SD_2="1.63" SE="0.22894722259134948" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="7.486565860934507"/>
<CONT_DATA CI_END="-1.1017184882834778" CI_START="-3.2382815117165213" EFFECT_SIZE="-2.1699999999999995" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="5.56" ORDER="2110" SD_1="2.15" SD_2="2.21" SE="0.5450516030615816" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="5.126036153880033"/>
<CONT_DATA CI_END="-0.4223751688241779" CI_START="-0.9976248311758222" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.09" ORDER="2111" SD_1="0.26" SD_2="0.65" SE="0.1467500594115862" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="7.948564362666198"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="43.0823341736012" CI_END="-27.798514892037286" CI_START="-44.514967263763836" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="-36.15674107790056" ESTIMABLE="YES" I2="65.18294496403752" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-11-04 21:05:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.5288370673638418E-4" P_Q="1.0" P_Z="2.2795406977165567E-17" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="167.36172482159301" TOTALS="YES" TOTAL_1="921" TOTAL_2="890" UNITS="" WEIGHT="99.99999999999999" Z="8.478582504848267">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.021178558095105" CI_START="-49.17882144190489" EFFECT_SIZE="-25.599999999999994" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="100.0" ORDER="2112" SD_1="67.86" SD_2="80.16" SE="12.030231998083446" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="5.8271298973621475"/>
<CONT_DATA CI_END="-28.85666953301901" CI_START="-63.44333046698099" EFFECT_SIZE="-46.15" ESTIMABLE="YES" MEAN_1="53.85" MEAN_2="100.0" ORDER="2113" SD_1="26.92" SD_2="28.85" SE="8.82328991929881" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.41634691902174"/>
<CONT_DATA CI_END="-22.10363180167417" CI_START="-80.55636819832583" EFFECT_SIZE="-51.33" ESTIMABLE="YES" MEAN_1="48.67" MEAN_2="100.0" ORDER="2114" SD_1="58.0" SD_2="110.67" SE="14.91168635182059" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="4.666370689313294"/>
<CONT_DATA CI_END="-21.804791794947036" CI_START="-52.195208205052964" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="100.0" ORDER="2115" SD_1="24.88" SD_2="31.88" SE="7.752799706989939" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="7.994889361651238"/>
<CONT_DATA CI_END="16.95734624017239" CI_START="-76.4173462401724" EFFECT_SIZE="-29.730000000000004" ESTIMABLE="YES" MEAN_1="70.27" MEAN_2="100.0" ORDER="2116" SD_1="69.82" SD_2="106.76" SE="23.8205123198366" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="2.475002250283945"/>
<CONT_DATA CI_END="-4.532958610129363" CI_START="-63.22704138987063" EFFECT_SIZE="-33.879999999999995" ESTIMABLE="YES" MEAN_1="66.12" MEAN_2="100.0" ORDER="2117" SD_1="42.86" SD_2="87.76" SE="14.973255438036794" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="4.644442845789256"/>
<CONT_DATA CI_END="-11.911932042321745" CI_START="-52.088067957678255" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="100.0" ORDER="2118" SD_1="56.4" SD_2="70.8" SE="10.249202595624395" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="6.6759395104761605"/>
<CONT_DATA CI_END="-44.01239000956119" CI_START="-60.327609990438816" EFFECT_SIZE="-52.17" ESTIMABLE="YES" MEAN_1="47.83" MEAN_2="100.0" ORDER="2119" SD_1="31.44" SD_2="27.09" SE="4.162122393464879" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="9.84692120027707"/>
<CONT_DATA CI_END="5.950071774408784" CI_START="-55.77007177440878" EFFECT_SIZE="-24.909999999999997" ESTIMABLE="YES" MEAN_1="75.09" MEAN_2="100.0" ORDER="2120" SD_1="78.07" SD_2="68.77" SE="15.745223900964042" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="4.379227675610893"/>
<CONT_DATA CI_END="7.425114582168156" CI_START="-36.20511458216816" EFFECT_SIZE="-14.39" ESTIMABLE="YES" MEAN_1="85.61" MEAN_2="100.0" ORDER="2121" SD_1="90.91" SD_2="106.06" SE="11.130365024175441" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="6.244116089567312"/>
<CONT_DATA CI_END="-18.7902322158218" CI_START="-67.52976778417819" EFFECT_SIZE="-43.16" ESTIMABLE="YES" MEAN_1="56.84" MEAN_2="100.0" ORDER="2122" SD_1="63.16" SD_2="52.63" SE="12.43378346561662" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="5.648448839378037"/>
<CONT_DATA CI_END="-39.44848033239019" CI_START="-63.77151966760981" EFFECT_SIZE="-51.61" ESTIMABLE="YES" MEAN_1="48.39" MEAN_2="100.0" ORDER="2123" SD_1="16.13" SD_2="22.58" SE="6.204970991068371" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.833909330547012"/>
<CONT_DATA CI_END="19.6967376881291" CI_START="-25.736737688129093" EFFECT_SIZE="-3.019999999999996" ESTIMABLE="YES" MEAN_1="96.98" MEAN_2="100.0" ORDER="2124" SD_1="59.4" SD_2="52.35" SE="11.590385265910918" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="6.027795897095833"/>
<CONT_DATA CI_END="3.5723621880353846" CI_START="-32.61236218803538" EFFECT_SIZE="-14.519999999999996" ESTIMABLE="YES" MEAN_1="85.48" MEAN_2="100.0" MODIFIED="2010-04-02 14:47:03 +1000" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="58.06" SD_2="65.72" SE="9.230966655890427" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="7.200224626824647"/>
<CONT_DATA CI_END="-19.815631126216957" CI_START="-58.244368873783046" EFFECT_SIZE="-39.03" ESTIMABLE="YES" MEAN_1="60.97" MEAN_2="100.0" ORDER="2125" SD_1="38.67" SD_2="39.75" SE="9.803429565718316" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="6.902439464894076"/>
<CONT_DATA CI_END="-38.75397996197093" CI_START="-91.52602003802907" EFFECT_SIZE="-65.14" ESTIMABLE="YES" MEAN_1="34.86" MEAN_2="100.0" ORDER="2126" SD_1="23.85" SD_2="59.63" SE="13.462502498086" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="5.216795401907328"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-04-21 13:22:13 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="15.458272818681506" CI_END="0.02710950213273554" CI_START="-0.007681320538608366" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="0.009714090797063585" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="41.77874782282666" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-1.5668784581845872" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.0125978415177697" METHOD="MH" MODIFIED="2008-04-21 13:21:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0790930324796919" P_Q="1.0" P_Z="0.27373600643737184" Q="0.0" RANDOM="NO" SCALE="0.31" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="744" TOTAL_2="713" WEIGHT="100.00000000000001" Z="1.0944994480098142">
<NAME>Gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.06506606014519739" CI_START="-0.016873289060860032" EFFECT_SIZE="0.024096385542168676" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2127" O_E="0.0" SE="0.020903279308289474" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" VAR="4.3694708584036284E-4" WEIGHT="10.627620024136078"/>
<DICH_DATA CI_END="0.00921318947937224" CI_START="-0.00921318947937224" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2128" O_E="0.0" SE="0.0047006932535723625" STUDY_ID="STD-Collet-1993" TOTAL_1="210" TOTAL_2="213" VAR="2.2096517064180724E-5" WEIGHT="29.148462949646913"/>
<DICH_DATA CI_END="0.18499142654036987" CI_START="-0.2849914265403699" EFFECT_SIZE="-0.05000000000000002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2129" O_E="0.0" SE="0.11989578808281798" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.014374999999999999" WEIGHT="2.756494484171841"/>
<DICH_DATA CI_END="0.06950137136663781" CI_START="-0.06950137136663781" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2130" O_E="0.0" SE="0.03546053494597643" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" VAR="0.0012574495386548155" WEIGHT="3.716162934216852"/>
<DICH_DATA CI_END="0.024731034452344775" CI_START="-0.024731034452344775" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2131" O_E="0.0" SE="0.012618106581253542" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" VAR="1.5921661369587396E-4" WEIGHT="10.75032848827018"/>
<DICH_DATA CI_END="0.10556303608924769" CI_START="-0.058002060479491586" EFFECT_SIZE="0.02378048780487805" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2132" O_E="0.0" SE="0.04172655667627565" STUDY_ID="STD-Mora-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.001741105532058444" WEIGHT="5.581050560545456"/>
<DICH_DATA CI_END="0.054836151839082845" CI_START="-0.054836151839082845" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2133" O_E="0.0" SE="0.027978142594263674" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" VAR="7.827764630249513E-4" WEIGHT="4.753954255310856"/>
<DICH_DATA CI_END="0.11887000264211246" CI_START="-0.02796091173302155" EFFECT_SIZE="0.045454545454545456" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2134" O_E="0.0" SE="0.03745755420337249" STUDY_ID="STD-Riedl_x002d_Seifert-1995" TOTAL_1="99" TOTAL_2="108" VAR="0.0014030683668985883" WEIGHT="14.2378932486789"/>
<DICH_DATA CI_END="0.09244043383036071" CI_START="0.0075595661696392855" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2135" O_E="0.0" SE="0.02165368045797037" STUDY_ID="STD-Schaad-2002" TOTAL_1="120" TOTAL_2="100" VAR="4.68881877375888E-4" WEIGHT="15.035424459119133"/>
<DICH_DATA CI_END="-0.019622895770861626" CI_START="-0.3803771042291384" EFFECT_SIZE="-0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2136" O_E="0.0" SE="0.0920308258988073" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="20" VAR="0.008469672915616582" WEIGHT="3.392608595903804"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.076019523918079" CI_END="0.01484713697083909" CI_START="-0.007137217316340053" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0038549598272495183" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-1.8283572849085827" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.413980143396361" METHOD="MH" MODIFIED="2008-04-21 13:22:13 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9063381879932767" P_Q="1.0" P_Z="0.4918559285349774" Q="0.0" RANDOM="NO" SCALE="0.11" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="744" TOTAL_2="725" WEIGHT="99.99999999999999" Z="0.6873599583194561">
<NAME>Skin adverse events</NAME>
<GROUP_LABEL_1>Immunostimulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunostimulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.017066648577470492" CI_START="-0.07262220413302604" EFFECT_SIZE="-0.027777777777777776" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2137" O_E="0.0" SE="0.022880229794514276" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" VAR="5.235049154497789E-4" WEIGHT="10.52054376252906"/>
<DICH_DATA CI_END="0.032693003574160016" CI_START="-0.004121575002731444" EFFECT_SIZE="0.014285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2138" O_E="0.0" SE="0.009391646700470048" STUDY_ID="STD-Collet-1993" TOTAL_1="210" TOTAL_2="213" VAR="8.820302774644995E-5" WEIGHT="28.85478398510447"/>
<DICH_DATA CI_END="0.09221383405689625" CI_START="-0.09221383405689625" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2139" O_E="0.0" SE="0.04704873905044542" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0022135838462369077" WEIGHT="2.7287220267603822"/>
<DICH_DATA CI_END="0.13699883497870807" CI_START="-0.06007575805563116" EFFECT_SIZE="0.038461538461538464" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2140" O_E="0.0" SE="0.05027505469203477" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" VAR="0.0025275811242870872" WEIGHT="3.6787215471880708"/>
<DICH_DATA CI_END="0.024731034452344775" CI_START="-0.024731034452344775" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2141" O_E="0.0" SE="0.012618106581253542" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" VAR="1.5921661369587396E-4" WEIGHT="10.642015904365492"/>
<DICH_DATA CI_END="0.04695277726265357" CI_START="-0.04695277726265357" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2142" O_E="0.0" SE="0.023955938799391764" STUDY_ID="STD-Mora-2002" TOTAL_1="41" TOTAL_2="40" VAR="5.738870037602037E-4" WEIGHT="5.524819906033367"/>
<DICH_DATA CI_END="0.054836151839082845" CI_START="-0.054836151839082845" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2143" O_E="0.0" SE="0.027978142594263674" STUDY_ID="STD-Pech-1987" TOTAL_1="35" TOTAL_2="34" VAR="7.827764630249513E-4" WEIGHT="4.7060568287606594"/>
<DICH_DATA CI_END="0.018762594444429695" CI_START="-0.018762594444429695" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2144" O_E="0.0" SE="0.009572928172367781" STUDY_ID="STD-Riedl_x002d_Seifert-1995" TOTAL_1="99" TOTAL_2="108" VAR="9.164095379331273E-5" WEIGHT="14.094442468657974"/>
<DICH_DATA CI_END="0.03233421928850263" CI_START="-0.01566755262183596" EFFECT_SIZE="0.008333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2145" O_E="0.0" SE="0.0122455749924413" STUDY_ID="STD-Schaad-2002" TOTAL_1="120" TOTAL_2="100" VAR="1.4995410689550373E-4" WEIGHT="14.883938327783904"/>
<DICH_DATA CI_END="0.05894118482258899" CI_START="-0.05894118482258899" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2146" O_E="0.0" SE="0.03007258566356807" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" VAR="9.043604084926399E-4" WEIGHT="4.365955242816612"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-11-04 21:05:43 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>OM-85 trials</NAME>
<CONT_OUTCOME CHI2="59.21951771984345" CI_END="-0.6608681651174001" CI_START="-1.7480009490720363" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2044345570947181" ESTIMABLE="YES" I2="86.49094030477163" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2010-04-02 14:49:04 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.629731208462886E-10" P_Q="1.0" P_Z="1.4062136978496612E-5" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.47552244830509577" TOTALS="YES" TOTAL_1="437" TOTAL_2="415" UNITS="" WEIGHT="100.0" Z="4.3428887224867365">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1016581888643131" CI_START="-2.478341811135687" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="5.04" MODIFIED="2010-03-31 11:50:13 +1000" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="3.42" SD_2="4.04" SE="0.606307983467643" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="9.122492866781089"/>
<CONT_DATA CI_END="-1.5007630558322724" CI_START="-3.2992369441677285" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.2" MODIFIED="2010-03-31 11:52:49 +1000" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="1.4" SD_2="1.5" SE="0.45880278987817846" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.211679770387331"/>
<CONT_DATA CI_END="-1.744595245795114" CI_START="-4.1754047542048855" EFFECT_SIZE="-2.96" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="8.0" MODIFIED="2010-03-31 11:54:14 +1000" MODIFIED_BY="[Empty name]" ORDER="203" SD_1="1.99" SD_2="2.55" SE="0.6201158612055342" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="8.942875135727462"/>
<CONT_DATA CI_END="0.37643712055884815" CI_START="-1.6964371205588484" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="2.22" MODIFIED="2010-03-31 11:54:47 +1000" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="1.55" SD_2="2.37" SE="0.5288041661653643" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="10.185261067319377"/>
<CONT_DATA CI_END="-1.3160946877113417" CI_START="-1.8039053122886588" EFFECT_SIZE="-1.5600000000000003" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.99" MODIFIED="2010-03-31 11:56:29 +1000" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="0.94" SD_2="0.81" SE="0.1244437725450837" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="15.664618555000635"/>
<CONT_DATA CI_END="0.1554326822839398" CI_START="-7.2554326822839394" EFFECT_SIZE="-3.55" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.55" MODIFIED="2010-03-31 12:00:06 +1000" MODIFIED_BY="[Empty name]" ORDER="206" SD_1="2.05" SD_2="5.36" SE="1.8905616182296816" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="1.8992461779724594"/>
<CONT_DATA CI_END="0.5869265775424103" CI_START="-0.76692657754241" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.98" MODIFIED="2010-03-31 12:02:48 +1000" MODIFIED_BY="[Empty name]" ORDER="207" SD_1="1.77" SD_2="1.56" SE="0.3453770492120879" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="12.931008293757456"/>
<CONT_DATA CI_END="0.08872831063952019" CI_START="-0.80872831063952" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.48" MODIFIED="2010-04-02 14:49:04 +1000" MODIFIED_BY="[Empty name]" ORDER="486" SD_1="1.44" SD_2="1.63" SE="0.22894722259134948" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="14.568842120855189"/>
<CONT_DATA CI_END="-0.4223751688241779" CI_START="-0.9976248311758222" EFFECT_SIZE="-0.7100000000000001" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.09" MODIFIED="2010-03-31 12:03:45 +1000" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="0.26" SD_2="0.65" SE="0.1467500594115862" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="15.473976012199001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.258416209499956" CI_END="-22.345260146977672" CI_START="-49.46239690720521" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-35.90382852709144" ESTIMABLE="YES" I2="75.20027037891576" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2010-11-04 21:05:43 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.371922807293153E-5" P_Q="1.0" P_Z="2.1019074031171214E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="275.3655561745296" TOTALS="YES" TOTAL_1="437" TOTAL_2="415" UNITS="" WEIGHT="100.00000000000003" Z="5.190091523483583">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.021178558095105" CI_START="-49.17882144190489" EFFECT_SIZE="-25.599999999999994" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="100.0" MODIFIED="2010-03-31 12:13:29 +1000" MODIFIED_BY="[Empty name]" ORDER="209" SD_1="67.86" SD_2="80.16" SE="12.030231998083446" STUDY_ID="STD-Ahrens-1984" TOTAL_1="83" TOTAL_2="72" WEIGHT="11.391660643452845"/>
<CONT_DATA CI_END="-28.85666953301901" CI_START="-63.44333046698099" EFFECT_SIZE="-46.15" ESTIMABLE="YES" MEAN_1="53.85" MEAN_2="100.0" MODIFIED="2010-03-31 12:13:53 +1000" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="26.92" SD_2="28.85" SE="8.82328991929881" STUDY_ID="STD-Del_x002d_Rio_x002d_Navarro-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.548497013623603"/>
<CONT_DATA CI_END="-21.804791794947036" CI_START="-52.195208205052964" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="100.0" MODIFIED="2010-03-31 12:14:26 +1000" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="24.88" SD_2="31.88" SE="7.752799706989939" STUDY_ID="STD-Guti_x00e9_rrez_x002d_Tarango-2001" TOTAL_1="26" TOTAL_2="28" WEIGHT="14.265135831883049"/>
<CONT_DATA CI_END="16.95734624017239" CI_START="-76.4173462401724" EFFECT_SIZE="-29.730000000000004" ESTIMABLE="YES" MEAN_1="70.27" MEAN_2="100.0" MODIFIED="2010-03-31 12:14:41 +1000" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="69.82" SD_2="106.76" SE="23.8205123198366" STUDY_ID="STD-G_x00f3_mez_x002d_Barreto-1998" TOTAL_1="26" TOTAL_2="30" WEIGHT="5.678270150353137"/>
<CONT_DATA CI_END="-44.01239000956119" CI_START="-60.327609990438816" EFFECT_SIZE="-52.17" ESTIMABLE="YES" MEAN_1="47.83" MEAN_2="100.0" MODIFIED="2010-03-31 12:15:14 +1000" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="31.44" SD_2="27.09" SE="4.162122393464879" STUDY_ID="STD-Jara_x002d_P_x00e9_rez-2000" TOTAL_1="99" TOTAL_2="100" WEIGHT="16.35028612827317"/>
<CONT_DATA CI_END="2.807258324771361" CI_START="-130.72725832477136" EFFECT_SIZE="-63.96" ESTIMABLE="YES" MEAN_1="36.04" MEAN_2="100.0" MODIFIED="2010-03-31 12:15:47 +1000" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="36.94" SD_2="96.58" SE="34.065553679262976" STUDY_ID="STD-Maestroni-1984" TOTAL_1="11" TOTAL_2="9" WEIGHT="3.3329532446720216"/>
<CONT_DATA CI_END="19.6967376881291" CI_START="-25.736737688129093" EFFECT_SIZE="-3.019999999999996" ESTIMABLE="YES" MEAN_1="96.98" MEAN_2="100.0" MODIFIED="2010-03-31 12:16:28 +1000" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="59.4" SD_2="52.35" SE="11.590385265910918" STUDY_ID="STD-Schaad-1986" TOTAL_1="45" TOTAL_2="49" WEIGHT="11.680536299781222"/>
<CONT_DATA CI_END="3.5723621880353846" CI_START="-32.61236218803538" EFFECT_SIZE="-14.519999999999996" ESTIMABLE="YES" MEAN_1="85.48" MEAN_2="100.0" MODIFIED="2010-04-02 14:50:26 +1000" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="58.06" SD_2="65.72" SE="9.230966655890427" STUDY_ID="STD-Schaad-2002" TOTAL_1="98" TOTAL_2="85" WEIGHT="13.271936941367052"/>
<CONT_DATA CI_END="-38.75397996197093" CI_START="-91.52602003802907" EFFECT_SIZE="-65.14" ESTIMABLE="YES" MEAN_1="34.86" MEAN_2="100.0" MODIFIED="2010-03-31 12:17:00 +1000" MODIFIED_BY="[Empty name]" ORDER="216" SD_1="23.85" SD_2="59.63" SE="13.462502498086" STUDY_ID="STD-Zagar-1988" TOTAL_1="29" TOTAL_2="22" WEIGHT="10.480723746593926"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-11-04 21:05:51 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>D53 trials</NAME>
<CONT_OUTCOME CHI2="124.61882566414641" CI_END="-0.792448813776513" CI_START="-1.8550724986886542" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3237606562325837" ESTIMABLE="YES" I2="91.97553022450197" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2010-03-31 12:30:06 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.3306690738754696E-16" P_Q="1.0" P_Z="1.0435675528940465E-6" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.6500881757982452" TOTALS="YES" TOTAL_1="539" TOTAL_2="528" UNITS="" WEIGHT="100.0" Z="4.883239941299613">
<NAME>Mean number of ARTIs</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3316150177586536" CI_START="-1.2083849822413464" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.5" MODIFIED="2010-03-31 12:22:13 +1000" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="0.87" SD_2="1.66" SE="0.22366991725321037" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="10.496211043147275"/>
<CONT_DATA CI_END="-0.22207806937025065" CI_START="-3.0979219306297496" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="4.9" MODIFIED="2010-03-31 12:22:57 +1000" MODIFIED_BY="[Empty name]" ORDER="218" SD_1="2.1" SD_2="4.3" SE="0.7336471190143768" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="6.183966263234166"/>
<CONT_DATA CI_END="-0.2977983010580436" CI_START="-1.3022016989419565" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.5" MODIFIED="2010-03-31 12:23:44 +1000" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="1.41" SD_2="1.77" SE="0.2562300648906099" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="10.267064590900143"/>
<CONT_DATA CI_END="0.32027477745065713" CI_START="-3.000274777450657" EFFECT_SIZE="-1.3399999999999999" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="5.38" MODIFIED="2010-03-31 12:24:38 +1000" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="4.2" SD_2="3.7" SE="0.8470945336479101" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="5.373107310510404"/>
<CONT_DATA CI_END="0.09795918493936284" CI_START="-0.4779591849393632" EFFECT_SIZE="-0.19000000000000017" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.32" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="1.2" SD_2="1.4" SE="0.14692065120111814" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="10.94068130088787"/>
<CONT_DATA CI_END="-1.4049852256450903" CI_START="-3.6550147743549104" EFFECT_SIZE="-2.5300000000000002" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.73" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="0.86" SD_2="2.05" SE="0.5739976771149281" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.501897023616617"/>
<CONT_DATA CI_END="-0.17848866792485393" CI_START="-0.6415113320751459" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.95" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="0.6" SD_2="0.5" SE="0.11812019705529174" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="11.066446913668365"/>
<CONT_DATA CI_END="-2.4459868002065677" CI_START="-3.9540131997934327" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.2" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="1.0" SD_2="1.4" SE="0.3847076812334269" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.207716381029671"/>
<CONT_DATA CI_END="-0.10762579619944795" CI_START="-1.012374203800552" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.92" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.5" SD_2="0.8" SE="0.2308074063446176" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="10.44780356932634"/>
<CONT_DATA CI_END="-1.5835401314099058" CI_START="-2.296459868590094" EFFECT_SIZE="-1.94" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="3.25" MODIFIED="2010-03-31 12:28:15 +1000" MODIFIED_BY="[Empty name]" ORDER="226" SD_1="0.2" SD_2="0.6" SE="0.18187062180825983" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="10.756652501573942"/>
<CONT_DATA CI_END="-1.1017184882834778" CI_START="-3.2382815117165213" EFFECT_SIZE="-2.1699999999999995" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="5.56" MODIFIED="2010-03-31 12:29:52 +1000" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="2.15" SD_2="2.21" SE="0.5450516030615816" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="7.758453102105192"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.135561919021214" CI_END="-33.7190882272163" CI_START="-53.21917839946358" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-43.46913331333994" ESTIMABLE="YES" I2="54.82382585730998" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2010-11-04 21:05:51 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.014428721737542172" P_Q="1.0" P_Z="2.3683418846117618E-18" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="131.20005823775463" TOTALS="YES" TOTAL_1="539" TOTAL_2="528" UNITS="" WEIGHT="100.00000000000001" Z="8.738209411418117">
<NAME>Percent difference in ARTIs</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-22.10363180167417" CI_START="-80.55636819832583" EFFECT_SIZE="-51.33" ESTIMABLE="YES" MEAN_1="48.67" MEAN_2="100.0" MODIFIED="2010-03-31 12:34:18 +1000" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="58.0" SD_2="110.67" SE="14.91168635182059" STUDY_ID="STD-Garabedian-1990" TOTAL_1="75" TOTAL_2="69" WEIGHT="6.999319961193306"/>
<CONT_DATA CI_END="-4.532958610129363" CI_START="-63.22704138987063" EFFECT_SIZE="-33.879999999999995" ESTIMABLE="YES" MEAN_1="66.12" MEAN_2="100.0" MODIFIED="2010-03-31 12:35:00 +1000" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="42.86" SD_2="87.76" SE="14.973255438036794" STUDY_ID="STD-Hauguenauer-1987" TOTAL_1="45" TOTAL_2="42" WEIGHT="6.963082692506542"/>
<CONT_DATA CI_END="-11.911932042321745" CI_START="-52.088067957678255" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="100.0" MODIFIED="2010-03-31 12:35:00 +1000" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="56.4" SD_2="70.8" SE="10.249202595624395" STUDY_ID="STD-H_x00fc_ls-1995" TOTAL_1="78" TOTAL_2="78" WEIGHT="10.474956111913087"/>
<CONT_DATA CI_END="5.950071774408784" CI_START="-55.77007177440878" EFFECT_SIZE="-24.909999999999997" ESTIMABLE="YES" MEAN_1="75.09" MEAN_2="100.0" MODIFIED="2010-03-31 12:36:07 +1000" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="78.07" SD_2="68.77" SE="15.745223900964042" STUDY_ID="STD-Lacomme-1985" TOTAL_1="47" TOTAL_2="40" WEIGHT="6.527537585084298"/>
<CONT_DATA CI_END="7.425114582168156" CI_START="-36.20511458216816" EFFECT_SIZE="-14.39" ESTIMABLE="YES" MEAN_1="85.61" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="90.91" SD_2="106.06" SE="11.130365024175441" STUDY_ID="STD-RB10-1994" TOTAL_1="153" TOTAL_2="161" WEIGHT="9.701346179207505"/>
<CONT_DATA CI_END="-37.667921566016204" CI_START="-97.99207843398379" EFFECT_SIZE="-67.83" ESTIMABLE="YES" MEAN_1="32.17" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="23.06" SD_2="54.96" SE="15.389098305835422" STUDY_ID="STD-RB17-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.724197282045309"/>
<CONT_DATA CI_END="-18.7902322158218" CI_START="-67.52976778417819" EFFECT_SIZE="-43.16" ESTIMABLE="YES" MEAN_1="56.84" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="63.16" SD_2="52.63" SE="12.43378346561662" STUDY_ID="STD-RB21-1988" TOTAL_1="45" TOTAL_2="42" WEIGHT="8.658772240928412"/>
<CONT_DATA CI_END="-39.44848033239019" CI_START="-63.77151966760981" EFFECT_SIZE="-51.61" ESTIMABLE="YES" MEAN_1="48.39" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="16.13" SD_2="22.58" SE="6.204970991068371" STUDY_ID="STD-RB22-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.582460660800743"/>
<CONT_DATA CI_END="-11.696924046879992" CI_START="-110.04307595312" EFFECT_SIZE="-60.87" ESTIMABLE="YES" MEAN_1="39.13" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="54.35" SD_2="86.96" SE="25.088765069659928" STUDY_ID="STD-RB24-1990" TOTAL_1="16" TOTAL_2="17" WEIGHT="3.2533768427431444"/>
<CONT_DATA CI_END="-48.72347055823274" CI_START="-70.65652944176725" EFFECT_SIZE="-59.69" ESTIMABLE="YES" MEAN_1="40.31" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:02 +1000" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="6.15" SD_2="18.46" SE="5.595270896950067" STUDY_ID="STD-RB25-1990" TOTAL_1="13" TOTAL_2="12" WEIGHT="15.228063759206865"/>
<CONT_DATA CI_END="-19.815631126216957" CI_START="-58.244368873783046" EFFECT_SIZE="-39.03" ESTIMABLE="YES" MEAN_1="60.97" MEAN_2="100.0" MODIFIED="2010-03-31 12:37:36 +1000" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="38.67" SD_2="39.75" SE="9.803429565718316" STUDY_ID="STD-Vautel-1993" TOTAL_1="32" TOTAL_2="32" WEIGHT="10.88688668437079"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-04-18 09:44:12 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-04-18 07:40:34 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-04-18 07:40:48 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-04-18 07:40:48 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-04-18 07:40:46 +1000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-04-18 07:40:44 +1000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Any IS compared with placebo, outcome: 1.1 Mean number of ARTIs.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2011-04-18 09:44:12 +1000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Any IS compared with placebo, outcome: 1.2 Per cent difference in ARTIs.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2011-04-18 07:40:39 +1000" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-006.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: OM-85 trials, outcome: 6.2 Per cent difference in ARTIs.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2011-04-18 07:40:37 +1000" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-007.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: D53 trials, outcome: 7.2 Per cent difference in ARTIs.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-03-04 14:58:51 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-03-04 14:35:16 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-05-18 16:39:09 +1000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-04 14:35:16 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2005); MEDLINE (January 1966 to January 2006); EMBASE (January 1990 to January 2006); PASCAL (up to January 2006); SciSearch (up to January 2006); and IPA (up to January 2006) for reports of trials.</P>
<P>Trials were identified using the Cochrane methodology searches phase 1 and phase 2 (Dickersin 1994). The following search strategy was combined with the highly sensitive search strategy used in MEDLINE and CENTRAL and adapted for EMBASE, PASCAL, SciSearch and IPA.</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1 exp Respiratory Tract Infections/<BR/>2 (respiratory tract infection$ or respiratory infection$)<BR/>3 or/1-2<BR/>4 exp Adjuvants, Immunologic/<BR/>5 (immunostimulants$ or immunomodulator$)<BR/>6 Immunobalt<BR/>7 (LW50020 or Luivac or Paspat)<BR/>8 Munostin<BR/>9 (OM-85 BV or Broncho-Vaxom)<BR/>10 Pulmonar-OM<BR/>11 D53<BR/>12 Ribomunyl<BR/>13 Ribovac<BR/>14 Immucytal<BR/>15 exp Lipopolysaccharides/<BR/>16 lipopolysaccharid$<BR/>17 (RU 41740 or Biostim)<BR/>18 exp Thymus Extracts/<BR/>19 calf thymus extract$<BR/>20 (thymic extract$ or thymomodulin)<BR/>21 exp Pelargonium/<BR/>22 (Pelargonium sidoides or Umckaloabo)<BR/>23 AM3<BR/>24 Inmunoferon<BR/>25 glycophosphopeptical<BR/>26 or/4-25<BR/>27 3 and 26</P>
<P>Identified articles were used as references for a Science Citation Index search. Bibliographies of all included trials as well as those of relevant reviews were searched to identify additional studies. Finally, a letter was sent to all first authors, as well as pharmaceutical companies that manufacture immunostimulant drugs, requesting data and references for any relevant published and unpublished trials. There were no language restrictions. We also searched for studies in the trial registration web site: metaRegister of Controlled Trials (http://www.controlled-trials.com/mrct/).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-03-04 14:58:51 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-03-04 14:36:50 +1000" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-04 14:58:51 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Embase.com (Elsevier) </HEADING>
<P>(Search strategy used for January 2010 to March 2011 update)</P>
<P>#29. #25 AND #28 400 3 Mar 2011<BR/>#28. #26 OR #27 841,770 3 Mar 2011<BR/>#27. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti AND [embase]/lim 802,449 3 Mar 2011<BR/>#26. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp AND [embase]/lim 237,948 3 Mar 2011<BR/>#25. #3 AND #24 3,234 3 Mar 2011<BR/>#24. #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 114,581 3 Mar 2011<BR/>#23. 'immunostimulating agent'/de OR 'immunomodulating agent'/de AND [embase]/lim 11,919 3 Mar 2011<BR/>#22. levamisole:ab,ti AND [embase]/lim 3,610 3 Mar 2011<BR/>#21. pidotimod:ab,ti OR adimod:ab,ti AND [embase]/lim 68 3 Mar 2011<BR/>#20. glycophosphopep:ab,ti AND [embase]/lim 3 Mar 2011<BR/>#19. am3:ab,ti OR imunoferon:ab,ti OR immunoferon:ab,ti OR inmunoferon:ab,ti AND [embase]/lim 144 3 Mar 2011<BR/>#18. pelargonium*:ab,ti OR umckaloabo:ab,ti AND [embase]/lim 249 3 Mar 2011<BR/>#17. 'pelargonium sidoides extract'/de AND [embase]/lim 98 3 Mar 2011<BR/>#16. 'thymus extract':ab,ti OR 'thymus extracts':ab,ti OR 'thymic extract':ab,ti OR 'thymic extracts':ab,ti OR thymomodulin*:ab,ti AND [embase]/lim 556 3 Mar 2011<BR/>#15. 'thymus extract'/de AND [embase]/lim 514 3 Mar 2011<BR/>#14. ru41740:ab,ti OR 'ru-41740':ab,ti OR 'ru 41740':ab,ti OR biostim:ab,ti AND [embase]/lim 122 3 Mar 2011<BR/>#13. lipopolysaccharide*:ab,ti AND [embase]/lim 48,375 3 Mar 2011<BR/>#12. 'lipopolysaccharide'/exp AND [embase]/lim 53,723 3 Mar 2011<BR/>#11. ribomunyl:ab,ti OR ribovac:ab,ti OR immucytal:ab,ti AND [embase]/lim 68 3 Mar 2011<BR/>#10. d53:ab,ti AND [embase]/lim 40 3 Mar 2011<BR/>#9. 'pulmonar-om':ab,ti OR 'pulmonar om':ab,ti AND [embase]/lim 1 3 Mar 2011<BR/>#8. bronchovaxom:ab,ti OR 'broncho-vaxom':ab,ti OR 'broncho vaxom':ab,ti AND [embase]/lim 113 3 Mar 2011<BR/>#7. 'om 85 bv':ab,ti OR om85bv:ab,ti OR 'om-85 bv':ab,ti AND [embase]/lim 51 3 Mar 2011<BR/>#6. immunobalt:ab,ti OR lw50020:ab,ti OR luivac:ab,ti OR paspat:ab,ti OR munostin:ab,ti AND [embase]/lim 18 3 Mar 2011<BR/>#5. immunostimulant*:ab,ti OR immunomodul*:ab,ti OR immunoadjuvant*:ab,ti OR (immuno* NEAR/1 adjuvant*):ab,ti AND [embase]/lim 30,022 3 Mar 2011<BR/>#4. 'immunological adjuvant'/exp AND [embase]/lim 11,700 3 Mar 2011<BR/>#3. #1 OR #2 158,887 3 Mar 2011<BR/>#2. (respiratory NEAR/5 infection*):ab,ti AND 30,608 3 Mar 2011[embase]/lim<BR/>#1. 'respiratory tract infection'/exp AND 149,401 3 Mar 2011 [embase]/lim<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-03-04 14:36:30 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-03-04 14:36:30 +1000" MODIFIED_BY="[Empty name]">Search terms used for searching other databases</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-04 14:36:06 +1000" MODIFIED_BY="[Empty name]">
<P>Our library assistant searched for clinical trials on children with the term 'respiratory' in EMBASE, PASCAL, SciSearch and IPA from 2005 to March 2010, for the following interventions:</P>
<P>Immunostimulants OR immunomodulators<BR/>Bacterial lysates OR bacterial antigens OR bacterial extracts<BR/>LW50020 OR Luivac OR Paspat<BR/>OM-85 OR OM-85 BV OR Broncho-Vaxom<BR/>D53 OR Ribomunyl OR Ribovac OR Immucytal<BR/>RU 41740 OR Biostim<BR/>AM3 OR Inmunoferon OR glycophosphopeptical<BR/>Pidotimod<BR/>Levamisole<BR/>Echinacea</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>